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Abstract 
 
Ovine pulmonary adenocarcinoma (OPA) is a respiratory disease caused by jaagsiekte 
sheep retrovirus (JSRV). This virus induces the growth of large lung tumours in 
affected sheep and is a significant problem for the sheep industry. An interesting 
feature of OPA is that it occurs only in sheep. Goats may also be infected by JSRV but 
disease progression is limited to the early stages so that clinical signs do not develop. 
The ability of a virus to replicate in its host is dependent on a wide range of cellular 
proteins, including essential, required (‘dependency’) factors, and proteins that act to 
inhibit replication, referred to as restriction factors. Greater understanding of the roles 
of dependency and restriction factors can provide insights into pathogenesis and the 
species-specificity of infection. 
 
The aim of this study was to investigate the potential role of previously identified 
restriction factors on the replication of JSRV, and specifically whether APOBEC3 or 
TRIM5 proteins are responsible for the specificity of OPA for sheep. To examine this 
question, ruminant genes for APOBEC3 were cloned and their activity against JSRV 
was tested using a replication-defective reporter virus that expresses GFP. This system 
allows the activity of putative restriction factors to be measured quantitatively by flow 
cytometry. These experiments revealed that ruminant APOBEC3 proteins, including 
those from sheep, inhibit JSRV infection in vitro. Further analysis of the mechanism 
of restriction of JSRV by sheep APOBEC3 provided evidence for cytidine deaminase-
dependent and independent mechanisms against this virus. Analysis of virus purified 
from lung fluid from natural cases of OPA found that APOBEC3 is not encapsidated 
by JSRV in vivo, suggesting that JSRV somehow evades this restriction factor in 
infected sheep. Further studies using immunohistochemistry suggested that the 
16 
 
pulmonary epithelial cells targeted for infection by JSRV do not express APOBEC3. 
Collectively, these results indicate that JSRV is susceptible to ruminant APOBEC3 
proteins but evades restriction in vivo by having tropism for cells that do not express 
APOBEC3. The data also suggest that APOBEC3 is not responsible for the species 
tropism of JSRV, at least among ruminants. 
 
In order to extend the studies on the species-specificity of APOBEC, several human 
and mouse APOBEC proteins were analysed for their activity against JSRV. Murine 
APOBEC3 and human APOBEC3F were both able to restrict JSRV in vitro, while 
other human APOBECs tested were not. These results have impact for the 
development of murine model of OPA and for the development of JSRV as a gene 
delivery vector. 
 
To assess the impact of TRIM5 on JSRV replication, derivatives of the permissive cell 
line CRFK were created that stably express TRIM5 from a range of ruminant and 
primate species. Infection studies performed in cell culture indicated that none of the 
TRIM5 proteins tested restrict JSRV, at least during the early stages of virus infection. 
Further studies are needed to examine other potential mechanisms of activity of 
TRIM5 against JSRV. 
 
This thesis has revealed new insights into host-pathogen interactions in OPA that may 
contribute to the development of control strategies against this disease. In addition, 
these data provide a background for the future development of JSRV as a gene 
delivery vector.  
17 
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1.1 Overview of Ovine Pulmonary Adenocarcinoma 
 
Ovine Pulmonary Adenocarcinoma (OPA) is a transmissible lung cancer of sheep first 
reported at the end of the 19th century (Dykes, 1888). Jaagsiekte sheep retrovirus 
(JSRV) is the causative agent of OPA, which is distributed worldwide with the 
exception of Iceland, Australia and New Zealand (Fan et al., 2003). OPA is also called 
SPA (Sheep Pulmonary Adenomatosis) or Jaagsiekte, in Afrikaans the word Jaag 
means chase and siekte means sickness, which refers to the laboured breathing of 
affected animals after herding (Tustin, 1969). Apart from sheep, JSRV may also infect 
goats although almost without any clinical signs (De las Heras et al., 2003a). Sheep 
are the only species that develops OPA. The aim of this project is to investigate host 
factors responsible for the species-specificity of JSRV infection. 
 
1.1.1 Epidemiology and clinical signs of OPA 
 
The clinical signs of OPA are "harsh breathing" and over-production of lung fluid 
(Griffiths et al., 2010). Lung fluid is thought to be responsible for disease 
transmission, which occurs mainly via the respiratory route (Dungal, 1938). An 
alternative route of transmission affects newborn lambs by suckling, because virus is 
present in milk and colostrum of JSRV positive ewes (Grego et al., 2008). Other 
clinical signs include progressive loss of weight, decreased milk production, dyspnoea, 
coughing and increased susceptibility to opportunistic respiratory infections (De las 
Heras et al., 2003a). A simple diagnostic test for OPA is called the wheelbarrow test 
which, after lowering the sheep’s head, may release up to 500 ml of lung fluid through 
the nose. This fluid contains 10
7
 to 10
10 
of JSRV RNA copies per ml (Cousens et al., 
2009). The virus is able to survive for several weeks in conditions of low temperature 
and high humidity (Cousens et al., 2009). 
 
The development of OPA occurs from several months to years after infection. Some 
JSRV infected sheep do not show clinical signs even though they may have tumours in 
their lungs and will not be recognized by farmers. Therefore, this long asymptomatic 
period enhances the spread of the disease. Currently, there is no effective control for 
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OPA and no accurate diagnostic test suitable for detecting the disease in individual 
animals during the early stages of infection (Griffiths et al., 2010). 
 
In natural infection it takes several months until the clinical signs of OPA are visible, 
but in experimental settings even 10 days after intra-tracheal inoculation of lambs 
some early tumour lesions may be visualised by immunohistochemistry (Griffiths et 
al., 2010, Martineau et al., 2011, Murgia et al., 2011). Usually adult sheep aged 1-4 
years are affected by the disease. However, sheep of all ages are susceptible to OPA 
(Gonzalez et al., 1993). In comparison to older animals the progress of the disease 
amongst lambs is faster due to the more rapid cell division, which enhances integration 
of the provirus and spread of the tumour (Murgia et al., 2011). After the onset of 
clinical signs the animal dies a few months later (Dungal, 1938). The mortality within 
an infected flock is the highest (up to 50% per year) during the first years of an 
outbreak and then decreases to around 5% per year (Griffiths et al., 2010, De las Heras 
et al., 2003a). 
 
1.1.2 Pathology of OPA 
 
OPA lesions are located in the lungs, although thoracic lymph nodes may also be 
affected (Rosadio et al., 1988). The size of the tumour ranges from 0.5 to 2 cm nodules 
to large half-lobe sized lesions in both lungs. Two pathological forms of OPA are 
recognised; classical OPA (see Fig. 1.1), which is the most common, and atypical 
OPA (Garcia-Goti et al., 2000). During post-mortem examination of classical OPA, 
the lungs are enlarged and may weigh three times more than normal. In contrast to the 
surrounding healthy pink coloured tissue the neoplastic regions are greyish and form 
"hard" tumours located usually in cranioventral parts of the lungs (Griffiths et al., 
2010, De las Heras et al., 2003a). In the advanced stages of disease the affected areas 
are white and very solid due to fibrosis. Opportunistic bacterial infections, principally 
Mannheimia haemolytica pneumonia, are common in OPA. The atypical form of OPA 
is characterised by white granular structures that are easy to differentiate from healthy 
tissue and are usually present in the diaphragmatic lobe (De las Heras et al., 2003a). 
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Fig. 1.1 Gross pathology of a natural OPA case  
Reproduced with permission from Griffiths et al. 2010. Panel A shows appearance of the 
classical form of OPA in an adult sheep is shown. The tumour-affected, enlarged part of the 
right lung is marked by an arrow. Affected areas are darker than normal tissue. Panel B 
displays lung section at the level of the arrow in (A). Dense and greyish tumour is located 
adjacent to normal healthy pink lung in the dorsal region of the lobe. 
 
Until recently, no antibody or T cell responses specific to JSRV antigens had been 
detected in sheep (DeMartini et al., 2003). The expression of enJSRV and its similarity 
with exogenous JSRV is thought to cause immune tolerance to viral antigens (see 
Section 1.3.) (Spencer et al., 2003, Summers et al., 2006). However, there are 
indications for the occurrence of other immunosuppressive mechanisms involved in 
OPA pathogenesis. It was suggested that the presence of surfactant proteins in lung 
fluid could suppress the activity of macrophages (Summers et al., 2005). However, 
OPA-specific immune responses were detected and tumour regression was reported in 
sheep co-infected with JSRV and ovine lentivirus (Hudachek et al., 2010). 
Surprisingly, in this experimental setting neutralising antibodies against JSRV Env 
were detected, which correlated with regression (Hudachek et al., 2010). Moreover, 
CD3+ T cells infiltrated the lung tissue, although there was no evidence that these 
cells were specific to JSRV (Hudachek et al., 2010). 
 
1.1.3 Histopathology 
 
The histopathological features of OPA are non-encapsulated neoplastic foci 
originating from the alveolar and bronchiolar epithelia (Platt et al., 2002, De las Heras 
et al., 2003a). The tumour nodule structure consists of acinar and papillary 
proliferations towards the neighbouring structures, which is shown in Fig. 1.2. 
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Fig. 1.2 Histological analysis of transformed lung tissue 
Copied with permission from (Griffiths et al., 2010). Panels A and B – haematoxylin and eosin 
staining of OPA-affected lung; Panels C and D – immunohistochemical detection of Env using 
anti-Env (SU) antibody. 
 
The fibrovascular connective tissue supports the structure and usually forms the centre 
of advanced tumour nodules. The classical form of OPA has a higher proportion of 
JSRV-positive cells than the atypical form. Another difference between the two forms 
of OPA is based on the prevalence of leukocytes in the surrounding stroma. In both 
cases the nodule may be infiltrated by macrophages but in case of the atypical form 
also by CD4 and CD8 lymphocytes and B cells (De las Heras et al., 2003a, Summers 
et al., 2012). The presence of leukocytes is enhanced by the presence of secondary 
bacterial infections (Garcia-Goti et al., 2000, Wootton et al., 2006a, Martineau et al., 
2011). 
 
Clara cells and type II pneumocytes are suspected to be the cell types of origin of the 
OPA tumour, although the occurrence of undifferentiated cells suggests that 
progenitor or stem cells may be the first that become infected and transformed 
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(Martineau et al., 2011, Wootton et al., 2006b, Griffiths et al., 2010, Platt et al., 2002, 
Murgia et al., 2011). Developed OPA tumours express surfactant protein-C (SP-C), 
which is a characteristic marker of type II pneumocytes. In contrast, Clara cell-specific 
protein (CCSP), which is a Clara cell marker was detected only in a fraction of 
tumours analysed (Murgia et al. 2011). In order to determine early targets of JSRV 
infection experimental inoculation was performed (Martineau et al., 2011). Ten days 
later, single JSRV-infected cells were identified in alveolar and bronchiolar regions. 
Immunohistochemistry showed that those cells were expressing SP-C or CCSP, 
implying that primary differentiated epithelial cells are infected by JSRV. 
Additionally, cells were detected that expressed the JSRV Env protein, but did not 
express either SP-C or CCSP (Martineau et al. 2011). This observation was confirmed 
in the other study (De las Heras et al., 2014) 
 
In order to investigate the species specificity barriers of OPA, Caporale and colleagues 
performed experimental infection of goat kids, which resulted in a different 
macroscopic and histopathological tumour pattern compared to tumour in infected 
lambs (Caporale et al., 2013b). Interestingly, the tumour appeared to originate in 
similar cell types in both species. However, the number of infected goat cells was 
significantly lower and the tumour nodules in goats were significantly smaller and less 
abundant than those in lambs. This suggests that caprine cells are vulnerable to viral 
infection and transformation, but also implies that goat cells restrict viral replication, 
most likely at a late stage in replication, enabling fewer rounds of infection within the 
lung (Caporale et al., 2013b). Infected lambs have multiple tumour foci of polyclonal 
origin and the tumour spread is expected to be enhanced by a viral progeny from 
primary infected and transformed cells. 
 
1.1.4 OPA as a model for human lung cancer 
 
The histological features of OPA resemble human bronchioloalveolar carcinoma 
(BAC). Human BAC is a rare type of lung cancer, which on the basis of 
histopathology, has been classified as an adenocarcinoma with a pure 
bronchioloalveolar growth pattern (Mornex et al., 2003). Smoking is the major risk 
factor of most lung cancers. However, the prevalence of BAC has a weak association 
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with smoking, which suggests other risk factors, such as genetic factors or infectious 
agents (Sun et al., 2007). 
 
From 30 to 40% of human lung adenocarcinomas contain an antigen that is detected 
by immunohistochemistry using antibodies to JSRV Gag (De las Heras et al., 2000a, 
De las Heras et al., 2007, Hopwood et al., 2010). A recent study showed an increased 
prevalence of an antigen detected by antibodies to JSRV Env in advanced stages of 
some types of human lung tumours (Linnerth-Petrik et al., 2014). PCR amplification 
using enJSRV specific primers was positive in the majority of BAC samples among 
Sardinian patients, while only one out of ten non-Sardinian patients was found to be 
positive (Rocca et al., 2008). However, those results contradict other studies where no 
JSRV was detected by PCR in lung tumour samples (Yousem et al., 2001, Hopwood et 
al., 2010). To date, no solid proof of association of BAC and JSRV has been found, 
although research on OPA has contributed to a better understanding of the process of 
carcinogenesis (Griffiths et al., 2010). 
 
1.2 JSRV classification, structure and replication 
 
Retroviruses are a large family of viruses that are responsible for a variety of diseases. 
They are classified into two subfamilies (orthoretrovirinae and spumavirinae) and 
seven genera based on their sequence similarity in the reverse transcriptase (RT) 
protein (Linial et al. 2005) (see Fig. 1.3). 
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Fig. 1.3 Phylogenetic relationship between different retroviruses based on amino acid 
sequence similarity in the reverse transcriptase (RT) protein. 
Classification of retroviruses divides them into two subfamilies: spumaretrovirinae (yellow) and 
orthoretrovirinae (orange), which includes seven genera (Linial, M. et al 2005). JSRV (boxed 
in blue) belongs to the betaretrovirus genus. MMTV, (mouse mammary tumour virus); MPMV 
(Mason-Pfizer monkey virus); HERV-K (human endogenous retrovirus-K); ENTV-1and   
ENTV-2, (Enzootic nazal tumour virus type -1 and -2); SIV (simian immunodeficiency virus); 
FIV, (feline immunodeficiency virus); EIAV, (equine infectious anaemia virus); VMV, (Visna-
Maedi virus); HTLV-1 and -2, (human T-lymphotropic virus type 1 and type 2); BLV, (bovine 
leukaemia virus); RSV, (Rous sarcoma virus); FeLV, (feline leukaemia virus); GALV, (gibbon 
ape leukaemia virus); MMLV, (Moloney murine leukaemia virus); PFV, (primate foamy virus); 
SFV-3, (simian foamy virus type 3); BFV, (bovine foamy virus); WDSV, (walleye dermal 
sarcoma virus); WEHV-1 and -2, (walleye epithelial hyperplasia virus type 1 and type 2). 
Reproduced with permission from (Griffiths et al., 2010). 
 
1.2.1 JSRV structure 
 
The retroviral genome consists of at least four structural genes gag, pro, pol and env. 
In the case of more complex retroviruses additional regulatory and accessory genes are 
present. The gag gene encodes at least three proteins: matrix (MA), capsid (CA), and 
nucleocapsid (NC) (see Fig. 1.4 and Fig. 1.5). These proteins are formed by the 
cleavage of a Gag precursor polyprotein by the protease (PR), which may be encoded 
by a separate open reading frame gene, pro, or in the same open reading frame as gag 
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(alpharetroviruses) or pol (gammaretroviruses and lentiviruses). The pol gene encodes 
the viral enzymes reverse transcriptase (RT) and integrase (IN). The env gene encodes 
the envelope glycoproteins: surface (SU) and transmembrane (TM) (Engelman, 2010) 
(see Fig. 1.5). JSRV additionally has a unique highly conserved reading frame named 
orf-x that overlaps the pol gene region, although its function is unknown (Griffiths et 
al., 2010, Palmarini et al., 2002). 
 
 
 
Fig. 1.4 The retroviral virion structure 
Two positive-sense ssRNA molecules together with MA, CA, NC, RT, IN and PR proteins are 
associated with the retroviral core. The viral capsid is enveloped by a lipid bilayer in which the 
envelope Env glycoprotein surface SU domain is anchored by the transmembrane TM domain. 
 
 
 
 
Fig. 1.5 The JSRV genome 
 The JSRV RNA genome contains gag, pro, pol, env genes and an additional orf-x reading 
frame (grey boxes). The products encoded by these genes are displayed below the boxes. 
The retroviral RNA is flanked by two 5’ and 3’ long terminal repeats (blue boxes). Figure not to 
scale. 
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Betaretrovirus genomes are highly conserved among different isolates. For example 
mouse mammary tumour virus (MMTV) genomes show 96% sequence similarity 
(Walsh et al., 2010). Three genomes of JSRV from viruses isolated over a 13-year 
period, including 2 British isolates JSRV21 (Palmarini et al., 1999a), JSRVJS7 
(DeMartini et al., 2001) and one South-African isolate JSRVSA (York et al., 1991) 
share 93% or greater sequence similarity. Similarly, there is 96% identity between 
ENTV-1 isolated from Europe in 1999 and a recent ENTV-1 isolate from North 
America (Walsh et al., 2010), with the highest polymorphism in LTR and Orf-x 
(Walsh et al., 2010). In contrast, some other retroviral genomes are characterised by 
high variability, for example quasi-species of VMV (Visna-Maedi virus) and CAEV 
(Caprine Arthritis Encephalitis Virus) show 84% sequence similarity in gag and pol 
and less than 78% in env (Overbaugh and Bangham, 2001). 
 
It is likely that sequence variation is constrained in some viruses by the fact that some 
coding and non-coding RNA sequence elements may be overlapping. Sequence 
variability occurs due to the pressure of the host immune system and the error prone 
process of reverse transcription and RNA transcription. However, mutated viral 
progeny may often be defective. For example, the majority of even single mutations 
affecting the CA (capsid) encoding region can result in virus attenuation (Rihn et al., 
2013). 
 
1.2.2 Replication of JSRV 
 
The replication cycle of JSRV can be divided into early and late events. Early events 
include viral entry, uncoating, reverse transcription and integration. The late events are 
transcription, translation, virion assembly, budding and maturation (see Fig. 1.6). 
Retroviral replication depends on the interplay between both dependency and 
restrictive factors which determine the species specificity and cellular tropism of the 
virus (Engelman, 2010, Goff, 2007, Martin-Serrano and Neil, 2011, Maillot et al., 
2013). 
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Fig. 1.6 Replication cycle of JSRV 
The virus enters the cell by receptor binding and endocytosis. After membrane fusion and 
uncoating, reverse transcription is initiated. Newly synthesised viral DNA is imported into the 
nucleus where it integrates into the host genome as a provirus. Transcribed viral RNA is a 
template for translation of the viral structural proteins which form new virions. Fully transcribed 
viral RNA is packaged into the assembling virion as genomic RNA. Once the virion is released 
by budding, the maturation occurs which is required for infectivity. Copied with permission 
from (Griffiths et al., 2010). 
 
1.2.3 Early phase of JSRV replication cycle 
 
Initially, the SU domain of the Env glycoprotein binds to the cellular receptor, which 
for JSRV has been identified as hyaluronidase-2 (Hyal-2) (Rai et al., 2001). Rabbit, 
goat, cow and human but not mouse Hyal-2 are able to support infection mediated by 
JSRV Env (Miller, 2008). Rat Hyal-2 can also function as a JSRV receptor but only if 
overexpressed in target cells in culture (Miller, 2008). The fact that heterologous  
Hyal-2 proteins interact with JSRV Env indicates that the cellular receptor is not a 
major species determinant of infection. Endocytosis of JSRV is mediated by cellular 
dynein. The entry of JSRV into the cytoplasm is a pH-dependent process, the virus 
particle fuses with endosomal membranes allowing the release of the viral core into 
the cytoplasm (Bertrand et al., 2008, Cote et al., 2012). 
 
Reverse transcription is initiated when the JSRV core enters the cytoplasm. The viral 
ssRNA is converted into a dsDNA form within a structure referred to as the reverse 
transcription complex (RTC). The reverse transcription reaction is initiated by 
annealing of primer to the primer binding site (PBS) located at the 5’end of the viral 
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RNA (see Fig. 1.7). This reaction utilises a Lys-3 tRNA molecule as a primer which is 
encapsidated into the virion during assembly. 
 
Once reverse transcription is complete, this structure becomes the pre-integration 
complex (PIC). Newly synthesised DNA is trafficked in the PIC towards the nucleus 
utilising cytoskeletal components, finally reaching the microtubule organising centre 
(MTOC) located on the external nuclear membrane (McDonald et al., 2002, Gaudin et 
al., 2013). 
 
Fig. 1.7 Mechanism of reverse transcription 
Reverse transcription is initiated by a tRNA molecule acting as a primer which anneals to the 
primer binding site (PBS) on the viral genomic RNA. This results in the synthesis of minus 
strand strong-stop DNA containing R and U5 sequences. Due to the RNAse H activity of RT, 
the 5’ end of the viral RNA is then degraded and the newly synthesized DNA anneals to the 3’ 
end of viral RNA (first strand transfer). The minus strand DNA is then further elongated. The 
copied RNA is degraded by RNAse H with the exception of a short region of adenosine and 
guanidine nucleotides, the polypurine tract (PPT), which promotes the initiation of plus DNA 
strand priming and its elongation after second strand transfer. Reverse transcription is 
completed when viral dsDNA is flanked on both sides by long terminal repeats (LTR). Figure 
based on (Engelman, 2010). 
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For most retroviruses, including JSRV, entry of viral DNA into the nucleus is 
dependent on cellular division as it requires the destabilisation of the nuclear 
membrane during mitosis, because the PIC cannot get through nuclear pores. 
However, lentiviruses are an exception as may be actively transported into the nucleus 
regardless of the cell cycle by the utilisation of the nucleopore complex (NPC) (Patton 
et al., 2004). Nuclear import is enabled by the interaction of the central poly purine 
tract (cPPT) sequence which is a triple stranded DNA structure (Zennou et al., 2000). 
 
 
When the viral DNA reaches a suitable site in chromatin, integrase (IN) catalyses its 
insertion into the host genome. Initially, the active IN multimer processes the 3’ ends 
of viral DNA near conserved CA/GT dimers, which enables hydrolysis of target DNA 
and insertion of viral DNA (Panganiban and Temin, 1983). Once inserted in the host 
cell genome the virus DNA is referred to as a provirus (Coffin, 1997). Cousens, et. al. 
analysed the integration sites in a number of different OPA tumours and showed that 
there may be a common JSRV integration site located on sheep chromosome 16 
(Cousens et al., 2004). 
 
1.2.4 Late phase of infection 
 
Transcription of viral genes is under the control of the viral promoter and enhancer 
elements located in the U3 region of the LTR (Fig. 1.8). In the case of JSRV, this 
process depends on tissue-specific transcription factors such as lung and liver specific 
hepatocyte nuclear factor-3 (HNF-3) and the ubiquitous CCAAT enhancer binding 
protein alpha C/EBPα (McGee-Estrada and Fan, 2007). These transcription factors 
play an important role in virus tropism and in consequence its pathogenesis which 
results in cancer. 
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Fig. 1.8 JSRV provirus and its transcripts 
The organisation of the JSRV proviral genome and its RNA transcripts are shown. The 
positions of the splice donors (SD), splice acceptors (SA), and premature termination sites are 
highlighted. The function of many transcripts is still unknown. Figure adapted from (Palmarini 
et al., 2002, Palmarini and Fan, 2003, Caporale et al., 2009). 
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There are two main transcripts generated by alternative splicing: full length viral RNA, 
and an Env coding transcript (see Fig. 1.5.3). The full-length RNA is utilised in 
translation to produce Gag, Pro and Pol proteins, but also may be packaged in newly 
synthesised virions. Expression of Gag, Pro and Pol takes place in the cytoplasm, 
where capsid assembly also occurs. Env is co-translationally targeted to the ER where 
it undergoes cleavage to obtain SU, TM and SP (Caporale et al., 2009). Processed 
envelope glycoprotein is targeted to the plasma membrane where budding of viral 
progeny occurs. Maturation of newly synthesized viral particles is mediated by PR 
(Caporale et al., 2009). 
 
Recently, the Rej regulatory protein has been identified as a factor upregulating export 
of the full viral RNA and enhancing new viral particle formation (Caporale et al., 
2009). Rej is encoded by the 5’ end of env and is either a product of multiply spliced 
env gene (Hofacre et al., 2009) or a post-translationally cleaved Env SP (Caporale et 
al., 2009). Rej function corresponds to its retroviral homologues Rem and Rec of 
MMTV and HERV-K respectively as well as Rev of HIV-1 (Mertz et al., 2009, 
Hofacre et al., 2009). 
 
1.3 Other Retroviruses 
1.3.1 Enzootic nasal tumour viruses (ENTV-1 and ENTV-2) 
 
Enzootic nasal tumour viruses are the aetiological causes of enzootic nasal 
adenocarcinoma in sheep (ENTV-1) (De las Heras et al., 1993) and goats (ENTV-2) 
(De las Heras et al., 1991). These viruses are the closest known relatives to JSRV 
(92% sequence similarity) and, as for JSRV, their genome appears to be extremely 
stable among different isolates (Bai et al., 1996, Walsh et al., 2010, Garcia-Goti et al., 
2000). The majority of sequence differences between JSRV and ENTV are present in 
the LTR (Cousens et al., 1999, Ortin et al., 2003). The sequence of the TM region of 
Env isolated from infected sheep and goats suggests that ENTV-1 and ENTV-2 are 
different viruses and not geographical variants (Cousens et al., 1999, Ortin et al., 
2003). 
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ENTV-affected flocks are characterised by a low level of cases over many years (0.1 
to 6.6% per annum) (Charray et al., 1985). Respiratory malfunction, skull deformation 
and bulging eyes may be a clinical sign of a tumour growing in the nasal cavity 
(Charray et al., 1985). The disease has been reported in Africa, Europe, Asia and 
North and South America (De las Heras et al., 2003b), but has not been described in 
New Zealand or the UK (Griffiths et al., 2010). Diseases with similar pathology were 
reported among cattle in India (Rajan, 1987) and in moose and deer in Sweden (Borg 
and Nilsson, 1985), but their cause is unknown. 
 
Although ENTV-1 and ENTV-2 are different viruses, the pathology of the disease 
they cause is similar in the two host species. Both viruses are able to transform 
secretory epithelial cells of the ethmoid turbinate but analysis of their tissue 
distribution by the specific PCR, demonstrated that ENTV-1 is present only in the 
tumour, while ENTV-2 causes a more disseminated lymphoid infection (Ortin et al., 
2003). Similarly to OPA, tumours in ENT cause fluid production and there is no 
antibody response to ENTV in infected animals (Ortin et al., 1998). 
 
JSRV and ENTV enter the cell via the Hyal-2 receptor and replicate in the airway 
epithelial cells (Dirks et al., 2002, Miller, 2003). ENTV transforms secretory epithelial 
cells of the nasal gland in their ruminant hosts (Miller, 2003, De las Heras et al., 
2003b). Surprisingly, in mice the expression of the ENTV Env in airway epithelia 
caused similar lung tumour lesions to JSRV Env (Wootton et al., 2006a). ENTV uses 
the same receptor as JSRV, although it requires a slightly more acidic pH for optimal 
infection (Cote et al., 2011). 
 
1.3.2 Mouse mammary tumour virus (MMTV) 
 
MMTV is a betaretrovirus which is transmitted to offspring through milk. The first 
report of transmission of mouse mammary carcinoma by a cell free agent from milk 
was by Joseph Bittner in 1942 (Bittner, 1942). MMTV can be transmitted in two ways, 
either by exogenous virus present in milk of affected animal or by an endogenous 
virus via the germ line (Bentvelzen and Daams, 1969). 
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During virus transmission, gut-associated B cells and dendritic cells are the primary 
targets of infection (Held et al., 1993). They express virus encoded superantigen 
(SAG) and present it in association with class II major histocompatibility complex to 
cognate CD4 T cells containing a particular class of Vβ chains as part of their 
alpha/beta receptors (Ross, 2000, Golovkina et al., 1994). This process causes constant 
proliferative stimulation of a large subset of T cells and in consequence the 
enhancement of proliferation of infected B cells, thereby increasing the virus reservoir 
(Choi et al., 1991). MMTV replication in activated lymphocytes leads ultimately to 
virus transmission to mammary epithelial cells. During puberty, gonadotrophin 
hormone levels increase, resulting in high levels of MMTV transcription in the 
dividing mammary cells. The ubiquitous viral expression in lymphoid cells causes 
impairment of the immune response to MMTV and enables it to persist in its host 
(Ross, 1998). Virus expression in mammary epithelium is further enhanced by 
proliferation during pregnancy and upregulated level of glucocorticoids during this 
period (Ross, 1998). 
 
Three stages of tumourigenesis have been identified in infected MMTV mice: 
preneoplastic hyperplastic nodules, malignant tumour and finally distant metastatic 
lesions (often in the lung) (Callahan, 1996). Every stage of mammary carcinogenesis 
results from the clonal outgrowth of cells containing increased numbers of MMTV 
provirus (Callahan, 1996). 
 
MMTV induces tumours through insertional activation of cellular oncogenes (see 
Section 1.7.2). Some of the mutations present in transformed cells as a result of 
integration of MMTV are relevant to the development of human breast cancer. A high 
throughput analysis of MMTV-induced mammary tumours has been performed 
(Theodorou et al., 2007), which identified 33 common insertion sites in potential 
candidate oncogenes. The expression of human orthologs of those genes was often 
deregulated in human breast cancers and was associated with a number of tumour 
parameters, which determined their malignancy. The computational analysis showed 
that those genes were often connected with signalling pathways mainly associated 
with development and growth factor signalling (Theodorou et al., 2007). The study of 
MMTV cis-interactions resulting from virus integration enabled the discovery of 
oncogenes and pathways present in human cancers such as members of the Wnt family 
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(Ross et al., 2006) and ITAM-mediated signaling, which contribute to the novel 
mechanism of transformation (Katz et al., 2010). The use of the MMTV LTR to direct 
expression to murine epithelial cells enabled the creation of many transgenic mouse 
strains which are critical models for research on human breast cancer (Ross, 2010). 
 
1.3.3 Endogenous retroviruses 
 
Endogenous retroviruses (ERVs) originate from ancient exogenous retrovirus 
infections. When a retrovirus infects germ line cells it can result in integrated proviral 
sequences which are vertically transmitted to subsequent generations. ERVs are 
present in every vertebrate genome sequenced so far and represent approximately 8% 
of the human genome (Li et al., 2001). Initially, simple endogenous retroviruses 
related to alpha-, beta- and gamma- retroviruses were discovered, although more 
recently complex endogenous retroviruses have been identified, e.g. rabbit endogenous 
lentivirus (Katzourakis et al., 2007). 
 
The sheep genome contains at least 27 copies of endogenous betaretroviruses related 
to JSRV (enJSRV), and is an excellent example of virus-host coevolution (Arnaud et 
al., 2007a). The Env protein of enJSRV plays a role in sheep placental development 
(Palmarini et al., 2001a, Spencer et al., 2010). Other mammalian species have similar 
interactions with their ERVs (Dunlap et al., 2006a, Black et al., 2010b, Black et al., 
2010a, Spencer et al., 2010). 
 
The ERV genome is usually modified so that it loses its replication ability. However, it 
is common that some open reading frames (ORFs) are transcribed and viral proteins 
are expressed. In vitro experiments have demonstrated the potential protective role of 
ERV genes, which compete with their homologous genes during exogenous retrovirus 
infection. For example, enJSRV Env lacks transformation potential. However its 
similarity with the exogenous JSRV homologue results in the receptor interference by 
competition for binding to Hyal-2 (Spencer et al., 2003). The expression of enJS56A1 
Gag may interfere with trafficking of exJSRV Gag and in consequence restrict 
replication (Murcia et al., 2007, Arnaud et al., 2007b). The observation that enJSRVs 
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are not expressed significantly in type II pneumocytes and Clara cells, may explain the 
lack of those restrictions in target cells for exJSRV infection (Palmarini et al., 2000b). 
 
1.4 Oncogenesis by retroviruses 
 
Carcinogenesis is one of the possible outcomes of retroviral infection. The first report 
of transmission of cancer by cell-free filtrates was published in 1908. Ellermann and 
Bang studied erythro-myeloblastic leukaemia in chickens caused by what was later 
identified as myeloblastosis virus (AMV) (Maeda et al., 2008, Ellermann, 1908). In 
the 1980s research on human T-lymphotropic virus type-1 (HTLV-1) provided the 
first evidence of retrovirus mediated cancer among humans (Yoshida et al., 1982). 
Retroviruses can be divided into acute transforming viruses and non-acute 
transforming retroviruses, depending on the mechanism of tumourigenesis, as 
described below. 
 
Moreover, some retroviruses cause immunosuppression which supports the 
development of cancer through various mechanisms. For example HTLV-1 Tax 
impairs the immune system by upregulation of the NFκB pathway and destabilisation 
of interleukin expression including upregulation of immunosuppressive IL-13 (Currer 
et al., 2012). MMTV is able to induce the expression of immunosuppressive IL-10 in 
B-cells by signalling through Toll-like receptor 4 (Jude et al., 2003). A significant 
portion of the AIDS-affected population develops some kind of cancer due to 
depletion of CD4+ cells and chronic immune system activation. Moreover, AIDS 
patients are extremely prone to other oncogenic viruses such as Kaposi’s sarcoma 
herpes virus (Bellan et al., 2003, Dalgleish and O'Byrne, 2002). 
 
1.4.1 Acute transforming viruses 
 
Acute transforming viruses cause transformation due to the presence of host-derived 
oncogenes captured in their genome. Animals infected with acute-transforming viruses 
are affected by transformation within days to weeks after infection (Maeda et al., 
2008). Acute transforming viruses are often replication defective unless the same cell 
becomes superinfected by a replication competent helper virus. 
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The first viral oncogene to be described was V-Src which is responsible for inducing 
cancer by Rous Sarcoma Virus (RSV) (Stehelin et al., 1976). The homology between 
V-Src and cellular Src led to the definition of proto-oncogenes (Stehelin et al., 1976). 
Depending on their mechanism of interaction, proto-oncogenes are classified into the 
following groups: receptor tyrosine kinase, non-receptor tyrosine kinase, 
serine/threonine kinase, transcription factor, cyclins, G-protein and growth factor 
(Rosenberg, 1997; Maeda et al. 2008). Proto-oncogenes can be any protein involved in 
the control of cell growth and differentiation. Their capture into the viral genome is 
caused by cross packaging of an expressed cellular host-gene, which later during 
reverse transcription recombines and leads to the emergence of a hybrid RNA. This 
process often results in creation of a replication-defective virus, which needs a helper 
virus for its replication. The helper virus is responsible for provision of viral proteins 
in order to form the virion, which packages RNA of the replication-defective virus 
(Muriaux and Rein, 2003). 
 
1.4.2 Non acute transforming retroviruses 
 
These viruses are carcinogenic due to insertional mutagenesis (see Fig. 1.9). The 
integration of provirus into the host genome may alter the expression of cellular genes. 
In cases when the genes affected are responsible for cellular growth and proliferation 
control, this may result in oncogenic transformation several months or years          
post-infection (Pedersen, 2010). 
 
Proviral integration may impact on the expression of genes defined as cellular proto-
oncogenes (Fig. 1.9). This is the mechanism of oncogenesis exhibited by non-acute 
transforming retroviruses. This process may affect loci present a long distance from 
the provirus (Singhal et al., 2011, Uren et al., 2005). The in vivo transformation is a 
rare event and often requires multiple infection events, which is why non-acute 
transforming viruses in general do not promote transformation in vitro (Pedersen, 
2010).  
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Fig. 1.9 Mechanisms of activation of cellular proto-oncogenes 
(A) Insertion of promoter (B) U3 enhancer activation (C) Read-through transcription resulting 
in chimeric transcripts causing expression of proto-oncogenes fused with viral genes (D) 
Disruption of the 3’ end of a cellular oncogene results in upregulated expression due to the 
presence of a polyadenylation signal located in the viral LTR. Figure adapted from (Maeda et 
al., 2008). 
 
1.4.3 Mechanism of transformation induced by JSRV 
 
JSRV represents a group of acutely transforming trans-activating retroviruses, whose 
main feature is the presence of viral oncogenes unrelated to cellular sequences. In the 
case of JSRV, Env is responsible for oncogenesis and it was demonstrated that 
expression of this glycoprotein alone causes transformation in vitro (Maeda et al., 
2001, Rai et al., 2001) and in vivo (Caporale et al., 2006, Wootton et al., 2005). 
Various cell lines and tissues from different species can be transformed by JSRV Env 
expression (Maeda et al., 2001, Wootton et al., 2006a, Rai et al., 2001, Maeda et al., 
2005). The transformation mechanism is based on the triggering of protein kinase 
signalling cascades involved in cellular proliferation. 
 
The VR3 region located in the cytoplasmic tail domain of TM is a major determinant 
of the transformation potential of Env (Palmarini et al., 2001b, Fan et al., 2003). The 
YXXM motif present in VR3 interacts with a signalling pathway mediated by PI3K 
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(phosphatidyl inositol 3-kinase) - Akt. Disruption of this motif by mutation of tyrosine 
(Y590D) abolished the transformation potential. The exJSRV Env shares high 
similarity to enJSRV Env, except in the VR3 domain of TM where the YXXM motif 
is not present in enJSRV, which explains the lack of transformation potential of 
enJSRV (Fan et al., 2003). 
 
It has been suggested that the SU domain of JSRV Env also plays a role in 
tumourigenesis by binding with Hyal-2 (Danilkovitch-Miagkova et al., 2003). The 
deletion of the Hyal-2 gene is often observed in human lung cancer (Rai et al., 2000, 
Rai et al., 2001). Experiments on the human epithelial cell line BEAS-2B showed 
JSRV Env mediated downregulation of Hyal-2 control on RON tyrosine kinase 
signalling (Danilkovitch-Miagkova et al., 2003). 
 
The activation of the mitogen-activated protein kinase ERK signalling pathway was 
demonstrated as an alternative JSRV transformation mechanism (De Las Heras et al., 
2006). The alternative cellular signalling pathways proposed to have a role in JSRV 
transformation are presented in Fig. 1.10. 
 
Since JSRV Env is a powerful oncogene, the mechanism of OPA carcinogenesis is 
unlikely to be connected with insertional mutagenesis or oncogene transduction 
(Cousens et al., 2004). However, the analysis of natural OPA cases, revealed the 
occurrence of a common JSRV integration site on chromosome 16, which may suggest 
a role for insertional mutagenesis in some cases of OPA (Cousens et al., 2004, Philbey 
et al., 2006). 
 
Sprouty2 has been described as a tumour suppressor because its overproduction 
decreases nodule growth and motility of transformed cells (Chitra et al., 2010). While 
the direct interaction of Sprouty2 with JSRV Env has not been described, it is 
suggested that the oncostatic mechanism is based on the interference with the same 
signalling pathway that is utilised by Env (Chitra et al., 2010). 
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Fig. 1.10 Mechanisms of JSRV/ENTV transformation 
The Ras-MAPK and PI3k transformation pathways have been shown to play a role in JSRV 
Env mediated transformation (Maeda et al., 2005, Hull and Fan, 2006). Hsp90 and Src may 
play a role in JSRV transformation (Varela et al., 2008). Rac1 has been identified to play role 
in both JSRV-1 and ENTV-1 transformation (Maeda and Fan, 2008). Sprouty2 has been 
reported to interfere with some of the transformation pathways (Chitra et al., 2010). Figure 
adapted from (Maeda et al. 2008). 
 
1.5 Restriction factors 
 
Cellular resistance to retroviral infection is determined by host proteins known as 
restriction factors. Many sophisticated intracellular mechanisms that inhibit 
retroviruses at various stages of their replication have been described. Several 
restriction factors have been identified and include APOBEC3 (Harris et al., 2003), 
TRIM5α (Stremlau et al., 2004), tetherin (Neil et al., 2008), SAMHD1 (Hrecka et al., 
2011, Laguette et al., 2011) and others (Liu et al., 2011, Marno et al., 2014), which 
were initially identified during studies on HIV-1 and SIV. They have been described 
as a part of innate immunity and determine the specificity of viral infection at the 
cellular level. A high throughput screen has been performed to identify potential   
HIV-1 restriction factors using small-interfering RNA (siRNA), which has identified 
114 genes with significant capability to inhibit infection (Liu et al., 2011). Therefore it 
is possible that additional retroviral restriction factors may yet be discovered. 
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In response, retroviruses have developed evasion strategies to counteract cellular 
restriction factors in a similar way as escape mutants evading the host immune 
response (Sawyer et al., 2005). In the process of co-evolution, retroviruses, as well as 
their hosts, are continuously developing and improving these mechanisms. The study 
of these viral-host interactions may enable the creation of vaccines and drugs against 
persistent retroviral infections (Huthoff and Towers, 2008). 
 
1.5.1 APOBEC 
 
APOBEC (apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like) 
proteins belong to a family of activation-induced cytidine deaminase (AID) molecules, 
which are able to edit nucleic acids by changing cytosine to uracil. This family 
consists of activation-induced cytidine deaminase (AID) and APOBEC1 (A1); 
APOBEC2 (A2), APOBEC3 (A3), APOBEC4 (A4) molecules. AID activity has been 
described to be responsible for generating antibody diversity in activated B-cells 
(Muramatsu et al., 1999). The cytidine deamination activity of APOBEC was initially 
discovered in A1, which edits apoB mRNA at a specific site in gastrointestinal tissues 
(Chester et al., 2000). Subsequently, A1 and A3 family members were shown to 
inhibit replication of various viruses in contrast to AID and A2 whose antiviral activity 
has not been documented (Ikeda et al., 2011, Koito and Ikeda, 2013). 
 
1.5.1.1 Apobec3 restriction 
 
Mammalian A3 genes are located between conserved flanking genes CBX6 and CBX7 
(see Fig. 1.11). Each A3 gene encodes a protein which includes one or two zinc-
coordinating motifs denoted Z1, Z2 or Z3, which are responsible for cytidine 
deaminase activity. The number of A3 proteins varies between species from one in 
mice to seven in primates (Harris and Liddament, 2004, Jonsson et al., 2006). There 
are three A3 genes present in the ovine genome and these encode four proteins: A3-Z1, 
A3-Z2, A3-Z3 and A3-Z2Z3, which is a fusion protein formed by alternative splicing 
of the Z2 and Z3 genes (LaRue et al., 2008). 
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Fig. 1.11 Schematic representation of mammalian APOBEC3 loci 
Adapted from (LaRue et al., 2008, LaRue et al., 2009). Mammalian APOBEC genes are 
flanked by genes CBX6 and CBX7. Each APOBEC3 gene encodes a protein including one or 
two zinc-Coordinating motifs Z1 (green), Z2 (yellow) or Z3(blue). 
 
The deamination of cytidines during reverse transcription converts these nucleotides to 
uracil, which results in G to A mutations on the positive sense retroviral DNA and in 
consequence leads to integration of a defective provirus or to degradation of viral 
DNA (Harris and Liddament, 2004, Bishop et al., 2008). The degradation of DNA is 
based on the detection and removal of uracils by UNG2 (Uracil DNA Glycosylase), 
resulting in the emergence of abasic sites which render the DNA molecule prone to 
other nucleases such as APEX1, TREX1, DNAse 1 and 2 (Stenglein et al., 2010). 
 
In addition to the cytidine deaminase-mediated hypermutation, A3 family proteins 
inhibit viral replication through additional mechanisms. Some A3 proteins act to 
inhibit reverse transcription in a dose dependent manner regardless of the cell type 
(Bishop et al., 2008). Those mechanisms of A3 mediated restriction are shown 
in Fig. 1.12. 
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Fig. 1.12 Restriction mechanism of APOBEC3 
A primary infected cell (left) packages A3 into virion progeny. A3 activity is exhibited during the 
next round of infection (right). The antiviral mechanism of A3 is based on the enzymatic 
inhibition of reverse transcription or cytidine deamination which leads to editing of newly 
synthesized DNA (hypermutation). In consequence it may lead to degradation of viral DNA or 
integration of attenuated provirus. 
 
A3 is packaged into retrovirus virions during assembly and its activity is exhibited 
during infection of the next target cell at the reverse transcription step (Huthoff and 
Towers, 2008). In addition to retroviruses, A3 proteins are able to edit the genetic 
material of other parasitic elements including hepadnaviruses (Turelli et al., 2004), 
retrotransposons (Koito and Ikeda, 2013), parvovirus, adeno-associated virus 
(Narvaiza et al., 2009), herpesviruses (Suspene et al., 2011) and human papillomavirus 
(Vartanian et al., 2008). 
 
There are many unresolved questions about the biology of A3 proteins and it is still 
not known how A3s distinguish host from non-self ssDNA. It has been suggested that 
human A3 proteins may be oncogenic; for example, C to T mutations in breast cancer 
cells are likely to be caused by A3B (Burns et al., 2013, Nik-Zainal et al., 2012, Taylor 
et al., 2013, Nowarski and Kotler, 2013, Demorest et al., 2011). 
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1.5.1.2 Structural features of APOBEC3 
 
All APOBEC3 proteins include one or two cytidine deaminase domains, which 
coordinate a zinc ion by a histidine and two cysteines, while a glutamate is predicted 
to promote the formation of a hydroxide ion that is essential for deamination (Harris 
and Liddament, 2004, Navarro et al., 2005). A3 proteins are classified into A3-Z1,  
A3-Z2 and A3-Z3 depending on their cytidine deaminase domain amino acid 
specificity. All A3 proteins are characterized by the specific consensus amino acid 
sequence in their Z-motifs which is HxEx(24-31)Cx(2-4)C (where x can be any 
residue) (LaRue et al., 2008, LaRue et al., 2009). A unique feature of Z1 domains is 
the isoleucine adjacent to a conserved arginine which is present in all DNA 
deaminases (Chen et al., 2008).  
 
Z2 domains possess a unique tryptophan-phenylalanine motif located five residues 
after the (pseudo)catalytic glutamate. Z3 domains contain the unique TWSPCx(2-4)C 
zinc-coordinating motif, while the Z1 and Z2 domains include a SWS/TPCx(2-4)C 
motif (LaRue et al., 2009). 
 
 
Recently high resolution structures have been published of the cytidine deaminase 
domains of human A3A (Byeon et al., 2013), A3C (Kitamura et al., 2012), A3F (Bohn 
et al., 2013) and A3G (Chen et al., 2008, Li et al., 2012). The crystal structures 
analysed by X-ray and NMR revealed globular proteins containing six α-helices and 
five β-sheets forming a specific motif (α1-β1-β2/2’-α2-β3-α3-β4-α4-β5-α5-α6) (Chen 
et al., 2008, Vasudevan et al., 2013, Li et al., 2012). 
 
1.5.1.3 Evasion of APOBEC3 by retroviruses 
 
Many retroelements have developed strategies to inhibit restriction of their host’s A3 
factors. Notably, these evasive mechanisms may not work in the presence of A3 
proteins from other species, even if they are closely related. For example, the study of 
vif deletion mutants revealed that HIV and SIV Vif acts as an adaptor protein and 
directs A3G to ubiquitin-dependent proteasomal degradation (Yu et al., 2003). 
Similarly, the Bet protein of primate foamy virus is responsible for escape from A3 
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restriction (Perkovic et al., 2009). Simple retroviruses such as MLV and MPMV do 
not encode a Vif protein, although they are resistant to their host’s A3. MLV encodes 
a glycosylated Gag protein that enhances capsid integrity and in consequence protects 
the reverse transcription complex from A3 (Stavrou et al., 2013). MPMV poorly 
incorporates A3 of rhesus monkey into virions. However, murine A3 binds to MPMV 
Gag efficiently, and restricts its replication (Doehle et al., 2006). 
 
Recent findings indicate that the species-specificity of the antiviral activity of A3 
needs to be revaluated since there are some reports of the natural host A3 inhibiting 
viral replication. A3 proteins of the natural host have been shown to restrict equine 
infectious anemia virus (EIAV) (Zielonka et al., 2009) and MLV (Takeda et al., 2008, 
Stieler and Fischer, 2010). The restriction of MMTV by mouse A3 was demonstrated 
by challenge of animals with knockdown of this gene (Okeoma et al., 2007, Ross, 
2009). Moreover, it was proven that various A3 alleles present in the different murine 
strains influence MMTV resistance (Okeoma et al., 2009b). Also, in humans an A3G 
haplotype has been reported that correlates with increased probability of HIV-1 
infection (Valcke et al., 2006). 
 
Much of the data on A3 activity against retroviruses comes from in vitro 
overexpression studies. However, it is possible that such experimental systems can 
produce artefactual results. Therefore, there is a need for further investigation to 
determine whether restriction factors are expressed in vivo at a level that is required 
for effective restriction. In addition, the differential cell and tissue expression patterns 
play a role in the significance of restriction by the different kinds of A3 proteins 
(Stavrou et al., 2014). It has been demonstrated that the distribution of expression and 
the activity function of human A3G and A3F varies between cell subsets and tissues, 
and may be induced by cytokines such as interferon-α (IFNα) in dendritic cells (DC) 
and macrophages (Koning et al., 2009). Administration of LPS (lipopolysaccharide) to 
mice increased the level of IFNα, which resulted in the upregulation of A3, TRIM and 
tetherin expression and in consequence enhanced resistance to MMTV (Okeoma et al. 
2009b). In the same experiment an increased ratio of MMTV-restrictive mature 
dendritic cells (mDC) to immature DCs (iDC) was detected. This is significant since 
DC are the primary cells infected by MMTV (Okeoma et al., 2009a). 
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1.5.2 Tetherin 
 
Research conducted on HIV carrying a deletion of the regulatory gene vpu (HIVΔvpu) 
revealed the presence of a restriction factor that prevents viral particle release. Due to 
the mechanism of its action this factor was called tetherin (Neil et al., 2008, McNatt et 
al., 2013). Tetherin has subsequently been shown to restrict numerous enveloped 
viruses including retroviruses, filoviruses, influenza virus (Jouvenet et al., 2009), 
flaviviruses, rhabdoviruses (Weidner et al., 2010), arenavirus and herpesvirus families 
(Evans et al., 2010). 
 
1.5.2.1 Tetherin restriction mechanism and its structure 
 
Tetherin, also called BST-2, CD317 or HM1.24, is a type II transmembrane protein 
(Neil et al., 2008, Hammonds et al., 2012a). Its N-terminus is in the cytoplasm, and its 
internal ectodomain is attached to the membrane by a C-terminal 
glycosylphosphatidylinositol (GPI) membrane anchor (see Fig. 1.13) (Hammonds et 
al., 2012b). 
 
 
 
Fig. 1.13 The structure of tetherin  
Tetherin contains transmembrane (TM) and glycophosphatidylinositol (GPI) membrane 
anchors placed within the membrane. Extracellular CC - coiled coil domain; potential N-linked 
glycosylation sites are marked; Y - tyrosine residues present in endocytic motif are highlighted 
in red. Highlighted cysteines (green) are involved in the creation of disulfide links which permit 
dimerization. Numbers represent the residue location in human tetherin. Model based on 
(Hammonds et al., 2012b). 
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The cytoplasmic domain is responsible for interaction with cytoskeletal actin. The 
internal domain’s cysteine and α-helical structures enable dimerisation of tetherin. 
Potentially, the inhibition of viral release by tetherin occurs by holding of fully formed 
virions to the cell surface which prevents their release and spread (Neil et al., 2008). 
Virions can also be internalized by endocytosis and undergo degradation mediated by 
RING-type 3 ubiquitin ligase (Evans et al., 2010). 
 
1.5.2.2 Restriction of JSRV by tetherin 
 
Two forms of tetherin are expressed by sheep, denoted BST-2A and BST-2B, both 
restrict exJSRV, enJSRV and ΔvpuHIV (Arnaud et al., 2010). The ovBST-2B is less 
restrictive than ovBST-2a and this may be explained by the lack of a GPI anchor in 
ovBST-2B (Arnaud et al., 2010). The interaction between enJSRV and tetherin may be 
relevant to the function of the sheep placenta. Placental morphogenesis of the sheep 
embryo is dependent on enJSRV expression (Dunlap et al., 2006b). During early 
pregnancy, enJSRV expression is regulated by interferon tau production. Interferon tau 
elevates the production of tetherin in the ovine trophoblast, mainly in the endometrial 
stromal cells. However, in luminal and glandular epithelial cells, the lack of tetherin 
may explain high enJSRV expression. These results correlate with the finding that the 
cells responsible for exJSRV replication lack tetherin expression (Arnaud et al., 2010). 
 
Several mechanisms for evading tetherin activity have been described (Neil et al., 
2008, Evans et al., 2010, McNatt et al., 2013). HIV-1 Vpu was identified as a factor 
responsible for escape from tetherin restriction by the interaction between the 
transmembrane domains of these two proteins (Neil et al., 2008). This leads to cellular 
internalisation, resulting in abrogation of tetherin’s antiviral properties by the 
downregulation of its levels on the cell surface (Neil et al., 2008, Evans et al., 2010, 
McNatt et al., 2013). Both SIV and HIV-2 Env reduce the BST-2 activity by binding 
to its exodomain, which causes endocytosis of the Env-BST-2 complex and its 
degradation (Douglas et al., 2010). SIVmac Nef inhibits BST-2 by interaction with a 
GDIWK motif present in the cytoplasmic domain of BST-2. Human BST-2 does not 
include this five amino acid fragment which may explain its restrictive character 
towards SIVmac (Douglas et al., 2010). FIV Env shields the budding virus from a 
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potentially restrictive tetherin; however in this case the tetherin also is a cofactor 
required for optimal particle release during budding (Morrison et al., 2014). 
 
1.5.3 TRIM5 
 
Tripartite motif protein 5α (TRIM5α or T5α) is a major post-entry determinant for the 
host range of retroviral infection (Huthoff and Towers, 2008). Its antiretroviral 
properties were discovered during a study on the orthologue from rhesus macaque, 
which potently inhibited HIV replication (Stremlau et al., 2004, Sodroski, 2004). 
MPMV, which naturally infects old world monkeys, has been shown to be restricted 
by T5α of new world primates including squirrel monkey and tamarin monkey (Diehl 
et al., 2008). 
 
1.5.3.1 TRIM5 structure 
 
T5 proteins have a number of conserved domains collectively denoted (RBCC): a 
RING domain, 1 or 2 B-boxes and a coiled coil. Because of alternative splicing, 
several isoforms of T5 may be expressed, but only T5α exhibits antiretroviral activity, 
due to the presence of a C-terminal PRY/SPRY, or B30.2 domain. Features of T5α 
structure are shown in Fig. 1.14. 
 
 
 
 
Fig. 1.14 Composition of TRIM5α domains 
N terminal RBBC domains are fused to the C-terminal B30.2 domain by the L2 (linker 2 
peptide). 
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The RING (Really Interesting New Gene) domain contains from 40 to 60 amino acids 
and is present in approximately 600 human genes (Deshaies and Joazeiro, 2009, 
Francis et al., 2013). The RING domain located at the N-terminus of T5 proteins has a 
zinc-coordinating motif and possesses E3 ubiquitin ligase activity, which mediates the 
proteasomal degradation of viral capsids (Stremlau et al., 2004). This is the main, but 
not the only, mechanism of T5α restriction because deletion of the RING domain 
significantly decreases but does not abolish huT5α activity against N-MLV (Perez-
Caballero et al., 2005). 
 
The B-Box domain of T5 is involved in the multi-oligomerisation of the molecule and 
subsequently, the creation of cellular bodies (Li and Sodroski, 2008). Mutations of the 
B-Box domain that prevent formation of multimerised organised structures decrease 
the restrictive character of rhT5 although not to the same degree for all retroviruses (Li 
and Sodroski, 2008). The coiled coil and linker peptide 2 domains enable dimerisation 
of T5α, which enhances its ability to bind CA and to restrict replication (Langelier et 
al., 2008). 
 
The B30.2 domain binds viral capsids and in this sense it acts as a pattern recognition 
receptor for retroviral capsids (Huthoff and Towers, 2008). Notably, this interaction is 
highly species and virus specific and even a single amino acid substitution in the viral 
capsid protein may significantly change its susceptibility to T5α inhibition. Similarly, 
often the mutation of one residue in the B30.2 PRY/SPRY v1 variable region can 
cause a switch in the specificity of T5α restriction (Diaz-Griffero et al., 2008). 
 
It has been demonstrated that various T5α alleles may have different antiviral 
functions (Goldschmidt et al., 2006, Rahm et al., 2013). The most common human 
T5α alleles are not protective against HIV, although haplotypes associated with the 
slower progression of the disease have been identified (Goldschmidt et al., 2006, 
Rahm et al., 2013). 
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1.5.3.2 TRIM5 restriction mechanism 
 
T5α function is not yet fully understood although it appears to induce premature 
dissociation of viral cores by promoting their proteasomal degradation (Diehl et al., 
2008). However, inhibition of proteasomal degradation does not completely abolish 
the antiretroviral activity of T5α, which suggest the presence of additional restriction 
mechanisms (Diaz-Griffero et al., 2008). 
 
The owl monkey is the only New World Primate that restricts HIV-1 infection 
(LaBonte et al., 2002, Stremlau et al., 2004); (Sayah et al., 2004), It appears that this 
resistance is caused by the unique Cyclophilin A which is a part of T5 and 
CyclophilinA (TRIMCyp) fusion protein, which is responsible for HIV-1 CA binding. 
The structural difference between T5α and TRIMCypA is based on the substitution of 
the B30.2 domain with CypA (Sayah et al., 2004). Feline T5 does not contain       
PRY-SPRY capsid-binding domain and therefore has no restriction potential against 
retroviruses (McEwan et al., 2009, Koba et al., 2013). 
 
In addition to its direct antiviral effects, T5α can also trigger innate immune responses 
in infected cells. In this way it may act additionally as a pattern recognition receptor, 
responsible for sensing of viral infection (Pertel et al., 2011, de Silva and Wu, 2011). 
By its connection with the E2 ubiquitin-conjugating enzyme complex               
UBC13-UEV1A, T5α has the potential to activate the TAK1 kinase complex, which 
mediates the immune response by stimulation of expression of NF-κB and MAPK 
inflammatory genes (Pertel et al., 2011, de Silva and Wu, 2011). 
 
In addition to the well-characterised post-entry activity of TRIM5, there is some 
evidence that T5α may also inhibit late steps of retroviral replication. Both the rhesus 
monkey T5α and African green monkey TRIM5α can inhibit HIV-1 Gag production 
by targeting this polyprotein precursor to degradation (Sakuma et al., 2007). 
Moreover, a cleaved form of rhT5α is encapsidated in HIV-1 viral particles suggesting 
the possibility that it has additional antiviral functions (Sakuma et al., 2007). 
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1.5.3.4 TRIM5 proteins among ruminants 
 
T5 has been extensively studied in primates, but relatively little is known in other 
species. Due to their number and the rapid evolution of TRIM genes it is difficult to 
define which genes are actually the true homologues (Si et al., 2006, Han et al., 2011, 
Malfavon-Borja et al., 2013). 
 
One of the bovine T5 proteins has been shown to restrict HIV-1 and N-tropic MLV (Si 
et al., 2006). Recently a number of goat and sheep T5 alleles have been described 
(Jauregui et al., 2012). The Ov1 and Ov2 variants of sheep T5α exhibited inhibition of 
MVV in contrast to the Ov4 allele which did not restrict MVV (Jauregui et al., 2012). 
 
1.5.3.5 Properties of other TRIM family proteins 
 
There are nearly 100 TRIM genes present in the human genome and a significant 
proportion of these are synthesised as multiple isoforms (Reymond et al., 2001, Han et 
al., 2011). The representatives of this family of proteins take part in various cellular 
processes, including cellular differentiation, apoptosis, oncogenesis, proliferation and 
innate immunity (Grutter and Luban, 2012). 
 
In addition to T5α, there are several other TRIM proteins that restrict retroviruses. 
Extensive analysis of the human and mouse TRIM families of proteins has identified 
inhibitors of HIV, N-MLV and B-MLV (Uchil et al., 2008). The expression patterns of 
feline TRIM proteins and their IFN-mediated upregulation has been reported (Koba et 
al., 2013). These studies showed that TRIM11, TRIM15 and TRIM31 inhibited 
retroviral entry. However, interestingly gene silencing of TRIM25, TRIM31 and 
TRIM62 interfered with viral release, suggesting their role in virus replication (Uchil 
et al., 2008). TRIM1 was shown to restrict N-MLV but not as effectively as T5α (Yap 
et al., 2004). 
 
TRIM28 is able to acetylate HIV-1 integrase within the PIC and subsequently inhibits 
the integration of provirus (Allouch et al., 2011). Moreover, it has been shown that 
TRIM28 protects mouse embryonic stem cells by binding to the MLV PBS, thereby 
preventing transcription from the proviral LTR (Wolf and Goff, 2007). TRIM22 
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localised in the nucleus acts as an inhibitor of HIV-1 transcription suppressing the 
HIV-1 LTR promoter mediated gene expression (Kajaste-Rudnitski et al., 2011, Barr 
et al., 2008). 
 
1.5.4 Restriction of retroviruses by SAMHD-1 
 
SAMHD1 (SAM domain and HD domain-containing protein 1) is a recently 
discovered restriction factor that inhibits retroviral replication in myeloid cells and 
macrophages (Laguette et al., 2011). Its antiviral activity is based on the reduction of 
the total pool of dNTPs that are present in the cytoplasm, which in consequence may 
interfere with the process of reverse transcription. SAMHD1 is an enzyme that 
exhibits phosphohydrolase activity, converting nucleotide triphosphates to a 
nucleoside and triphosphate. In doing so, SAMHD1 depletes the pool of nucleotides 
available to reverse transcriptase for viral cDNA synthesis and thus prevents viral 
replication (Lahoussa 2012). The Vpx proteins of HIV-2 and SIVagm enable the 
successful evasion of SAMHD1 activity (DeLucia et al., 2013). SAMHD1 is involved 
in HTLV-1 restriction by the emergence of transcription intermediates, which direct 
primary human monocytes to IRF3-mediated antiviral responses and apoptosis (Sze et 
al., 2013a). Moreover, it has been suggested that SAMHD1 plays a role in the immune 
sensing of retroviral infection (Sze et al., 2013b). 
 
1.6 Retroviral vectors 
 
Retroviral vectors can also be used to investigate infection mechanisms and various 
steps of viral replication. For example, there is no permissive cell culture system 
available for JSRV, partially because the JSRV LTR has low activity in the cultured 
cell lines tried to date (Palmarini et al., 2000a, Griffiths et al., 2010). Retroviral 
vectors based on JSRV are a powerful tool in the investigation of viral host-cell 
interactions that are present in OPA. Many aspects of OPA biology and pathogenesis 
have been revealed by utilisation of an infectious molecular clone of JSRV denoted 
pCMV2JS21 (Fig. 1.15) (Palmarini et al., 1999).  
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Fig. 1.15 Features of pCMV2JS21 
The plasmid pCMV2JS21 contains an infectious molecular clone of the exogenous JSRV21 
isolate (Palmarini et al., 1999). Figure adapted from (Maeda et al., 2001, Hofacre and Fan, 
2010). 
 
When pCMV2JS21 JSRV is introduced into producer cells by transfection, JSRV 
expression is under the control of the CMV immediate early promoter and results in 
the production of viral particles with the same structure and genome as wild-type 
JSRV (Palmarini et al., 1999). 
 
Retroviruses may be used to efficiently transduce target cell lines providing long-term 
and stable gene transfer even after several rounds of cell division (Durand and 
Cimarelli, 2011). Retroviral vectors are able to carry inserted genes up to 20kb (Shin 
et al., 2000). However, in practice the capability of retroviral vector RNA is limited to 
8kb because of the errors that occur during viral replication. In addition to their 
application in cell culture, retroviral vectors allow transduction of genes in vivo; for 
example, for use in gene therapy or in the creation of transgenic animals (Pages and 
Bru, 2004). 
 
Potential applications of retroviral vectors include expression of therapeutic 
recombinant proteins or siRNA molecules, targeted gene repair by homologous 
recombination, and vaccination either by antigens displayed in the vector virus or by 
expression of an immunogenic transgene (Mühlebach, 2010). Up to June 2014 
retroviruses had been used in approximately 406 clinical gene therapy trials 
(wiley.co.uk/genmed/clinical), which accounts for a significant part of the total 
number of gene therapy trials and is one of the most common methods of gene transfer 
to patients. Retroviral vectors’ advantage is their relatively low immunogenic 
character of the vector component compared to the more widely used adenovirus 
vectors which are more immunogenic due to pre-existing immunity (Mingozzi and 
High, 2013). 
  
pro 
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1.6.1 Safety of retroviral vectors 
 
Retroviral gene therapy has been successfully used as a treatment for a number of 
diseases including SCID (severe combined immunodeficiency) (Fischer et al., 2013) 
and GvHD (graft versus host disease) (Taflin et al., 2013). However, some trials have 
revealed the risk of cellular transformation induced by vector integration (Mühlebach, 
2010, Hacein-Bey-Abina et al., 2003). Due to the sequence similarity with endogenous 
retroviruses there is also a potential risk of recombination events leading to the 
emergence of replication competent virus (Donahue and Clark, 1992). There is also a 
possibility that vector particles might cross-package RNA from other retroviruses, 
which was documented as MPMV encapsidating HIV and SIV RNA (Al Shamsi et al., 
2010). This observation raises the question of whether there is a risk of creating 
recombinant replication-competent virus with pathogenic potential (Al Shamsi et al., 
2010). In order to improve vector safety, viral structural genes are provided in trans on 
a separate plasmid from the vector construct that carries the packaging signal and the 
transgene (Pages and Bru, 2004, Ismail et al., 2000). The further separation of env 
from gag-pol also increases the safety of a vector. 
 
Retroviral vector production may be based on transient transfection or stable gene 
expression in a producer cell line or a combination of both systems (Pages and Bru, 
2004). In order to maximize vector titre and safety, several systems have been 
developed. The development of self-inactivating vectors minimises the risk of 
insertional interference as in these constructs the enhancer elements in the U3 of the 
viral 3’LTR are deleted and transgene expression is driven by an internal promoter. 
The inclusion of splice sites in the vector greatly improves the level of transgene 
expression (Krall et al., 1996) and enables the removal of the packaging signal Ψ 
(Ismail et al., 2000). Localisation of the splice donor site in the 3’ LTR region and the 
splice acceptor site downstream of Ψ causes its removal in the target cell line during 
reverse transcription (Ismail et al., 2000). 
 
Vectors that remove all their genetic information other than the transgene may be 
created by the utilisation of site specific Cre recombinase which removes the sequence 
between LoxP sites (Pages and Bru, 2004). Furthermore, the utilisation of site specific 
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recombinases may enable insertion of the transgene in a precise locus (Artegiani and 
Calegari, 2013). 
 
Integration-defective lentiviral vectors have been developed in order to increase their 
safety by avoiding the potential risk of transformation. In addition integration-
defective lentiviral vectors, have reduced potential of silencing of the integrated 
transgene (Wanisch and Yanez-Munoz, 2009). Recently an integrase-deficient 
retroviral vector has been developed whose transgene insertion could only be achieved 
by locus targeted recombination (Huang et al., 2010). 
 
1.6.2 Features of retroviral vectors that enhance the efficiency of 
production and transduction 
 
There are several optional parts of a retroviral vector that enhance its production and 
the level of transgene expression (see Fig. 1.16). The addition of a lentiviral central 
polypurine tract (cPPT) greatly increases their transducing potential (Logan et al., 
2004). The presence of a cPPT enhances the efficient nuclear import of genetic 
material in non-dividing cells. The MPMV-derived cytoplasmic transport element 
(CTE) significantly enhances the export and stability of transcripts and allows the 
omission of Rev-like regulatory proteins from the vector production system (Pages 
and Bru, 2004). 
 
Fig. 1.16 Potential features present in a retroviral vector 
PBS - primer binding site; cppt – central polypurine tract; ppt - polypurine tract; +/- indicate 
features that are optional; ΔU3: deletion of transcriptional sequences within 3’ LTR. 
Reproduced from (Pages and Bru, 2004). 
 
The inclusion of picornaviral internal ribosomal entry site (IRES) mediating 5’ cap-
independent translation, enables the expression of two genes from a single RNA 
molecule (Martinez-Salas, 1999).  
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1.6.3 Retroviral vector pseudotyping 
 
Retroviral vector design enables the creation of viral particles containing structural 
proteins from the various kinds of retroviruses and a variety of envelope glycoproteins 
including those which originate from other viral families. Such utilisation of proteins 
from other viruses in a vector is referred to as pseudotyping. Such manipulations may 
enable gene transfer to be targeted to specific subsets of cells. Vesicular stomatitis 
virus envelope protein (VSV-G) is widely used in viral vector production due to the 
broad range of cell lines and organisms that allow its entry. Moreover, VSV-G is 
considerably more stable than some retrovirus Env proteins during ultracentrifugation 
and freezing (Burns et al., 1993). However, there are some disadvantages associated 
with VSV-G pseudotyping, such as cytotoxicity in the vector-producing cells. In 
addition, experiments with VSV-G pseudotyped vectors may result in the formation of 
tubulovesicular structures (TVS) during the preparation of viral stocks (Pichlmair et 
al., 2007). TVS may cause the carryover of DNA or induce immunomodulaion due to 
interaction with Toll like receptor 9 (Pichlmair et al., 2007). The Low-Density 
lipoprotein (LDL) receptor has been shown to mediate entry of VSV-G pseudotyped 
vectors (Finkelshtein et al., 2013). This explains the broad range of cell lines that are 
permissive for VSV-G pseudotyped virus entry, as the LDL receptor is ubiquitously 
expressed in various tissues and species (Finkelshtein et al., 2013). Additionally, a role 
for the endoplasmic reticulum chaperone protein gp96 in mediation of VSV-G 
enveloped virus entry had been described (Bloor et al., 2010). It should be noted that 
VSV-G pseudotyped vectors may enter the cell via a different pathway than the one 
mediated by Env, and this may influence early infection events. Therefore, it is worth 
conducting parallel experiments using natural envelope glycoprotein. 
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1.7 Aim of the project 
 
JSRV is primarily a sheep pathogen. Although it is also able to occasionally infect 
goats, it rarely results in clinical disease in this species. Recent data has provided 
evidence for restriction to JSRV in lung epithelial cells of goats although the precise 
mechanism is still unknown (Caporale et al., 2013b). Moreover, some cells are able to 
be infected by JSRV Env pseudotyped vectors (Rai et al., 2000) and a variety of cell 
lines from different species can be transformed by JSRV Env (Maeda et al., 2001, 
Alberti et al., 2002, Johnson et al., 2010). In order to examine the species specificity 
barriers of OPA, I studied the significance of A3 and TRIM5α in JSRV restriction. 
 
In this project I have investigated the impact of ruminant A3 proteins on JSRV 
replication (Chapter 3). Flow cytometry analysis of infected cells, sequencing of 
proviral sequences and reverse transcriptase assays provided insights into the 
mechanisms of A3 restriction of JSRV in vitro. Western blot assays on lung fluid from 
natural cases provided a significant contribution to understanding the role of A3 in the 
pathogenesis and epidemiology of OPA. In addition, I analysed the activity of human 
and murine A3 to investigate the possibility of using the mouse as an animal model for 
OPA (Chapter 4). 
 
TRIM5α was the second restriction factor investigated (Chapter 5). I made cell lines 
that stably express ruminant, rhesus macaque and human TRIM5α. Infectivity assays 
performed on these cells analysed the activity of various TRIM5α homologues against 
JSRV and HIV-1. These studies have extended the understanding of species specificity 
barriers of OPA and are relevant to speculation about connections between JSRV and 
human bronchioloalveolar carcinoma. The results obtained could contribute to the 
development of disease control strategies such as the creation of sheep that are 
resistant to OPA and provide important information for the potential utilisation of 
JSRV based vectors in gene therapy. 
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Chapter 2 – Materials and Methods 
 
  
58 
 
2.1 DNA plasmids  
 
2.1.1 pGEM-T Easy [Promega] 
 
 
 
Fig. 2.1 pGEM-T Easy plasmid map 
Red – MCS; green – LacZ ORF; blue – Beta-lactamase (AmpR); orange – Phage F1 region. 
 
2.1.2 pCI-Neo [Promega] 
 
        
Fig. 2.2 pCI-Neo vector map 
Grey – CMV promoter; red – MCS; green – SV40 polyadenylation signal; orange – Phage F1 
region; yellow – neomycin transferase (NeoR); blue – Beta-lactamase (AmpR). 
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2.1.3 pCMV2JS21 
 
Features of pCMV2JS21 are presented in Fig. 1.15. The rest of the plasmid is 
pBluescript which contains some sheep genomic DNA at 3’ end of provirus. 
 
2.1.4 pLNCX-2 [Clontech] 
 
Fig. 2.3 pLNCX-2 vector map  
orange – MLV 5’ and 3’ LTR; violet – psi plus packaging element; yellow – neomycin 
transferase gene (NeoR); grey – CMV promoter; red – MCS; blue – beta-lactamase (AmpR). 
 
2.1.5 pLPCX [Clontech] 
                                        
Fig. 2.4 pLPCX vector map 
Orange – MLV 5’ and 3’ LTR; violet – psi plus packaging element; yellow – puromycin 
resistance gene (PuroR); grey – CMV promoter; pink – LoxP site; red – MCS; blue – Beta-
lactamase (AmpR).  
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2.1.6 pEGFP-FLAG 
 
pEGFP-FLAG (made by David Griffiths) is a derivative of pEGFP-C1 [Clontech], 
produced by inserting a linker encoding a FLAG epitope tag and additional unique 
restriction sites immediately downstream of the Enhanced Green Fluoresent Protein 
(EGFP) ORF. 
 
 
Fig. 2.5 pEGFP-FLAG vector map 
Grey – CMV promoter; green - EGFP; red – MCS; blue – SV40 poly adenylation termination 
signal; orange – SV40 enchancer; yellow – neomycin transferase gene (NeoR). 
 
2.1.7 pVSV-G 
 
The pVSV-G contains the VSV envelope ORF inserted into pMDG [Addgene]. 
 
2.1.8 pCAG-JSEnv 
 
The pCAG plasmid [Addgene] modified by insertion of JSRV Env under the control 
of CAG promoter. 
 
2.1.9 pCMVJS-ΔE-CG 
 
pCMVJS-ΔE-CG (made by David Griffiths) is derived from pCMV2JS21, where the env gene 
was substituted by EGFP under the control of an internal CMV promoter. 
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Fig. 2.6 pCMVJS-ΔE-CG vector map 
Bright blue – beta-lactamase (AmpR); grey – CMV promoter; yellow – JSRV 5’ and 3’ LTR; red 
– JSRV gag; pink – JSRV pro; dark blue – JSRV pol; green – EGFP; orange – C terminal 
fragment of JSRV env. 
 
2.1.10 pCMV JSE SP-FLAG 
 
The pCMV JSE SP-FLAG is a derivative of pCMV3ΔGPJS21, which expresses only 
the SP peptide (encoded by the 5’ region of env) fused to a C-terminal FLAG epitope 
tag (Caporale et al., 2009). 
 
2.1.11 pIREShyg3 [Clontech] 
 
     
Fig. 2.7 pIREShyg3 vector map 
Pink – CMV promoter; green – EGFP; red – MCS; green – IRES (Internal Ribosome Entry 
Site); yellow – hygromycin resistance gene (HygR); orange – SV40 poly adenylation 
termination; blue – beta-lactamase (AmpR).  
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2.1.12 pCS-CG [Addgene] 
 
 
 
Fig. 2.8 pCS-CG vector map  
Grey – CMV promoter; yellow - HIV-1 LTR; violet – packaging signal (Ψ); red – Rev 
Responsive Element (RRE); green – EGFP; grey – SV40 promoter; dark green – bleomycin 
resistance gene (BleR) blue – Beta-lactamase (AmpR). 
 
2.1.13 pMDLg/pRRE  
 
 
 
Fig. 2.9 MDLg/pRRE 
Grey – CMV promoter; orange – beta globin intron; green – HIV gag; blue – central polypurine 
tract (CPPT); red – RRE (Rev Responsive Element); blue – Beta-lactamase (AmpR). 
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2.1.14 pCNC-Rev 
  
The pCNC-Rev plasmid provides the expression of Rev in mammalian cells (Ikeda et 
al., 2003). The expression of Rev from a separate plasmid enhances the safety of 
vector system. 
 
2.1.15 pHIT60 
 
The pHIT60 plasmid provides the expression of MLV Gag and Pol in mammalian 
cells (Markowitz et al., 1988). The expression of structural proteins from a separate 
plasmid enhances the safety of the vector system.  
64 
 
2.2 Primers 
 
Table 2.1 Oligonucleotide primers used in this project 
(F-forward; R-reverse) 
Primer Sequence 
A3Z1-F CTGCCGCTTGAACAACTTCAAGGAG (25) 
A3Z1-R TTGRATCAGTCTGGAGACAGTAGC (24) 
A3Z1-OA_Ex_F 
GATCGATCCTCGAGGCCACCATGGATGAAAACACCTTCACT
GAG (44) 
A3Z1-OA_ExHA_R 
GATCGATCGCGGCCGCTCAAGCGTAGTCTGGGACGTCGTA
TGGGTAGTTTTGCTGAGCCCTGAGAATG (68) 
A3Z1-BT_Ex_F 
GATCGATCGTCGACGCCACCATGGACGAATATACCTTCACT
GAG (44) 
A3Z1-BT_Ex_R 
GATCGATCGCGGCCGCTCAGTTTTGCTGAGTCTTGAGAAT
G (41) 
A3Z1-BT_ExHA_R 
GATCGATCGCGGCCGCTCAAGCGTAGTCTGGGACGTCGTA
TGGGTAGTTTTGCTGAGTCTTGAGAATG (68) 
A3Z2Z3-F ACAAAGGCCAGGGATGCAACCAGC (24) 
A3Z2Z3-R GGGATGAGAGTCTGATGCTCAAGC (24) 
A3Z2-F AGAGCCGGCCTGGGAGGTCACTC (23) 
A3Z2-R AGGCTGAGAAGGGAGGTAACRGTGG (25) 
A3Z3-Oa_ExF 
GATCGATCGTCGACGCCACCATGACGGAGGGCTGGGCTG
GATCAG (45) 
A3Z3-BT_Ex_F 
GATCGATCGTCGACGCCACCATGACCGAGGGCTGGGCTG
GGTCAG (45) 
A3Z2Z3-Ov-Exp-F 
GATCGATCGTCGACGCCACCATGCCCTGGATCAGCGACCA
CG (42) 
A3Z2-OA_Ex_R 
GATCGATCGCGGCCGCTCACCCGAGAATGTCCTCAAGCTC 
(40) 
A3Z2-Oa_ExHA_R 
GATCGATCGCGGCCGCTCAAGCGTAGTCTGGGACGTCGTA
TGGGTACCCGAGAATGTCCTCAAGCTC (67) 
A3Z2-OaBT_ExHA_R 
GATCGATCGCGGCCGCTCAAGCGTAGTCTGGGACGTCGTA
TGGGTACCCGAGAATGTCCTCAAGCTC (67) 
A3Z2-BT_Ex_F 
GATCGATCGTCGACGCCACCATGCCCTGGACCAGAGACTC
CAG (43) 
A3Z3-Oa_ExF 
GATCGATCGTCGACGCCACCATGACGGAGGGCTGGGCTG
GATCAG (45) 
A3Z3-BT_Ex_F  
GATCGATCGTCGACGCCACCATGACCGAGGGCTGGGCTG
GGTCAG (45) 
A3Z3-BT_Ex_R 
GATCGATCGCGGCCGCCTAAATTGGGGCCGTTAGGATCC 
(39) 
A3Z3-BT_ExHA_R 
GATCGATCGCGGCCGCTCAAGCGTAGTCTGGGACGTCGTA
TGGGTAAATTGGGGCCGTTAGGATCC (66) 
A3Z3-CAP_Ex_R 
GATCGATCGCGGCCGCCTAAGTTGGCGCTGTCAGGATCCT 
(40) 
A3Z3HA-CAP_Ex_R 
GATCGATCGCGGCCGCTAAGCGTAGTCTGGGACGTCGTAT
GGGTAAGTTGGCGCT (55) 
A3Z2Z3-Ov-Exp-R 
GATCGATCGCGGCCGCTCACTAAGTCGGCGCCGTCAGGAT
CCTCTG (46) 
A3Z2Z3HA-Ov-ExpR GATCGATCGCGGCCGCTCACTAAGCGTAGTCTGGGACGTC
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GTATGGGTAAGTCGGCGCCGTCAGGATCCTCTG (73) 
Z3xtF1 GGCTCTGCCAAGAGGGAGGGC (21bp) 
Z3xtR1  GTCCCTTATCTGAGAATGTTC (21bp) 
Z3xtF2 AGTCTTGCCAGGGYACTAAATGAC (24bp) 
Z3xtR2 AGAACTGGCATCGATACCTGGTC (23bp) 
TRIM-F1 GGCAGAATTTGAAAGATACACAAG (24bp) 
TRIM-R1 GTGTGTCAGATGTACTTACAGTAAG (25bp) 
Oa-TRIM-F-BCL 
GATCGATCTGATCAGCCACCATGGCTTCAGGAATCCTGATG
AAC (44bp) 
BtOa-TRIM-R 
GATCGATCGTCGACTCAACAGCTTGGTGAGCACATGTGCT
CACCAAGCTGTTGA (34bp) 
BtOa-TRIM-HA-R 
GATCGATCGTCGACTCAAGCGTAGTCTGGGACGTCGTATG
GGTAACAGCTTGGTGAGCACA (61bp) 
IRES-Hyg F 
GATCGATCGTCGACGGCGGTCGCACTAGAGGAATTC 
(36bp) 
IRES-Hyg R 
GATCGATCCTCGAGCTCTTGTTCGGTCGGCATCTACTC 
(38bp) 
Oa-TRIM-F-BCL 
GATCGATCTGATCAGCCACCATGGCTTCAGGAATCCTGATG
AAC (44bp) 
BtOa-TRIM-R GATCGATCGTCGACTCAACAGCTTGGTGAGCACA (34bp) 
IREShyg-F-Cla GATGGATCATCGATGGGCGGCCGCACTAGAGGAATTC (37) 
IREShyg-R-Bst GATCGATCTTCGAACTCTTGTTCGGTCGGCATCTACTC (38) 
1164 GFP F GTACGGTGGGAGGTCTATATAAGC (24) 
1164 GFP R AGCTCCCAGGACTTAACCCTTCAC (24) 
JS21EnvF GAATGAGGCACATGTACAACCTCC (24) 
JS21EnvR GCTGAGAGCCGTATTAATGCGTTG (24) 
CX-R TCTTTCATTCCCCCCTTTTTCTGG (24) 
LN-F GGTAGGCGTGTACGGTGGGAGGTC (24) 
IH-5-R  AAGCGGCTTCGGCCAGTAACGTTA (25) 
TRIM-R6 CCAAGTAGACATCTCTTCTCTGAC (24) 
TRIM-F3 GGTTCAGGTGACCCTGAATTCTC (23) 
TRIM-R3 TTCTYTGACACGTCTACCTCCCAG (24) 
TRIM-F2 CTCCAATCATGTCTGCAGAGGCTG (24) 
Primers and probes used for quantitative PCR 
P1 TGGGAGCTCTTTGGCAAAAGCC (22) 
P6  TGATATTTCTGTGAAGCAGTGCC (23) 
JSRV-T-FAM probe FAM-AGCAAACATCCGARCCTTAAGAGCTTTCAAAA-BHQ 
 
The alignments of primers which were used in cloning are shown (see Fig 3.3 to 3.6 
and Fig 3.4). The accession numbers of published TRIM5 and APOBEC3 sequences 
are shown in Table 3.1 and Table 5.1.
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 2.3 Molecular Cloning 
 
2.3.1 Preparation of competent cells 
 
A stationary phase culture of JM109 [Promega] was diluted 1:100 with 500 ml LB 
(Luria Bertani Broth) [Moredun Services], cultured until the optical density (OD) 
(λ = 600 nm) was 0.4-0.6 (typically 2-3 h), then incubated on ice for 10 min and 
centrifuged at 1800  g for 10 min at 4°C. The cells were suspended in 20 ml ice cold 
100 mM CaCl2, incubated on ice for 30 min, centrifuged at 1800  g for 10 min at 4°C 
and resuspended in 8 ml of ice cold 100 mM CaCl2 15% glycerol [Fisher Scientific]. 
Cells were then aliquoted to tubes, snap frozen and stored at -80°C for later use. In 
some cases commercial competent JM109 cells [Promega] were utilised. 
 
2.3.2 Transformation 
 
In order to transform bacteria, 50 µl of competent JM109 were mixed with 1 µl of 
plasmid DNA or ligation complexes and incubated on ice for 30 min. The cells were 
then incubated at 42°C for 50 s before placing on ice for 2 min. SOC medium (0.5 ml) 
[Sigma] was added and the cells incubated at 37°C for 30 min with shaking. Between 
50 µl to 200 µl of transformed bacteria were plated on LB-agar plates containing 
100 µg/ml ampicillin. 
 
2.3.3 Bacterial glycerol stocks 
 
Bacterial glycerol stocks were prepared for long term storage of desired transformed 
clones. Between 200 to 600 µl of overnight bacterial culture was mixed with glycerol 
to a final concentration of 15% Glycerol and stored at -80°C. 
 
2.3.4 Small scale DNA purification – Qiagen Miniprep kit 
 
DNA was purified from 5 ml of overnight culture using the Plasmid Mini kit [Qiagen] 
according to the supplier’s instructions. The DNA was eluted in 50 µl of water. This 
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kit is based on ion exchange chromatography where DNA binds to a silica column and 
after washes is eluted with water. 
 
2.3.5 Large scale DNA purification – Maxiprep plasmid purification 
 
For large scale purification of transfection grade plasmid DNA, the Endofree Maxi kit 
[Qiagen] was utilised, starting with 100 ml to 500 ml of stationary phase culture. The 
procedure was conducted according to the supplier’s manual. DNA was eluted using 
1 ml of water. 
  
2.3.6 Agarose gel DNA electrophoresis  
 
Agarose gel DNA electrophoresis was used to separate DNA by size. Agarose gels 
were prepared by solubilisation of agarose to a final concentration of 1% to 1.5% in 
TAE buffer (40 mM Tris acetate [Sigma] 1 mM EDTA [Sigma]. Ethidium bromide 
[Promega] was added to a concentration of 0.5 µM. Once set, the gel was put in an 
electrophoresis tank containing TAE buffer. Samples were prepared by adding 1/6 
volume of loading buffer (40% glycerol, orange-G [Sigma]) and were loaded and run 
on the gel alongside DNA size markers (Hyperladder I or Hyperladder IV [Bioline]). 
The DNA in the gels was visualised using a UV transilluminator [Uvi Tec]. 
 
2.3.7 Purification of DNA from agarose gels 
 
DNA was purified from agarose gel slices using a Qiagen Gel extraction kit, according 
to the manufacturer’s protocol with minor changes. In order to improve the yield of 
DNA, QG buffer was modified by addition of 500 µl 3 M sodium acetate per 20 ml 
QG. Agarose gel slices were dissolved by 30 min incubation at 50°C. After the DNA 
binding and washing steps, columns were centrifuged 40 s at 2000  g. DNA was 
eluted using water. 
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2.3.8 Restriction enzyme digestion of DNA 
 
Digestion of DNA was conducted in a reaction mixture containing the appropriate  
10 buffer [Roche or Promega] and restriction enzyme [Roche or Promega], which 
was incubated for 1 to 4 h at 37°C, with the exception of SwaI, which was incubated 
for at least one hour at 25°C. 
 
2.3.9 DNA ligation 
 
DNA was ligated using 3U of T4 DNA ligase [Promega] and the supplied buffer 
[Promega] in a reaction volume of 20 µl. DNA was added in a molar ratio of 3:1 
(insert to vector), the amount of vector used in a single reaction varied from 
5 to 50 ng. Ligation reactions were incubated overnight at room temperature. 
 
Alternatively, some ligations were performed using the Clonables 2 reagent [Merck], 
which was mixed with water and DNA. Those ligation reactions were incubated at 4°C 
to 12°C for 2 h. Prior to ligation, all digested plasmids were treated with shrimp 
alkaline phosphatase [Promega], in order to eliminate 5’ terminal phosphates, which 
minimised the probability of plasmid re-ligation and occurrence of vectors lacking the 
insert. Two units of shrimp alkaline phosphatase [Promega] was added at the end of 
digestion reaction and incubated at room temperature for 30 min, afterwards alkaline 
phosphatase was inactivated by 15 min incubation at 70°C. 
 
2.3.10 RNA extraction 
 
RNA was extracted from tissues or cultured cells using an RNAeasy kit [Qiagen] 
according to the supplier’s protocol. Prior to RNA extraction, cells were homogenized 
using a Qiashredder column [Qiagen]. For homogenization of tissue, samples were 
added to lysing matrix D tubes [MP Biomedicals] containing ceramic beads and 
processed in a Precellys 24 [Precellys] tissue homogenizer set to two rounds of 30 s at 
5000-6000 rpm separated by 2 min pause for 30 s. 
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2.3.11 DNA extraction from cells 
 
DNA was extracted from cells using the DNA Blood and Tissue kit [Qiagen] as 
recommended. DNA was eluted in AE buffer. 
 
2.3.12 Reverse transcriptase PCR (RT-PCR) 
 
One-step Superscript 2 Platinum Taq polymerase [Invitrogen] was used to amplify 
various genes from RNA. The volume of RT-PCR reaction was 25 µl, which 
contained 12.5 µl 2 supplied buffer, 100 U RT/Taq and a pair of primers, each in a 
concentration of 200 nM. Each reaction used as a template 50-400 ng RNA. Water 
[Sigma] was added to make the final volume of reaction mixture up to 25 µl. 
 
2.3.13 High fidelity DNA PCR 
 
KOD Polymerase [Novagen] was used to amplify DNA. Reactions were carried out in 
a volume of 50 µl, which contained 5 µl of the supplied KOD Polymerase 10 buffer, 
0.2 mM dNTPs [Novagen], 1 U KOD polymerase, 1-4 mM MgSO4 [Novagen] and a 
pair of primers, each at a concentration of 300 nM. As template either 1 ng of plasmid 
DNA or between 50-200 ng DNA purified from tissue or cells was used. 
 
2.3.14 Addition of ‘A’ overhangs 
 
KOD polymerase has a proofreading ability, therefore it produces blunt ended 
amplicons. In order to enable the ligation of KOD PCR products into pGEM-T Easy, 
adenosine overhangs were added using Flexi Taq Polymerase [Promega]. The reaction 
mixture contained gel-purified DNA and 0.2 mM dNTPs [Novagen], 5 U Flexi Taq 
Polymerase [Promega], 2.5 mM MgCl2 in a total volume of 100 µl and was incubated 
for 2 h at 72°C. 
 
2.4 Mammalian cell culture 
 
All mammalian cell lines (listed in Table 2.2) were cultured in T-75 flasks (vent-cap; 
Corning) at 37°C in a humidified incubator, with 5% CO2. In order to passage cells 
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they were washed using PBS and dispersed using 0.0125% trypsin [Moredun services] 
and Versene (3.2 mM EDTA) [Moredun services]. Since 293T cells are sensitive to 
digestion and relatively easy to disperse, the trypsin/versene mixture was diluted 
tenfold in PBS before use. 
 
2.4.1 Cell lines used in this project 
 
Table 2.2 Cell lines used in this project 
Cell line Species, cell type Medium
 
Reference 
293T Human, fetal kidney cells, A (Graham et al., 1977) 
CPT-Tert Sheep, fibroblasts, A (Arnaud et al., 2010) 
CRFK Cat, kidney; A (Crandell et al., 1973) 
CRFKovH2 
Cat, kidney, stably expressing 
sheep Hyal-2 
A This study 
BOMAC Cow, macrophages A (Stabel and Stabel, 1995) 
RK13C Rabbit, epithelial renal B (Beale, 1963) 
MDBK Cow, epithelial like A (Madin and Darby, 1958) 
TIGEF Goat, fibroblasts C (Da Silva Teixeira et al., 1997) 
 
A - Iscove's Modified Dulbecco's Medium (IMDM) [Sigma], 
     supplemented with 4 mM Glutamine and 9% FCS [Biosera] 
B - Minimum Essential Medium Eagle (MEME) [Sigma], 
     supplemented with 1% non essential amino acids [Sigma], 
     2 mM Glutamine [Moredun Services] and 9% FCS 
C - Dulbecco's Modified Eagle Medium (DMEM) [Sigma], 
     2 mM Glutamine and 9% FCS 
 
 
2.4.2 Transfection of mammalian cells 
 
Transfection was performed using Fugene-HD [Roche] as recommended. Briefly 
OptiMEM [GIBCO] was added to DNA (100 µl per 2 µg of DNA). Then Fugene-HD 
[Roche] was added (3 µl per 1 µg of DNA). Transfection complexes were formed 
during 20 min incubation at room temperature and then added to approximately 90% 
71 
 
confluent cells in T-75 flasks containing 5 ml medium or 6 well plates containing from 
0.5 ml to 1 ml medium per well. Cells were incubated with transfection complexes for 
16-18 h before medium was replaced with fresh. 
 
2.4.3 Creation of CRFK cells which stably express ovine Hyal-2 
 
CRFKoH2 cells were generated by transduction of parent CRFK cells with a murine 
leukaemia virus (MLV) vector pLNCX2 expressing ovine Hyal-2, the cellular receptor 
for JSRV. Stably transduced cells were selected in 500 μg/ml G418 (Sigma) and used 
as a polyclonal population. 
 
2.5 Production of retroviral vectors 
Production of virus stocks was initiated by transfection of producer cell line (see 
Section 2.4.2).  
 
2.5.1 Virus harvest and concentration 
 
Culture supernatant (SN) was replaced with 10 ml fresh medium 16 h after 
transfection complexes were first added. On the following day SN was harvested, 
centrifuged at 1800  g for 10 min at 4°C and filtered through a 0.45 µm filter 
[Sartorius], then frozen at -80°C. Supernatants from 42 h and 66 h were optionally 
pooled and concentrated from 5 to 200 times (usually 25 ) by ultracentrifugation at 
100,000  g for 2 h at 4°C and resuspended in serum-free IMDM [Sigma]. 
 
2.5.2 Cell lysate preparation 
 
Cells were harvested and washed in 10 ml cold PBS per T75 flask, centrifuged at 
430  g for 10 min at 4°C. The cell pellet was resuspended and lysed using 1 ml RIPA 
buffer containing 50 U of benzonase [Novagen], incubated on ice for 2h, inverting 
tubes occasionally. RIPA buffer contains 150 mM NaCl, 1% Igepal [Sigma], 0.5% 
Sodium deoxycholate, 0.1% SDS [Sigma] and 50 mM Tris pH 8.0. 
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2.6 Western blotting 
 
2.6.1 Sample preparation 
 
Each sample was mixed with Laemmli sample buffer (4) and then boiled for 2 min. 
 
Laemmli sample buffer 4 contains 0.26 M SDS [Sigma], 0.25 M Tris pH 6.8,      
10% ß-mercaptoethanol [BDH chemicals], 40% glycerol and 0.01% bromophenol 
blue. 
 
2.6.2 SDS- PAGE electrophoresis 
 
SDS PAGE was performed using the Laemmli method (Laemmli, 1970) and utilised a      
10-15% resolving gel and a 3% stacking gel. 
 
Laemmli Resolving Gel Buffer (4) contains 1.5 M Tris (base), 13 mM SDS (pH 8.8). 
 
Laemmli stacking buffer (2) was made by solubilising 0.5 M Tris (base) and 13 mM 
SDS in water up to final volume. Afterwards the pH was adjusted to pH 6.8. 
 
Electrode buffer (5) contains 127 mM Tris (7.9), 0.96 M Glycyine, 13 mM SDS. 
 
Stacking gel was made by mixing 3 ml Laemmli stacking buffer (2), 4 ml water, 1 ml 
acrylamide (30%) [Severn Biotech], 50 µl 10% ammonium persulphate [Sigma] and 
10 µl TEMED [Sigma]. 
 
Resolving gel was made by solubilising 0.6 g sucrose [Fisher] in 4 ml water and then 
adding 3 ml Laemmli gel buffer (4), 5 ml acrylamide (30%) [Severn Biotech], 50 µl 
10% ammonium persulphate [Sigma], 10 µl TEMED [Sigma]. 
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2.6.3 Protein transfer 
 
Semi-dry transfer was performed using a BioRad transfer apparatus applying 15V for 
48 min. Protein was transferred to Hybond ECL nitrocellulose [GE Healthcare]. 
 
Transfer buffer 10 contains 0.2 M Tris (7.9), 1.53 M glycine solubilised in water up 
to a final volume.  
 
Transfer buffer 1 was made by diluting 100 ml transfer buffer 10 in 200 ml 
methanol and 700 ml H2O. 
 
2.6.4 Antibody – binding 
 
The nitrocellulose membrane with transferred proteins was incubated overnight at 4°C 
in blocking solution (PBS, 5% dried skimmed milk [Marvel], 0.2% Tween-20). On the 
next day blocking solution was removed, and the membrane was incubated for 1 h 
with primary antibody in PBS, 5% Marvel. 
 
For detection of HA-tagged proteins 1:1000 diluted Mouse HA.II Clone 16B12 
monoclonal antibody IgG [Covance] was used. For JSRV Gag detection 1:1000 
diluted Rabbit anti-Gag polyclonal serum (Salvatori et al., 2004) was used. For 
detection of ovine A3-Z2 and A3-Z3, custom rabbit polyclonal antibodies 
[Proteintech] were employed (1:1000 dilution). 
 
Afterwards, blots were washed in PBS 0.1% Tween20 [Fisher Scientific] three times 
for 10 min each. Then incubated with horseradish peroxidise [HRP] conjugate 
secondary antibody, 1:1000 diluted Goat anti-rabbit [Dako] or Rabbit anti mouse 
[Dako] in (PBS 5% Marvel). Subsequently, blots were washed three times for 10 min 
using PBS, 0.1% Tween20. After a final wash in PBS, blots were developed using 
Amersham ECL Western Blotting Detection Reagents [GE Healthcare]. The 
OPTIMAX 2100 X-Ray film processor [PROTEC] or ImageQuant imager 
[GE Healthcare], were used to develop or capture the western blot image. 
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2.7 In vitro infections 
 
2.7.1 Infection protocol (12 well plate) 
 
1  105 cells were plated in each well of a twelve well plate on the day prior to 
infection. Before infection cells were washed using PBS and medium was replaced 
with 0.5 ml fresh medium containing 8 µg/ml polybrene (1,5-dimethyl-1,5-
diazaundecamethylene polymethobromide) [Sigma]. Then virus was added to the cells 
and incubated for 16 h and before replacing with fresh medium. As a negative control, 
uninfected cells and cells infected by heat inactivated virus were used. Virus was heat-
inactivated by incubation at 70°C for 20 min. 
 
2.7.2 Preparation of cells for flow cytometry analysis 
 
Three days post-infection cells were examined by UV microscopy. Then cells were 
harvested by dispersion using 0.5 ml trypsin/versene mix per well. After 10 min 0.5 ml 
of serum-containing media was added to stop digestion. Cells were washed using 
10 ml PBS and centrifuged at 430  g for 5 min. Cells were fixed by 15 min 
incubation in 1 ml of 1% paraformaldehyde [Fisher] diluted in PBS. Then, the cells 
were centrifuged at 430  g for 5 min and suspended in 1% sodium azide [Sigma] 
diluted in PBS. Cells were filtered through a 0.7 mm filter [BD Falcon] before flow 
cytometric analysis. 
 
2.7.3 Flow cytometry 
 
Flow cytometry analysis of GFP fluorescent or intracellular immunostained cells was 
performed using CYAN apparatus [Dako] or MACS Quant and Summit software 
[Beckman Coulter]. Cells lacking the GFP were used as a negative control. In the case 
of immunostaining, cells without the epitope recognised by the antibody were used. 
Readout of at least 20000 cells enabled an accurate determination of as little as 0.5% 
percentage of positive cells with a confidence interval of 0.01. However, in most cases 
the infectivity was higher, and usually from a single assayed well, at least 50000 cells 
were counted.  
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The adjustment of minimal sample size according to the probability of the event is 
shown in the formula below. 
Sample size = Z
2  (P)  (1-P) / c2 
Z = Z value (e.g. 1.96 for 95% confidence level) 
P = percentage picking a choice, expressed as decimal 
c = confidence interval, expressed as decimal 
 
The percentage of positive cells infected by A3 containing stocks or their median 
fluorescence values, were compared to cells infected by a reference “no A3” virus 
stocks. The relative infectivity values were obtained from the average percentage of 
positive cells in wells infected by the test virus, divided by the average percentage 
value of positive cells infected by the control virus (ie., virus prepared in the absence 
of A3. Error bars on plots reflect the experimental variability and show the standard 
deviation values between wells infected in triplicate by the same virus stocks. The 
relative fluorescence intensity values were calculated similarly to the relative 
infectivity, but taking into account the median fluorescence of positive cells. The 
student two-tailed t-test method with unequal variance was used to verify the 
significance of results. Due to a multiple comparison, obtained p-values were 
corrected using the Bonferroni method. 
 
2.8 Sucrose gradient purification of retroviral particles 
 
In order to enhance the purification of retroviral particles, sucrose gradient 
ultracentrifugation was performed. Retroviral particles are purified on the principle 
that their virion buoyant density is approximately 1.16 g/ml which corresponds to a 
particular sucrose concentration (York et al., 1991, Palmarini et al., 1995, Palmarini et 
al., 1999b). Initially, sucrose solutions of 65%, 42%, 33% and 20% (weight to 
volume) in TNE buffer were prepared, which were subsequently sterilised by 0.2 µm 
filtering and stored at 4°C. Equal volumes of sucrose solutions were added slowly to a 
centrifuge tube, starting with a highest concentration of sucrose, then tubes were 
stored vertically on ice for approximately 1 h. Samples were applied on the surface: 
for 36 ml tubes the maximum of 2 ml was applied and for 13 ml tubes up to 0.5 ml of 
a sample was added. Tubes were balanced for centrifugation by adding a small amount 
of TNE buffer.  
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Tubes containing the sucrose step gradients were centrifuged at 100,000  g at 4°C for 
16 h using the “slow acceleration” and “brake off” deceleration functions in order to 
avoid disturbing the density gradient. After centrifugation, the tube was placed 
vertically and the bottom of the tube was punctured by a 19G needle and fractions 
(0.5 ml) were collected. 
  
The density of fractions was measured by refractometer [Bellingham-Stanley] using 
the formula: 
 
Density [g/ml] = [2.6465  (refractive index)] – 2.5286      (Griffiths, 1996) 
 
Samples were stored at -80°C prior to further experiments. 
 
 
2.9 Concentration of lung fluid 
 
Lung fluid was obtained from OPA sheep, filtered through gauze and clarified first by 
centrifugation for 10 min at 430  g and 4°C, followed by 1800  g at 4°C for 10 min. 
The supernatant was then applied to a glycerol cushion in a SW 32Ti ultracentrifuge 
tube. The glycerol cushion consisted of a bottom layer of 1.5 ml of 
50% glycerol / TNE (ingredients TNE) and 1.5 ml top 25% glycerol / TNE. Lung fluid 
was concentrated at least 200  by ultracentrifugation at 100,000  g at 4°C for 2 h 
and suspended in TNE buffer. 
 
2.10 Materials and methods regarding APOBEC experiments 
 
2.10.1 Cloning of sheep, goat, cow APOBEC3 proteins 
  
RNA purified (see Section 2.3.10) from the cell lines CPT-Tert (sheep), TIGEF (goat) 
and BOMAC (cow) was used as a template for RT-PCR amplification of ruminant  
A3-Z2, A3-Z3, and A3-Z2Z3 genes. In order to amplify sheep and cow A3Z1, mRNA 
isolated from small intestine was used as a template. Consensus primers were designed 
to sequences located external to reading frames and used to amplify the A3 genes.  
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The mix used was as described in Section 3.11 and the RT-PCR program used was 
50°C 30 min, 94°C 30s, 40 cycles (94°C 15s, 50°, 55° or 60°C 30s, 72°C 1 min), 72°C 
10 min. 
 
RT-PCR products were gel purified (see Section 2.3.7) and ligated into pGEM-T Easy 
(see Sections 2.3.9 and 2.3.14), which enabled sequencing using SP6 and T7 primers 
to identify clones with the desired sequences. The selected pGEM-T Easy clones were 
used as templates for high fidelity PCR using KOD polymerase [Novagen] 
(see Section 2.3.13). Subsequently, additional primers were used to add a C-terminal 
HA tag coding sequence and appropriate restriction sites to A3 sequences to facilitate 
their cloning into the mammalian expression vector pCI-Neo. The primer sequences 
are shown in Table 2.2. The details for construction of each vector are described 
below. The PCR program was 94°C 2 min, 25 cycles (94°C 15s, 50 or 55 or 60°C 30s, 
72°C 1 min), 72°C 10 min. Products were gel purified before digestion and ligation 
(see Section 2.3.7, 2.3.9). pCI-Neo was digested using SalI and NotI and was gel 
purified (see Sections 2.3.8 and 2.3.7) in order to prepare it for subsequent ligations. 
 
The cow and sheep A3-Z1 coding sequences were amplified by RT-PCR utilising 
consensus external primers designed to ruminant A3-Z1 open reading frame, A3Z1-F 
and A3Z1-R. The sheep A3-Z1HA sequence was reamplified from gel-purified        
RT-PCR product (see Section 2.3.13) using KOD polymerase [Novagen]. Forward 
primer A3Z1-OA_Ex_F added an XhoI site and a Kozak consensus site upstream of 
the start codon. A haemagglutinin tag and NotI restriction site was added to the 3’ of 
the ORF using A3Z1-OA_ExHA_R primer. The PCR product was digested using 
XhoI and NotI restriction enzymes and inserted into SalI and NotI gel-purified 
digested   pEGFP-FLAG (see Section 2.1.6), which enabled sequencing. In order to 
clone sheep  A3-Z1HA into pCI-Neo, pEGFP-Ci S A3-Z1 was cut using XhoI and NotI 
and ligated into pCI-Neo using T4 Ligase [Promega]. The cow A3-Z1HA was 
reamplified from   RT-PCR product using KOD polymerase [Novagen]. The forward 
primer A3Z1-BT_Ex_F added the SalI site and Kozak consensus site upstream of start 
codon. The reverse primer A3Z1-BT_ExHA_R added the NotI restriction site and a 
HA tag to the 3’ of the ORF which enabled cloning into pCI-Neo. 
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For RT-PCR amplification of ruminant A3-Z2, primers A3Z2-F and A3Z2-R were 
used. Reamplification and cloning of sheep and goat A3-Z2 into pCI-Neo, was enabled 
by forward A3Z2Z3-Ov-Exp-F and reverse primer A3Z2-OaBT_ExHA_R. The cow 
A3-Z2 was reamplified utilising the selected pGEM-T Easy clone as a template and 
using A3Z2-BT_Ex_F and A3Z2-OaBT_ExHA_R primers. A3-Z2 PCR products were 
digested by SalI and NotI, gel-purified and cloned into SalI and NotI digested         
pCI-Neo. 
 
In order to amplify A3-Z3 RT-PCR used the same reverse primer, A3Z2Z3-R, for all 
ruminants together with reverse primer A3Z3-Oa_ExF for sheep and goat A3-Z3 or 
A3Z3-BT_Ex_F for cow A3-Z3. A3-Z3HA reamplified using reverse primer        
A3Z3-BT_ExHA_R together with forward primer A3Z3-Oa_ExF for sheep,       
A3Z3-CAPHA_Ex_R for  goat, or A3Z3-BT_Ex_R for cow. PCR products were 
digested by SalI and NotI, gel purified and cloned into pCI-Neo cut with the same 
enzymes. 
 
RT-PCR amplification of ruminant A3-Z2Z3 employed forward primer A3Z2Z3-F and 
reverse A3Z2Z3-R. Sheep and goat A3-Z2Z3HA was reamplified by forward primer 
A3Z2Z3-Ov-Exp-F and reverse A3Z2Z3HA-ExpR. The cow A3-Z2Z3 was 
reamplified using A3Z2-BT_Ex_F and A3Z2Z3HA-ExpR. PCR products were 
digested by SalI and NotI, gel-purified and cloned into pCI-Neo cut with same 
enzymes. 
 
2.10.2 JSRV vector production for APOBEC3 experiments 
  
JSRV vectors were produced by transient transfection of 293T cells (see Section 2.4.1 
and 2.4.2). Retroviral vectors derived from the infectious molecular clone 
pCMV2JS21, were employed in this study. Production of virus stocks was performed 
either in T-75 flasks or 6-well plates. 
 
JSRV-based vectors were produced by transient transfection of confluent T75 flask of 
293T cells with 14 µg of DNA (see Table 2.3) using 42 µl of transfection reagent 
Fugene-HD (Roche) according to the manufacturer’s instructions (see Section 2.4.2). 
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Sixteen hours post-transfection, transfection complexes were replaced with 10ml fresh 
medium supplemented with additionally 5 mM sodium butyrate. Virus-containing 
supernatant (SN) was harvested after 42 h and 66 h post transfection, centrifuged at 
1800  g for 10 min at 4°C, filtered through a 0.45 µm filter [Sartorius] and frozen at  
-80°C. Then 42 h and 66 h supernatants were pooled and then concentrated  25 by 
ultracentrifugation at 100,000  g for 2 h at 4°C and resuspended in serum free IMDM 
[Sigma]. Aliquots were stored at -80°C. 
 
Table 2.3 Plasmids used in transfection to create JSRV stocks carrying 
APOBEC3 
 
Table 2.3 DNA used in transfection in order to produce JSRV vectors on a T-75 flask 
scale. 
Ten different stocks were made in each experiment (No A3-no APOBEC3, S- sheep, G- goat, 
C- cow; numbers represent µg of A3 encoding plasmid used during transfection of a confluent 
T-75 flask). For each stock 10 µg of DNA encoding viral proteins was included in the premix. 
In order to produce wild type JSRV, pCMV2JS21 was used. To make JSRV-GFP three 
plasmids were used (pCMVJS-ΔE-CG, pCMV JSE SP-FLAG and an envelope encoding 
vector (pCAG-JSEnv or pVSV-G). Various A3 genes were provided as a pCI-Neo vector in 
three different quantities for each species homologue (0.25 µg, 1 µg or 4 µg). The total amount 
of DNA was adjusted by the addition of empty pCI-Neo vector. The same type of A3-
containing stocks; either one of four paralogues Z1, Z2, Z3 or Z2Z3) were made in a single 
experiment.  
Virus Stock 
JSRV vector encoding 
plasmids 
A3 Expression 
vector 
pCI-Neo 
No A3 
 
 
pCMV2JS21 10 µg 
 
 
OR 
 
 
pCMVJS-ΔE-CG 7 µg 
 
pCMV JSE SP-FLAG 2 µg 
 
Envelope encoding vector 1 µg 
(pCAG-JSEnv or pVSV-G)  
 4 µg 
0.25 S A3 pCI-Neo S A3 0.25 µg 3.75 µg 
1 S A3 pCI-Neo S A3 1 µg 3 µg 
4 S A3 pCI-Neo S A3 4 µg  
0.25 G A3 pCI-Neo G A3 0.25 µg 3.75 µg 
1 G A3 pCI-Neo G A3 1 µg 3 µg 
4 G A3 pCI-Neo G A3 4 µg  
0.25 C A3 pCI-Neo C A3 0.25 µg 3.75 µg 
1 C A3 pCI-Neo C A3 1 µg 3 µg 
4 C A3 pCI-Neo C A3 4 µg  
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2.10.3 In vitro infections 
 
The CRFKovH2 cells were maintained in 10% FCS IMDM and infected in medium 
containing 8 µg/ml polybrene. 1  105 CRFKovH2 cells were plated in each well of 
twelve well plates on the day prior to infection. Virus was then added to the cells and 
incubated for 16 h. Volume of virus stock used was adjusted in order to balance the 
input amount of Gag on the basis of WB. Three days post-infection cells were 
harvested and either analysed by flow cytometry or subjected to DNA extraction. As a 
negative control non-infected cells and cells infected by heat inactivated virus (virus 
was incubated at 70°C for 20 min) were used. 
 
2.10.4 Quantitative PCR 
 
In order to determine the number of viral integration events, qPCR (quantitative PCR) 
was performed using DNA extracted from infected CRFKovH2 cells as a template. 
 
Virus stocks used for these series of infections and heat inactivated controls were 
treated for 1 h at 37°C with DNAse [Ambion] (4U of enzyme per 100 μl of virus 
stock) and the addition of supplied 10× buffer [Ambion] in order to remove residual 
DNA carried over from the transfection process. 
 
The 25 μl qPCR reaction mixture contained 2×PCR reaction mix [Applied 
Biosystems] and 14.8 mM MgSO4. Amplification and detection of exogenous JSRV 
was enabled by P1 and P6 primers (50 μM) (Holland et al., 1999, Palmarini et al., 
1996) and the JSRV-T-FAM probe (10 μM) (Cousens et al., 2009) (see Section 2.2.). 
 
Initially, the DNA concentration in the samples analysed was standardised to 50 ng/μl 
and 200 ng (4 μl) was added to each qPCR reaction. As a negative control, water was 
used or DNA was extracted (see Section 2.3.11) from non-infected cells and from cells 
subjected to heat inactivated virus stocks. As a positive control and standard for the 
number of JSRV copy number used, dilutions of DNA extracted from JS7 cells, which 
contain a single integrated JSRV provirus per cell (DeMartini et al., 2001), were used. 
These were diluted in the DNA extracted from non-infected CRFKovH2 cells in order 
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to have the same total amount of genomic DNA in each tube (see Sections 2.3.11 and 
2.4.1). 
Amplification, data acquisition and data analysis were performed on a Prism SDS7000 
(Applied Biosystems). Reaction conditions were 94°C for 10 min followed by 
40 cycles of (95°C for 15 s, 59°C for 30 s and 60°C for 30 s). 
 
2.10.5 Analysis of APOBEC3 induced hypermutations 
 
CRFK cells were infected with “APOBEC3 containing” or “No APOBEC3” virus 
stocks. As a negative control heat-inactivated virus was used. Cells were harvested 
three days post-infection and DNA was purified using Qiagen Blood and Tissue DNA 
extraction kit (see Section 2.3.11). A 928 bp fragment of GFP was amplified using 
primers GFP 1164 F and GFP 1164 R (see Table 2.1). PCR products were purified 
using Qiagen PCR purification kit and ligated into pGEM-T Easy which enabled 
sequencing. The Hypermut 2.0 program [www.hiv.lanl.gov] was used to identify the 
mutations present in each clone. 
 
2.10.6 Production of virus stocks containing human and mouse APOBEC 
 
Virus stocks made in the presence of human APOBEC were prepared by transfection 
of 293T cells plated in a six well plate using 2.8 μg of DNA for each well, according 
to Section 2.4.2. The DNA used in the transfection contained 2 μg of viral vector 
encoding genes (see Section 1.4 μg pCMVJS-DE-CG-1164, 0.4 μg pCMV JSE SP-
FLAG, 0.2 μg pCAG Env) and 0.8 μg of vector encoding APOBEC (pcDNA – human 
and mouse APOBEC; pCI-Neo – sheep A3-Z2Z3) or empty pCI-Neo plasmid as a 
negative control. The mass ratio of vector plasmid to APOBEC plasmid was similar to 
“4 μg stocks” (see Table 2.3). 
 
The pcDNA3 expression vectors for human APOBEC1, human APOBEC2, huA3DE, 
huA3F, huA3G and murine A3 were provided by Dr. B. Matija Peterlin and Dr Yong-
Hui Zheng (University of California, San Francisco USA). 
 
Each stock was prepared using two wells of a six well dish and supernatants from 
duplicate wells were pooled. Virus stocks were harvested, concentrated 50 × and 
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stored according to Section 2.5.1 Cellular extracts from producer cells were prepared 
according to Section 2.5.2. 
 
2.10.7 Western blot detection of V5-tagged human and mouse APOBEC 
 
Western blotting for detection of human and mouse V5-tagged APOBEC proteins was 
performed according to Section 2.6. The total volume of 15 μl of concentrated stock or 
cellular extract per well was utilised. Anti-V5 HRP antibodies [Invitrogen] diluted 
1:2000 were used for detection of human and mouse V5-tagged APOBEC proteins. 
 
2.10.8 Detection of APOBEC3 expression in sheep 
 
Detection of A3 expression in vivo has been performed by RT-PCR, lung 
immunohistochemistry and western blotting of concentrated lung fluid. 
 
Origin of anti sheep A3-Z2 and A3-Z3 antibodies 
 
Rabbit polyclonal antibodies to ovine A3-Z2 and A3-Z3 were provided by David 
Griffiths. These antibodies were generated by subcloning the coding sequence of each 
gene separately into pET-DUET (a bacterial expression plasmid; Merck) in-frame with 
an N-terminal polyhistidine tag. Expression of each protein in E.Coli was confirmed 
by IPTG induction prior to submitting purified plasmid DNA to a commercial provider 
(Proteintech) for large scale protein expression and immunisation of rabbits. Post-
immune sera were affinity purified for use in western blots (Proteintech). 
 
2.10.8.1 Collection of tissue samples 
 
Tissue samples were collected from sheep post mortem. Freshly dissected tissue pieces 
were put into tubes and snap frozen in liquid nitrogen before storage at -80°C. 
Samples from grossly unaffected normal lung, OPA affected lung, spleen, liver, 
kidney, muscle and lymph node were collected.  
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2.10.8.2 RT-PCR amplification of APOBEC3 and TRIM5 using RNA from 
various tissues 
 
RT-PCR was performed in order to determine if A3 and T5 were expressed in a panel 
of different sheep tissues. Template RNA extracted from sheep lung, liver, intestine, 
kidney, lymph node, muscle, spleen and OPA tumour was used (see Section 2.3.11). 
As a positive control RNA from the CPT-Tert cell line was used. The primers and   
RT-PCR programs utilised were identical to the ones used in RT-PCR for the first step 
cloning (see Section 2.10.1.1). 
2.10.8.3 Immunohistochemistry 
Processing cell pellets and embedding in wax 
 
In order to incorporate cells into wax blocks, they were initially dispersed by trypsin 
and pelleted by centrifugation at 430  g for 5 min, then fixed by incubation in 1 ml of 
10% buffered formalin. Afterwards, cells were pelleted by centrifugation and 
resuspended in PBS, then the washing step was repeated. Finally the cells were 
suspended in a small volume of 5% gelatin PBS solution. After solidification of 
gelatin the pellet was left in 80% ethanol overnight in order to dehydrate it. On the 
next day the gelatin pellet was placed in the processor on the overnight cycle and 
afterwards the pellet was embedded in wax. 
 
Immunohistochemistry method 
 
Initially sections were cut at 4 μm and mounted onto SUPERFROST®PLUS slides 
[Thermo Scientific] then dried overnight at 37°C. The wax was removed from sections 
using in xylene by two subsequent 5 min washes. Slides were rinsed in 100% ethanol 
for 2 min then 95% ethanol for 2 min, then placed in 3% hydrogen peroxide methanol 
for 20 min at room temperature and stirred in order to remove endogenous peroxidase. 
Slides were washed using running tap water for 5 min. Slides were placed in a metal 
rack in a 2 litre beaker containing antigen retrieval buffer (citric acid in one litre water 
add approx 25 ml of 1 M NaOH to pH 6) autoclave at 121°C for 10 min. After cooling 
to 50°C, slides were washed in water for 5 min. Slides were loaded into Sequenza 
chambers and washed in 0.05% Tween20 diluted in PBS.  
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In order to block any non-specific binding sites, 100 μl of 25% normal goat serum 
(Vector Laboratories S-1000) was applied for 30 min at room temperature. Afterwards 
applied primary antibody (1:10000 anti-A3-Z2; 1:20000 anti-A3-Z3 or pre-immune 
sera as a negative control) and incubated overnight at 4°C (origin of antibodies is 
shown in Section 2.10.8). On the next day slides were washed three times using 0.05% 
Tween20 diluted in PBS. Then 100 μl of secondary goat anti-rabbit HRP (Envision - 
Dako), was applied for 30 min at room temperature. Then the slides were washed three 
times using 0.05% Tween20 diluted in PBS, and applied 100 μl of DAB (3,3′-
Diaminobenzidine) solution, prepared according to the manufacturer’s instructions. 
The slides were rinsed with water, removed from the Sequenza machine then washed 
in running water. Nuclei were stained with haematoxylin [Cellpath] for 2 min, washed 
in water for 2 min, and then blued using STWS (Scots tap water substitute – 3.5 g 
sodium bicarbonate, 20 g magnesium sulphate, 1 litre water). Afterwards the slides 
were washed in running tap water for 2 min and dehydrated through graded ethanol 
(70%, 95%, 100%) and rinsed in xylene twice. Finally coverslips were mounted on the 
sections using Thermo Shandon mountant [Thermo Scientific]. 
 
2.10.9 Reverse transcriptase assay 
 
The Colorimetric Reverse Transcriptase Assay [Roche] was utilised to analyse the 
activity of RT present in virus stocks. The protocol was adjusted to test concentrated 
JSRV supernatant in each well. Initially, instead of suspending the viral pellet directly 
in lysis buffer, 5 μl of each of concentrated virus stock was mixed with 35 μl of the 
provided lysis buffer. Optionally the volume of virus stock used was adjusted in order 
to balance the input amount of Gag on the basis of WB. The following steps were 
performed according to the manufacturer’s instructions, utilising the provided poly-A 
as RNA template and allowing 3 h incubation for the reverse transcription step. 
 
Two-fold dilutions of the provided HIV-1 RT were employed in order to plot a 
standard curve, ranging from 1 ng to 15.6 pg per well. As a negative control 5 μl of 
serum free IMDM medium was used. Each virus stock was tested in triplicate. The 
interpretation of RT content in the virus stocks was based on the standard curve, where 
the absorbance of tested samples was within the range of standards. The RT activity 
values of A3 containing stocks, were compared to reference “no A3” virus stocks. The 
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student two-tailed t-test method with unequal variance, was used to verify the 
significance of the results. Due to a multiple comparison, obtained p-values were 
corrected using the Bonferroni method. 
 
2.11 Materials and methods regarding TRIM5 experiments 
 
Initially, T5 encoding ORFs were cloned into retroviral vector plasmids (see Section 
2.11.1). Afterwards, retroviral mediated transduction of CRFKovH2 cells, followed by 
their antibiotic selection enabled the creation of cell lines which stably express various 
T5 homologues. Expression of T5 was confirmed by flow cytometric analysis of anti-
HA labelled cells. The impact of T5 on HIV-1 and JSRV replication was performed 
according to Section 2.11.3. 
 
2.11.1 Cloning of TRIM5 encoding sequences. 
 
Sheep and goat T5 sequences were isolated by RT-PCR, cloned into pGEM-T Easy 
vectors and after selection of representative clones by sequencing, they were 
subsequently reamplified by a high fidelity PCR and cloned into pLNCX-2 vectors. 
Two bovine T5 coding sequences in pLPCX were kindly provided by Dr Joseph 
Sodroski (Dana-Farber Cancer Institute, USA). 
 
The pLPCX vectors encoding human and rhesus macaque T5 were obtained through 
the AIDS Reagent Program, Division of AIDS, NIAID, NIH - originally from 
Dr Joseph Sodroski, Dana-Farber Cancer Institute, USA). Both pLNCX-2 and pLPCX 
vectors with cloned T5 were further modified by insertion of an IRES-Hyg cassette in 
order to enhance their transduction ability (see Section 2.11.1.4). 
 
2.11.1.1 Isolation of sheep and goat TRIM5 sequences by RT-PCR 
 
Primers utilised in RT-PCR were designed to consensus fragments of sheep and cow 
sequences located external to the T5 reading frame (forward primer TRIM-F1 and 
reverse primer TRIM-R1 sequences are shown in Table 2.1).  
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RNA purified (Section 2.3.10) from goat PBMCs or sheep cell line CPT-Tert (Section 
2.7.1) was used as a template for amplification of sheep and goat T5 genes. 
Superscript 2 one-step platinium Taq [Invitrogen] was used for this reaction (see 
Section 2.3.12). The RT-PCR program used was 50°C 30 min, 94°C 30 s, 40 cycles 
(94°C 15 s, 55°C or 60°C 30 s, 72°C 1 min), 72°C 10 min. 
 
2.11.1.2 Cloning of sheep and goat TRIM5 ORFs into pGEM-T Easy 
 
RT-PCR products were gel purified (see Section 2.3.7) and cloned into pGEM-T Easy 
(see Section 2.1.1), which enabled sequencing using SP6 and T-7 primers in order to 
identify desired clones. 
 
2.11.1.3 Cloning of sheep and goat TRIM5 ORFs into retroviral vectors 
 
T5 ORFs were reamplified from selected plasmid clones by high fidelity PCR (see 
Section 2.3.13). Sequence similarity at the 5’ and 3’ ends of the goat and sheep 
T5 ORF allowed further cloning using the same set of primers (forward primer                       
Oa-TRIM-F-BCL and reverse primer BtOa-TRIM-HA-R sequences are shown in 
Table 2.1). The forward primer inserted a Kozak consensus sequence and BclI 
restriction site upstream the T5 start codon. The reverse primer inserted the HA tag 
and SalI site encoding sequence to the 3’ end of T5. 
 
High fidelity KOD polymerase was used in this reaction (see Section 2.3.13). The 
PCR program was 94°C 2 min, 25 cycles (94°C 15 s, 55 and 60°C 30 s, 72°C 1 min), 
72°C 10 min. 
 
The addition of BclI and SalI restriction sites enabled the insertion of reamplified, 
digested and gel purified T5 ORF into BglII and SalI digested pLNCX-2 expression 
vector (See Table 2.1). The T5 and HA-tag sequences present in the selected 
recombinant pLNCX-2 plasmids were verified by sequencing.  
87 
 
2.11.1.4 Addition of IRES-Hyg cassette to TRIM5 carrying pLNCX-2 or 
pLPCX vector. 
 
Insertion of the hygromycin B phosphotransferase (hygromycin resistance gene) and a 
IRES Internal Ribosome Entry Site (derived from encephalomyocarditis virus) located 
downstream of T5-HA ORF enabled the expression of both genes from the same 
transcript. 
 
High fidelity PCR using KOD polymerase (see Section 2.3.13) amplified an IRES and 
hygromycin cassette from plasmid pIREShyg3 (see Table 2.1). SalI and XhoI 
restriction sites were added during this reaction. The PCR program was 94°C 2 min, 
25 cycles (94°C 15 s, 55°C and 60°C 30 s, 72°C 1 min) 72°C 10 min. 
 
IRES-Hyg PCR products were gel purified and digested with SalI and XhoI which 
enabled cloning into pLNCX-2 carrying T5 ORF (linearised with SalI, treated with 
alkaline phosphatase and gel purified). Similarly the IRES-Hyg cassette was cloned 
into pLNCX-2 with the LacZ gene (provided by David Griffiths). 
 
All ruminant T5 ORFs and IRES-Hyg cassette junctions were sequenced in both 
directions to confirm their correctness using primers TRIM5-F2, TRIM5-F3,     
TRIM5-R2, TRIM5-R6, LN-F, CX-R (see Table 2.1). Human and rhesus monkey T5 
carrying plasmids were verified by LN-F and CX-R primers (see Table 2.1). 
 
2.11.2 Creation of cell lines stably expressing TRIM5α 
 
Cell lines that stably express various T5 proteins were generated in order to analyse 
the impact of those proteins on retroviral replication. Initially, MLV vectors were 
prepared (see Section 2.11.2.1) in order to transduce CRFKovH2 cells (see Section 
2.11.2.2). Antibiotic selection enabled the creation of cell lines expressing various T5 
(see Section 2.11.2.2), which was confirmed by RT-PCR (see Section 2.11.2.4) and 
flow cytometric analysis of anti-HA labelled cells (see Section 2.11.2.5).                    
β-galactosidase activity assay was performed to verify the transduction process 
(see Section 2.11.2.3). 
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2.11.2.1 Production of MLV retroviral vectors for TRIM5α experiments 
 
Murine leukaemia virus based vectors were made for efficient transduction of 
mammalian cells. Confluent 293T cells plated in six well plates were transfected 
(see Section 2.4.2) using 1 µg of DNA and 3 µl of Fugene HD per well. The DNA 
used for each transfection contained 0.3 µg pHIT60 (encoding MLV structural 
proteins) (Soneoka et al., 1995), 0.2 µg pVSV-G (envelope), 0.5 µg pLNCX-IH or 
pLPCX-IH (vectors containing MLV packaging signal, T5 or β-galactosidase encoding 
sequences, IRES-Hyg cassette see Table 2.1). MLV vectors carrying the T5 or LacZ 
gene were harvested on the second and third day post transfection, then filtered 
(0.45 µm), aliquoted and frozen at -80ºC. 
 
2.11.2.2 Transduction of CRFKovH2 cells in order to stably express TRIM5 
 
CRFKovH2 cells (see Section 2.4.1) were plated on the day before infection in a six 
well plate at a density of 10
6
 cells per well. Cells were infected by 3 h exposure to 
0.5 ml of MLV vector carrying various T5 or LacZ coding sequences. 
 
Selection of cells was based on a hygromycin resistance gene present in transduced 
cells. Antibiotic selection of T5α transduced cells was applied three days post-
infection. Non-transduced CRFKovH2 (see Section 2.4.1) were put under antibiotic 
selection in parallel. Hygromycin [Invitrogen] 500 μg/ml enabled the elimination of all 
non-transduced cells within two weeks. Successful selection was initially confirmed 
by the death of non-transduced cells after two weeks and expression of β-galactosidase 
in LacZ transduced cells. 
 
2.11.2.3 Beta-galactosidase staining of transduced cells 
 
β-galactosidase staining was used in order to detect transduction of cells and verify 
successful stable expression of the LacZ transgene after antibiotic selection. The 
medium was removed and cells were washed once with PBS. The cells were fixed for 
15 min using 0.5% glutaraldehyde [BDH] dissolved in PBS, then washed once with 
PBS before adding X-Gal substrate (5 mM potassium ferricyanide, 5 mM potassium 
89 
 
ferrocyanide, 2 mM magnesium chloride, 0.01% sodium deoxycholate, 0.02% NP40, 
2% DMF and 1 mg/ml X-gal [Promega]), and incubating at 37 ˚C for 1-4 h. After the 
colour had developed, the substrate was removed and PBS was added to wells. 
 
2.11.2.4 Immunolabelling of TRIM5α HA expressing cells 
 
The percentage of T5-expressing cells was determined by flow cytometry of 
intracellularly anti-HA labelled cells. Cells were dispersed by trypsin and diluted to 
5  105 cells in PBS containing 5% of heat inactivated fetal calf serum. Then cells 
were centrifuged at 430  g for 1 min and washed in PBS, before fixing in 1% 
PFA/PBS for 10 min at room temperature. Cells were again washed with PBS and 
suspended overnight at 4
o
C in 1 ml of permeabilisation and block buffer, which was a 
0.2% saponin [Sigma] solution in PBS and 20% heat inactivated goat serum [Moredun 
Research Institute]. 
 
On the next day cells were pelleted at 430  g for 1 min and then resuspended in 
200 µl of permeabilisation buffer, which is 0.2% saponin [Sigma] solution in PBS, 
containing primary antibody 1:1000 (Covance anti-HA) and incubated for 1 h at room 
temperature. The cells were then washed twice using permeabilisation buffer and 
incubated in FTIC-labelled secondary goat anti mouse antibody 1:1000 [Alexa Fluor] 
for 1 h at room temperature. Afterwards, cells were washed twice using 
permeabilisation buffer, and once using PBS. The cells were fixed in 1% PFA for 
10 min at room temperature, then washed in PBS and kept at 4
o
C until flow cytometric 
analysis. As a negative control, cells were incubated only with secondary antibody and 
also LacZ transduced CRFKovH2 was tested using the full-length protocol. 
 
2.11.3 HIV-1-GFP production 
 
HIV-1 GFP VSV-G pseudotyped vector was made in order to verify its restriction in 
cells stably expressing cow and rhesus macaque T5α. Confluent T75 flasks of 293T 
cells (see Section 2.4.1) were transiently transfected using 30 µl Fugene and 10 µg of 
DNA (see Section 2.4.2), which contained 3 µg pMDLg/pRRE (Dull et al., 1998), 
4.5 µg pCS-CG; 1 µg pCNCrev and 1.5 µg pVSV-G. After 16 h, transfection 
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complexes were removed and the media was replaced. Virus containing supernatant 
was harvested 48 h and 72 h after transfection, cellular debris was removed by 
centrifugation for 10 min at 1800  g at 4°C and filtered through a 0.45 µm filter 
[Sartorius]. Then virus was aliquoted and frozen at -80°C. 
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Chapter 3 - Impact of ruminant APOBEC3 on JSRV 
replication 
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3.1 Introduction 
 
The A3 family of proteins has been identified (Harris and Liddament, 2004) as a 
species specificity determinant for a number of viral infections (Holmes et al., 2007b, 
Mariani et al., 2003) (see Section 1.8.1). Due to its viral genome editing potential, this 
restriction factor has a significant impact on the evolution rate of many viruses (Jern et 
al., 2009) and retroelements (Anwar et al., 2013). 
 
The activity of ruminant A3 proteins against various retroviruses has been previously 
studied by a few groups (Dorrschuck et al., 2011, Jonsson et al., 2006, LaRue et al., 
2008). However, this project is the first study of the effect caused by ruminant A3 on 
JSRV replication and its relevance to OPA epidemiology. JSRV restriction mediated 
by ruminant A3 was analysed and the mechanism of this process was investigated 
according to the plan of experiments shown in Fig. 3.1. 
 
 
 
Fig. 3.1 The plan of investigation of the effect of ruminant APOBEC3 on JSRV 
replication in vitro. 
Blue boxes: assays; Red boxes: results 
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3.2 Results 
 
Initially, ruminant A3 genes were cloned (see Section 3.2.1) and their activity was 
investigated in vitro (see Sections 3.2.2 to 3.2.7). The experiments on the in vivo 
significance of A3 during JSRV infection are described in Sections 3.2.8; 3.2.8 and 
3.3.4. 
 
3.2.1 Cloning of ruminant APOBEC3 genes 
 
As a first step towards studying the activity of ruminant A3 against JSRV, each A3 
coding region was isolated by RT-PCR and subsequently cloned into a mammalian 
expression vector. This process is shown in Fig. 3.2. 
 
 
 
 
Fig. 3.2 Cloning strategy of APOBEC3 Z2 and Z2Z3 coding regions  
Ruminant A3-Z3 and cow A3-Z2 were isolated using a forward primer overlapping the start 
codon, while external primers were utilised for other isolated A3 proteins, A3-Z1 coding 
sequences were cloned into pEGFP-CI instead of pGEM-T Easy prior to cloning into pCI-Neo. 
A3-Z3 open reading frames were reamplified from pGEM-T Easy and then cloned to pEGFP-
C1 prior to cloning into pCI-Neo mammalian expression vectors. 
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3.2.1.1 APOBEC3 primer design 
 
Isolation and cloning of ruminant A3 genes was based on available sequences of cow 
and sheep A3 that had been published previously (LaRue et al., 2008). Primers were 
designed based on the nucleotide sequence alignment of sheep and cow A3 sequences 
shown in Table 3.1. 
 
Table 3.1 Published ruminant A3 gene sequences 
 
APOBEC3 gene ID number 
Sheep A3-Z1 GI 238637212 
Sheep A3-Z2 GI 238637214 
Sheep A3-Z3 GI 238637216 
Sheep A3-Z2Z3 GI 199945618 
Cow A3-Z1 GI 255652988 
Cow A3-Z2 GI 197359096 
Cow A3-Z3 GI 197359098 
Cow A3-Z2Z3 GI 118150803 
 
Where possible, consensus primers (see Section 2.2) were designed to sequences 
located external to coding regions. The consensus primers were used to amplify sheep 
and cow A3 coding sequences A3-Z2 (see Fig. 3.3) and A3-Z2Z3 (see Fig. 3.4). RNA 
purified from the cell lines CPT-Tert (sheep) and BOMAC (cow) was used as a 
template for RT-PCR amplification of ruminant A3-Z2, A3-Z3 and A3-Z2Z3 coding 
regions (see Section 2.3.12) (see Section 2.10.1). 
 
Sheep and cow A3-Z3 were amplified using forward primer A3Z3 OA-BT ExpF and 
the external reverse primer A3Z2Z3-R. Because of a lack of conserved sequences in 
the A3-Z3 transcript upstream of the start codon, a primer overlapping the start codon 
was used (see Fig. 3.5). Despite the nucleotide sequence polymorphism between those 
two homologues downstream of the start codon, the N-terminal protein sequence is 
conserved among cow and sheep. 
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S-A3Z2      TTCCGCAGAGCCGGCCTGGGAGGTCACTCACAGATAAGGGGTTTTTCTATCCGAGAGTCC 
C-A3Z2      ...AAA------------------------T------------------C---------- 
 
S-A3Z2      TGAGAGAGGAAGTGGAGCCCCTGCACTCAAGACAAAGGCCAGGGCTGCAACCAATGCCCT 
C-A3Z2      --------C---------------G-------------------A--------GCCTA-C 
             
S-A3Z2      GAGGCTACAGCCAGATGCCCTGGA 
C-A3Z2      ------------------------ /A3-Z2 coding sequence/ 
 
 
S-A3Z2      TGGCTGCAGAGCTTGAGGACATTCTCGGGTGAGGGCTTCCTTAGCCTGCCCCTTACCCCG 
C-A3Z2      ------A--------------------------------T-------C---T-------- 
                                             
S-A3Z2      ACCCACGGCCTCCCCCTCACCTCCGCCCACCGTCACCTCCCTTCTCAGCCTCCTCTTTCC 
C-A3Z2      ------------------------------T—-T-----------------------C-- 
                                          Y 
 
Fig. 3.3 Alignment of sheep and cow sequences located external to the A3-Z2 reading 
frame   
Forward primers A3Z2F-Ov and A3Z2F-Bt were designed to match sheep                          
(S- GI 238637214) or cow (C- GI 197359096) mRNA sequence respectively (yellow). Two 
primers were necessary due to different locations of the start codons (green). The reverse 
primer is complementary to a consensus ruminant sequence (blue) located downstream of 
the stop codons (red). The highlighted residue (Y) indicates a degenerate base in the primer 
in order to permit the amplification of both genes. The majority of the ruminant A3-Z2 coding 
region is not shown. Dashes indicate sites where cow sequence is identical to sheep; 
polymorphic residues are highlighted by letters in the cow sequence; dots indicate gaps in 
the alignment. 
 
 
 
S-A3Z2Z3     CCTGAGAGAGGAAGTGGAGCCCCCGCACTCAAGACAAAGGCCAGGGCTGCAACCAGCCTG 
C-A3Z2Z3     --G-------C------------T—-G-------------------A------------A 
 
S-A3Z2Z3     CCGAGGCTACAGCCAGATGCCCTGGA 
C-A3Z2Z3     --------------------------   / A3-Z2Z3 coding sequence/ 
 
 
S-A3Z2Z3     GGCGCCGACTTAGAAAAGATCTTCAGAGGCTTGAGCATCAGACTCTCATCCCCTTTTTCA 
C-A3Z2Z3     ---C--A-T-------------------------------------------T.--G--- 
 
 
Fig. 3.4 Alignment of sheep and cow sequences located external to the A3-Z2Z3 
reading frame   
Forward primers A3Z2F-Ov or A3Z2-Bt were designed to match sheep (S- GI 199945618) or 
cow (C- GI 118150803) mRNA sequence respectively (yellow). Two primers were necessary 
due to the different location of the start codons (green). The reverse primer is 
complementary to consensus region (blue) located downstream of the stop codon (red). The 
majority of the A3-Z2Z3 coding region is not shown. Dashes indicate sites where cow 
sequence is identical to sheep; polymorphic residues are highlighted by letters in cow 
sequence; dots indicate gaps in alignment. 
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S-Z3      ...........TTCCGCAGAGCCGGCCTGGGAGGTCACTCACAGATAAGGGGTTTTTCTA 
C-Z3      ..GGGTGGAGCC--A--T---AT--.---------TG--TT-----C----AC-G-C--- 
 
S-Z3      TCCGAGAGTCCTGAGAGAGGAAGTGGAGCCCCCGCACTCAAGACAAAGG.CCAGGGCTGC 
C-Z3      A.......................................-AG--GG--T--T---.A-. 
 
S-Z3      AACCAATGACGGAGGGCTGGGCTGGATCAGGCCTT 
C-Z3      TGT-T-----C--------------G-------A-   /A3-Z3 coding sequence/ 
 
 
S-Z3      CGGCGCCGACTTAGAAAAGATCTTCAGAGGCTTGAGCATCAGACTCTCATCCCCTTTTTC 
C-Z3      ----C--A-T-------------------------------------------.---G-- 
 
 
Fig. 3.5 Alignment of sheep and cow sequences located external to A3-Z3 reading 
frame   
The forward primer A3Z3-F was designed to bind a conserved sequence in the sheep       
(S- GI 238637216) and cow (C- GI 197359098) mRNAs (yellow and green underlined) 
overlapping the start codon (green). The reverse primer A3-Z3-R is complementary to a 
conserved ruminant sequence (blue) located downstream of the stop codons (red). The 
majority of ruminant A3-Z3 coding region is not shown. Dashes indicate sites where cow 
sequence is identical to sheep; polymorphic residues are highlighted by letters in cow 
sequence; dots indicate gaps in alignment. 
 
Cloning of sheep and cow A3-Z1 was more difficult than Z2, Z3 and Z2Z3. There 
were a number of unsuccessful RT-PCR amplifications using RNA extracted from 
sheep cell line CPT-Tert sheep as well as the cow cell lines: MDBK, BOMAC (see 
Section 2.4.1). Similarly there was a lack of A3-Z1 amplification when RNA extracted 
from a panel of sheep tissues including lung, muscle, spleen, liver, testicle, kidney, 
OPA tumour and mediastinal lymph node was used (data not shown). Additionally, 
RNA extracted from cow lung was tested, but still failed to yield a positive 
amplification product for A3-Z1. Neither utilisation of external primers nor primers 
designed for cloning into pCI-Neo failed to amplify A3-Z1. However, other A3 
paralogues were successfully amplification of from RNA, extracted from these tissues. 
 
Referring to submitted sequence of sheep Z1 in GenBank, it was identified in EST 
library that had been prepared from small intestine. Subsequently, cow and sheep 
intestine RNA was obtained (Craig Watkins, Moredun Research Institute) and A3-Z1 
was successfully amplified from both by David Griffiths (Moredun Research 
Institute). 
 
Cow and sheep A3-Z1 were amplified by RT-PCR utilising consensus external 
primers (A3Z1-F, A3Z1-R) to ruminant A3-Z1 ORF (see Fig. 3.6). 
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S-Z1      -CTCCTGCCGCTTGAACAACTTCAAGGAGGAGGCCACAGGCTGTGACTGAGCATAGCATC 
C-Z1      AGG-------------------------------------..C------------C---- 
 
S-Z1      AGAGGACTCGGAGCCAGGGACGACGCCTGATGGATGAA 
C-Z1      ------------------------A---------C--- /A3-Z1 coding sequence/ 
 
S-Z1      AACTGAAGGACGGACGCCAGCCTCTCTA.AGATGGCAGGAGGCCTCTATTCAACAGCAGC 
C-Z1      ----------T-----------------A---A--------A-----------------A 
 
S-Z1      ACAAAACACCTTCTTTCAAGAAATGTAAACATGCCATATGCTACTGTCTCCAGACTGATC 
C-Z1      ---------T------------G----------A---T---------------------T 
                                                                     Y 
S-Z1      CAAACAGAC 
C-Z1      --------- 
           
 
Fig. 3.6 Alignment of sheep and cow sequences located external to A3-Z1 reading 
frame 
 The forward primer A3Z1-F was designed to consensus sheep (S- GI:238637212) and cow 
(C- GI:255652988) sequence (yellow) upstream the start codons (green). The reverse 
primer is complementary to consensus ruminant sequence (blue) located downstream of the 
stop codons (red). The highlighted residue (Y) indicates a degenerate base in the primer in 
order to enhance the amplification of both genes. The majority of the ruminant A3-Z1 gene is 
not shown. Dashes indicate sites where cow sequence is identical to sheep; polymorphic 
residues are highlighted by letters in cow sequence; dots indicate gaps in alignment. 
 
The sheep and cow A3-Z1HA sequence was reamplified from purified RT-PCR 
product using high fidelity KOD polymerase. The PCR product was digested and 
inserted into SalI and NotI digested pEGFP-FLAG (see Section 2.1.16 and 2.10.1) for 
expression in mammalian cells. 
 
3.2.1.2 Cloning of goat APOBEC3 genes 
 
Goat A3 gene sequences have not been published previously but the cloning strategy 
for goat A3 genes was similar to the sheep and cow homologues. Therefore, external 
primers derived from the sheep and cow sequences flanking ORFs were utilised for 
isolation of goat A3.  
 
This approach was successfully used to clone goat A3-Z2, A3-Z3 and A3-Z2Z3 from 
RNA from a goat cell line (TIGEF). However, it was not possible to clone goat A3-Z1 
from TIGEFs and goat intestine tissue was not available for study. Therefore, goat  
A3-Z1 was not analysed in this project.  
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In order to eliminate the uncertainty connected with cloning A3-Z3 caused by the 
utilisation of a forward primer that overlaps the start codon (see Fig. 3.5), the goat  
A3-Z3 locus was investigated at the genome level. DNA extracted from the goat cell 
line TIGEF was used as a template for PCR. Consensus primers were designed based 
on sheep and cow sequences, located upstream of the A3-Z3 start codon (Z3xtF2) and 
downstream (Z3xtR1, Z3xtR2) (see Fig. 3.7). PCR products were cloned into    
pGEM-T Easy and sequenced. Moreover, recently some caprine genome sequence has 
become publically available (GenBank Accession: LOC102184324). This confirms 
that an authentic goat A3-Z3 was used in this study. 
 
Fig. 3.7 Investigation of goat 5’ A3-Z3 locus 
Locations of primers used are indicated in violet. They were used to amplify two sequences 
overlapping the 5’ region of the goat A3-Z3 coding sequence (green and orange). 
 
Amplified genes were cloned into pGEM-T Easy (see Section 2.1.1) and several 
clones of each PCR product were sequenced in order to avoid the selection of a clone 
with RT-PCR errors. More goat A3 clones were sequenced than sheep and cow, 
because the goat sequences had not been published at the time. For each A3 protein, a 
clone was selected that matched the consensus of all sequenced clones. 
 
The A3 clones selected for expression analysis all had amino acid sequences identical 
to the previously published sequences (LaRue et al., 2008) with the exception of four 
mismatches present in cow A3-Z1 and one sheep A3-Z1 residue (14
th
) was R in this 
study but G in the published sequence (see Fig. 3.8).  
 
All the analysed ruminant A3 homologues share high sequence similarity, however the 
newly identified goat sequences were more similar to their sheep than cow 
homologues, which reflects the closer relatedness of sheep and goats (see Fig. 3.8 to 
3.11).  
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A3-Z1 
                       G  
S-Z1      MDENTFTENFNNQRWPSKTFLCYMVERLDDENTATPLDEYKGFVRNKGRDQPGEPCHAEL   
C-Z1      ---Y---------GR----Y---YV----G.-ATI-------------L---EE------   
                                  M                            K 
           
S-Z1      YFLGQIRSWNLDRNQHYRLTCFISWTPCYNCAQKLTTFLKENHHISLHIFASRIYTVDDS   
C-Z1      ----K--------------------S---D------------R------L-P----RNHF   
                                                    H        S 
 
S-Z1      GSRQSGLCALQAAGARITIMTSKDFERCWVTFVDHKEKPFQPWEGLEVKSKKLCEELQAI   
C-Z1      -CH-----E------------FE--KH--E------G---------N---QA--A-----   
 
S-Z1      LRAQQN 
C-Z1      -KT--- 
 
 
Fig. 3.8 Alignment of sheep and cow A3-Z1 protein sequences 
The sheep (S- GI 238637212) and cow (C- GI 255652988) A3-Z1 have typical features which 
include the presence of conserved motifs (underlined; bold-conserved residues are discussed 
in section 1.5.1.2) (LaRue et al., 2009). A mismatch to the published sheep sequence is 
highlighted in pink, differences to published cow sequence are highlighted in red (published 
sequence amino acids are displayed above-sheep, or below – cow GI 255652988). The motif 
which includes isoleusine after arginine is unique to all Z1 domains (highlighted in green) 
(LaRue et al., 2009). Dashes indicate sites where cow sequence is identical to sheep; 
polymorphic residues are highlighted by letters in cow sequence; dots indicate gaps in 
alignment. 
 
A3-Z2  
 
S-Z2       ..........MPWIS...DHVARLDPETFYFQFHNLLYAYGRNCSYICYRVKTWKHRSPV 
G-Z2       ..........-----...----------------------------------R------- 
C-Z2       MQPAYRGYSQ---TRDSSE-M------------C-----NR--------K-ERR-YH-RA 
 
S-Z2       SFDWGVFHNQVYAGTHCHSERRFLSWFCAKKLRPDECYHITWFMSWSPCMKCAELVAGFL 
G-Z2       ------------------------------E----------------------------- 
C-Z2       ------------G--R--T-L------H-E----N-R----------------KE--D-- 
 
S-Z2       GMYQNVTLSIFTARLYYFQKPQYRKGLLRLSDQGACVDIMSYQEFKYCWKKFVYSQRRPF 
G-Z2       -----------A------------M---G------R------R----------N------ 
C-Z2       -RH--------T----N--EEGS-Q---R------H------Q----------N------ 
 
S-Z2       RPWKKLKRNYQLLAAELEDILG 
G-Z2       ---------------------- 
C-Z2       ------Y----R-VE------- 
 
 
Fig. 3.9 Alignment of sheep, goat and cow A3-Z2 protein sequences 
The sheep (S-), cow (C-) and goat (G-) A3s have typical features which include the presence 
of conserved motifs (underlined; bold-conserved residues are discussed in section 1.5.1.2) 
(LaRue et al., 2009). There is a WF tryptophan-phenylalanine motif five residues after 
glutamate in the Z2 domain and a zinc-binding motif SWSPCx2-4C, where “x” could be any 
amino acid. Dashes indicate sites where goat or cow sequence is identical to sheep; 
polymorphic residues are highlighted by letters in the cow sequence; dots indicate gaps in 
alignment. 
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A3-Z3 
  
S-Z3       MTEGWAGSGLPGRGDCVWTPQTRNTMNLLRETLFKQQFGNQPRVPPPYYRRKTYLCYQLK 
G-Z3       ------------Q----------------------------------------------- 
C-Z3       ---------H--Q-A-----G----------V-------------A-------------- 
 
S-Z3       ELDDLMLDKGCFRNKKQRHAEIRFIDKINSLNLNPSQSYKIICYITWSPCPNCASELVDF 
G-Z3       Q----T---------R-------------------------------------------- 
C-Z3       QRN--T--R------R---------------D----------------------N---N- 
 
S-Z3       ITRNDHLNLQIFASRLYFHWIKPFCRGLQQLQKAGISVAVMTHTEFEDCWEQFVDNQLRP 
G-Z3       ------------------------WK---K----------T------------------- 
C-Z3       ----N--K-E------------S-KM---D--N------------------------S-- 
 
S-Z3       FQPWDKLEQYSASIRRRLQRILTAPT 
G-Z3       -------------------------- 
C-Z3       -------------------------- 
 
 
Fig. 3.10 Alignment of sheep, goat and cow A3-Z3 protein sequences 
The sheep (S-), cow (C-) and goat (G-) A3s have typical features which include the presence 
of conserved motifs (underlined; bold-conserved residues are discussed in section 1.5.1.2) 
(LaRue et al., 2009). There is a zinc-binding motif TWSPCx2-4C characteristic of the Z3 
domain (bold and underlined), where “x” could be any amino acid. Dashes indicate sites where 
goat or cow sequence is identical to sheep; polymorphic residues are highlighted by letters in 
cow sequence; dots indicate gaps in alignment. 
 
The sequences of cloned ruminant A3 proteins were identical to published ones with 
the exception of one residue of sheep A3-Z1 and four residues in cow A3-Z1. 
Therefore, it makes them reliable for comparison to previously published studies. 
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A3-Z2Z3 
 
S-Z2Z3    ..........MPWIS...DHVARLDPETFYFQFHNLLYAYGRNCSYICYRVKTWKHRSPV 
G-Z2Z3    ..........-----...----------------------------------R------- 
C-Z2Z3    MQPAYRGYSQ---TRDSSE-M------------C-----NR--------K-ERR-YH-RA 
 
S-Z2Z3    SFDWGVFHNQVYAGTHCHSERRFLSWFCAKKLRPDECYHITWFMSWSPCMKCAELVAGFL 
G-Z2Z3    ------------------------------E----------------------------- 
C-Z2Z3    ------------G--R--T-L------H-E----N-R----------------KE--D-- 
 
S-Z2Z3    GMYQNVTLSIFTARLYYFQKPQYRKGLLRLSDQGACVDIMSYQEFKYCWKKFVYSQRRPF 
G-Z2Z3    -----------A------------M---G------R------R----------------- 
C-Z2Z3    -RH---------S---K--EEGS-Q----------H------------------------ 
 
S-Z2Z3    RPWKKLKRNYQLLAAELEDILGNTMNLLRETLFKQQFGNQPRVPPPYYRRKTYLCYQLKE 
G-Z2Z3    -----------------------------------------------------------Q 
C-Z2Z3    ------D----R-VE---------------V-------------A--------------Q 
 
S-Z2Z3    LDDLMLDKGCFRNKKQRHAEIRFIDKINSLNLNPSQSYKIICYITWSPCPNCASELVDFI 
G-Z2Z3    ----T---------R--------------------------------------------- 
C-Z2Z3    RN--T--R----------------------D----------------------N---N-- 
 
S-Z2Z3    TRNDHLNLQIFASRLYFHWIKPFCRGLQQLQKAGISVAVMTHTEFEDCWEQFVDNQLRPF 
G-Z2Z3    -----------------------WK---K------------------------------- 
C-Z2Z3    ---N--K-E------------S-KM---D--N------------------------S--- 
 
S-Z2Z3    QPWDKLEQYSASIRRRLQRILTAPT 
G-Z2Z3    ------------------------- 
C-Z2Z3    ------------------------I 
 
 
Fig. 3.11 Alignment of sheep, goat and cow A3-Z2Z3 protein sequences 
Residues different to sheep sequence (top) are displayed with letters; dashes indicate 
consensus residues; dots were used to highlight gaps in alignment. The sheep (S-), cow (C-) 
and goat (G-) A3s have typical features which include the presence of conserved motifs 
(underlined; bold-conserved residues are discussed in section 1.5.1.2) (LaRue et al., 2009). 
There is a WF tryptophan-phenylalanine motif five residues after glutamate in the Z2 domain 
and a zinc-binding motif SWSPCx2-4C and a zinc-binding motif TWSPCx2-4C characteristic for 
the Z3 domain, where “x” could be any amino acid. Dashes indicate sites where goat or cow 
sequence is identical to sheep; polymorphic residues are highlighted by letters in cow 
sequence; dots indicate gaps in alignment. 
 
3.2.1.3 Cloning of APOBEC3 genes into mammalian expression vectors 
 
In order to perform in vitro experiments, ruminant A3 genes were cloned into the 
mammalian expression vector pCI-Neo. The desired A3 pGEM-T Easy or pEGFP-CI 
(A3-Z1) clones were reamplified by a high fidelity PCR (see Section 2.3.13). When 
the similarity of ruminant A3 proteins allowed, then the same pair of primers was used 
for amplification of each A3 homologue. However, in some cases the protein sequence 
at the 5’ or 3’ end varied among different species and then species specific primers 
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were utilised. For example, the cow A3-Z2 domain has 10 more amino acids at the            
N-terminus and there is a polymorphism present in either C- or N- end of the A3-Z1 
and A3-Z2 protein. 
 
Each forward primer for expression inserted a Kozak consensus sequence (ACCGCC) 
(Kozak, 1987) upstream of the start codon and a haemagluttinin tag was added to the 
N-terminus of the sequence by the reverse primers. The primers used in those 
reactions contained restriction sites, which enabled cloning into pCI-Neo (see Section 
2.1; 2.2.2.; 2.10). Sheep and cow A3-Z1 were cloned into pEGFP-CI by replacing the 
GFP ORF (see Section 2.10.1) prior to subsequent cloning into pCI-Neo. 
 
3.2.2 JSRV packages ruminant APOBEC3s in vitro 
 
The antiviral activity of A3 proteins requires their expression in virus producing cells, 
where encapsidation occurs during virus assembly (Harris and Liddament, 2004). To 
determine whether JSRV encapsidates ruminant A3 proteins, they were coexpressed 
with plasmids encoding JSRV in 293T cells (see Section 2.10.2.2). Three different 
amounts of each A3 expressing plasmid were tested in these experiments (see Table 
2.3). Currently, there is no permissive cell line that enables JSRV replication in vitro, 
therefore retroviral vector pCMV2JS21 (see Section 2.1.3) (Palmarini et al., 1999), 
which is an infectious molecular clone of JSRV and its derivative reporter virus 
pCMVJS-ΔE-CG that encodes a CMV-EGFP reporter cassette were employed in this 
study (see Section 2.1.9). 
 
The expression of JSRV in 293T cells was detected using rabbit anti-Gag antibody by 
western blotting of cellular lysates and concentrated virus from culture supernatants 
(see Fig. 3.12 – 3.15) (see Sections 2.6. and 2.10.7). This antibody detected mainly 
unprocessed Gag in cellular extracts of transfected cells and processed CA protein of 
viral particles present in concentrated supernatant. The intensity of CA bands in 
concentrated supernatant was used to standardize inocula of the different virus stocks 
that were used to infect cells. A variation in the amount of CA detected in 
concentrated JSRV-GFP containing supernatant was observed. JSRV-GFP stock made 
by cotransfection with 4 µg of sheep or goat A3-Z2 HA or APOBEC Z2Z3 HA 
contained a decreased amount of CA in comparison to other stocks prepared at the 
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same time. Therefore the volume of those “4 µg stocks” was increased for infections. 
As an example a western blot picture of A3-Z2 stocks is shown in Fig.3.12. 
 
 
Fig. 3.12 Imbalance of CA content in stocks made in the presence of A3-Z2 
Panel (A) western blot detection of CA in concentrated JSRV-GFP made in the presence of 
ruminant A3-Z2. Transfection was performed in the presence of the indicated A3s (C- cow,   
G- goat, S- sheep) and a vector control (no A3). Numbers represent µg of A3 encoding vector 
during transfection. Arrows indicate bands where a lower amount of CA was detected (blue – 
4 µg of sheep A3-Z2; red - 4 µg of goat A3-Z2). Molecular weight marker See Blue2 bands 
representing protein size (kDa) are displayed on the left side of figure. Panel (B) amount of CA 
compared to “No A3 stock”, band density values were approximated using the ImageQuant TL 
Array software by the image rectangle background subtraction method. 
 
Figure 3.12 clearly shows the decreased CA content of JSRV-GFP stocks made by 
cotransfection with 4 µg of sheep and goat A3-Z2. The image shown was intentionally 
captured by relatively short exposure time in order to emphasise the disproportions. 
 
Notably, this effect was not seen with “4 µg cow A3-Z2 or Z2Z3 stocks” or JSRV21 
stocks. The blots presented in Fig. 3.13 - 3.16 were performed using standardized 
volumes of concentrated supernatant in order to ensure to infect cells with a similar 
amount of virus. In practice this means that identical volumes of each stock were used 
for infections and RT-assays, with the exception of sheep and goat A3-Z2 and A3-
Z2Z3 stocks which were adjusted on the total content of Gag by immunoblot 
comparison with dilutions of “No A3” stock or by analysis utilising ImageQuant TL 
Array software. Notably, RT-assay should not be used to normalise input amount of 
virus in those experiments because of the potential interference of A3 on reverse 
transcription.  
CA 
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The expression of HA-tagged ruminant A3 proteins in 293T cellular extracts and their 
encapsidation by JSRV-GFP was confirmed by anti-HA Western Blot (see Fig. 3.13 to 
3.16), (see Section 2.6). The filtration of virus containing supernatant and further 
ultracentrifugation ensured that the signal from HA-tagged A3 is from virus-associated 
protein, which is likely packaged into virions and is not an artefact of cellular debris or 
secreted protein present in the culture supernatant. To confirm this, the supernatant 
was analysed from cells transfected only with A3 expression vector without any virus 
encoding DNA.  
 
 
Fig. 3.13 JSRV encapsidates ruminant A3-Z1 
Panel (A) shows Western blot detection of Gag proteins in concentrated JSRV. Panel (B) 
demonstrates encapsidation of ruminant A3-Z1 by JSRV in analysed concentrated 
supernatants. JSRV Virus stocks were made by transfection together with the indicated A3s      
(C- cow, G- goat, S- sheep) or a vector control (no A3). Numbers represent µg of A3 encoding 
vector during transfection. Blots presented represent concentrated JSRV-GFP pseudotyped 
with JSRV Env or VSV-G Env (described below each image). Molecular weight marker See 
Blue2 bands representing protein size (kDa) are displayed on the left side of figure. 
  
A3-Z2 HA 
CA 
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Fig. 3.14 JSRV encapsidates ruminant A3-Z2 
Panel (A) shows Gag detection in cellular extract of 293T coexpressing ruminant A3-Z2. Panel 
(C) shows Western blot detection of Gag proteins in concentrated JSRV-GFP. Panel (B) 
shows detection of haemagglutinin tagged ruminant A3-Z2 in cellular extract of 293T. Panel 
(D) demonstrates encapsidation of ruminant A3-Z2 by JSRV in concentrated supernatants. 
JSRV Virus stocks were made by transfection together with the indicated A3s (C- cow,          
G- goat, S- sheep) or a vector control (no A3). Numbers represent µg of A3 encoding vector 
during transfection. Molecular weight marker See Blue2 bands representing protein size (kDa) 
are displayed on the left side of figure. 
 
 
The amount of encapsidated A3 present in the JSRV-GFP and expressed in producer 
cell line lysates increased with increasing amount of A3 expression plasmid used in 
transfection (see Fig. 3.13 to Fig. 3.16). A stronger band was observed where 4 μg of 
A3 expression vector was used than 1 μg, while 0.25 μg rarely gave a visible band. No 
HA signal was detectable by western blot of filtered and ultracentrifuged supernatant 
from cells transfected only with 4μg sheep A3-Z2Z3HA pCI-Neo (data not shown). 
 
  
A3-Z2 HA 
Gag 
CA 
106 
 
 
 
 
Fig. 3.15 JSRV encapsidates ruminant A3-Z3 
Panel (A) shows Gag detection in cellular extract of 293T coexpressing ruminant A3-Z3. Panel 
(C) shows western blot detection of Gag proteins in concentrated JSRV-GFP. Panel (B) shows 
detection of haemagglutinin tagged ruminant A3-Z3 in cellular extract of 293T. Panel (D) 
demonstrates encapsidation of ruminant A3-Z3 by JSRV in concentrated supernatants. JSRV 
Virus stocks were made by transfection together with the indicated A3s (C- cow, G- goat,      
S- sheep) or a vector control (no A3). Numbers represent µg of A3 encoding vector during 
transfection. Molecular weight marker See Blue2 bands representing protein size (kDa) are 
displayed on the left side of figure. 
  
A3-Z3 HA 
Gag 
CA 
107 
 
 
 
Fig. 3.16 JSRV encapsidates ruminant A3-Z2Z3 
 Panel (A) shows anti-Gag analysis of cellular extract of 293T coexpressing ruminant           
A3-Z2Z3. Panel (C) shows western blot detection of Gag proteins in concentrated JSRV-GFP. 
Panel (B) shows detection of haemagglutinin tagged ruminant A3-Z2Z3 in cellular extract of 
293T. Panel (D) demonstrates encapsidation of ruminant A3-Z2Z3 by JSRV in analysed 
concentrated supernatants. JSRV Virus stocks were made by transfection together with 
indicated A3s (C- cow, G- goat, S- sheep) or a vector control (no A3). Numbers represent µg 
of A3 encoding vector during transfection. Molecular weight marker See Blue2 bands 
representing protein size (kDa) are displayed on the left side of figure. 
  
A3-Z2Z3 HA 
Gag 
CA 
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3.2.3 Ruminant APOBEC3 restricts JSRV in vitro 
 
Having demonstrated that all the analysed ruminant A3 proteins were encapsidated by 
JSRV, it was next determined whether these proteins can restrict JSRV infectivity. As 
there is no permissive cell culture system supporting JSRV replication, retroviral 
vectors pCMV2JS21 (see Section 2.1.3) and its GFP-carrying derivative         
pCMV2JS-ΔE-CG were employed in this study (see Section 2.1.9). The use of GFP as 
a reporter enabled the study of their infectivity by flow cytometry (see Section 2.8.3). 
Parallel experiments were performed with viruses pseudotyped with JSRV Env or 
VSV-G. 
 
The number of infected cells (GFP expressing) was reduced when cells were infected 
with JSRV encapsidating any of ruminant A3s, however A3-Z1 and A3-Z3 did not 
cause as strong restriction as that mediated by A3-Z2 and A3-Z2Z3. The infectivity of 
JSRV-GFP decreased with increasing amounts of A3 expression plasmid used in 
transfection of 293T cells. Flow cytometric analysis of CRFK-ovH2 cells infected 
with JSRV-GFP demonstrated the ability of ruminant A3-Z1, Z2 and Z2Z3 to restrict 
JSRV in vitro (see Fig. 3.17). Notably, sheep A3-Z1, Z2 and Z2Z3 were able to inhibit 
infection almost with similar efficiency as their goat and cow homologues (as 
illustrated in Fig. 3.17). 
 
In addition to a decreased number of positive cells (see Fig. 3.17 and Fig. 3.19), there 
was a decrease in the fluorescence intensity of cells infected with JSRV-GFP made in 
the presence of increased amounts of A3 (see Fig. 3.18). The median fluorescence 
intensity of GFP-positive cells was reduced when cells were infected by JSRV-GFP 
carrying all ruminant A3s, however this effect was mild in cells infected by A3-Z3 
stocks (see Fig. 3.17). The GFP-positive cells infected by stocks made by co-
transfection with 4 µg of A3 are characterized by a FITC median value close to the 
baseline separating the GFP-positive from the GFP negative population. 
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Fig. 3.17 Restriction of JSRV by ruminant A3 proteins  
Bars represent relative infectivity of JSRV-GFP stocks made in the presence of various A3s 
(Z1, Z2, Z3 and Z2Z3). Flow cytometric results of CRFKovH2 cells infected by JSRV-GFP. 
The relative percentage of cells infected by virus produced in the presence of the indicated        
A3s (C- cow, G- goat, S- sheep) and a vector control (no A3), numbers on X-axis represent µg 
of A3 encoding vector during transfection. Values are based on the ratio of percentage     
GFP-positive cells infected by “A3 stocks” compared to cells infected by “No A3 stock”. The 
student two-tailed t-test method with unequal variance was used to verify the significance of 
results. The error bars report the standard deviation value between wells infected in triplicate. 
Plots present relative infectivity values of one of at least 2 experiments. 
 
There was a possibility of false positive readings of fluorescent cells due to their 
uptake of DNA which was carryover from the virus production process. That is why 
all analysed virus stocks were concentrated and heat inactivated virus was used as a 
negative control in every infection assay along with non-infected cells. Cells subjected 
to heat inactivated virus rarely contained any GFP-positive cells. Therefore, the 
passive transduction caused by DNA carryover was minimal since heat inactivated 
controls never contained more than 0.03% of GFP-positive cells. 
 
 A3-Z3 A3-Z2Z3 
A3-Z1 A3-Z2 
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Fig. 3.18 The impact of ruminant A3 on fluorescence of JSRV-GFP infected cells  
Bars represent fluorescence intensity median of cells infected by stocks made in presence of 
various A3s (Z1, Z2, Z3, Z2Z3). Flow cytometric results of CRFKovH2 cells infected by JSRV-
GFP – the relative median fluorescence of cells infected by virus produced in the presence of 
the indicated A3s (C- cow, G- goat, S- sheep) and a vector control (no A3), numbers represent 
µg of A3 encoding vector during transfection. Values are based on the fluorescence intensity 
median of GFP-positive cells infected by “A3 stocks” compared to cells infected by “No A3 
stock”. The student two-tailed t-test method with unequal variance was used to verify the 
significance of results. The error bars report the standard deviation value between wells 
infected in triplicate. Plots present relative fluorescence intensity values of one of at least 2 
experiments. 
 
3.2.4 VSV-G and JSRV Env pseudotyped viruses are restricted by APOBEC3 
to the same degree  
  
The experiments shown in Section 3.2.3 utilised wild type JSRV Env. In order to 
determine whether the envelope protein used influences the results, experiments 
utilising VSV-G pseudotyped JSRV-GFP were also performed (see Fig. 3.19). The 
detected lack of strong A3-Z1 and A3-Z3 inhibition of JSRV Env pseudotyped virus 
(see Fig. 3.17 and 3.18) required an investigation if JSRV Env does not mediate an 
evasion potential against those A3.  
A3-Z1 A3-Z2 
A3-Z3 A3-Z2Z3 
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Fig. 3.19 Restriction of JSRV (VSV-G) by ruminant A3 proteins 
Bars represent relative infectivity of JSRV-GFP stocks made in presence of various A3s     
(Z1, Z2, Z3 and Z2Z3). Flow cytometric results of CRFKovH2 cells infected by JSRV-GFP. 
The relative percentage of cells infected by virus made in the presence of the indicated A3s  
(C- cow, G- goat, S- sheep) and a vector control (no A3), numbers on X-axis represent µg of 
A3 encoding vector during transfection. Values are based on the ratio of percentage GFP-
positive cells infected by “A3 stocks” compared to cells infected by “no A3 stock”. The student 
two-tailed t-test method with unequal variance was used to verify the significance of results. 
The error bars report the standard deviation value between wells infected in triplicate. Plots 
present relative infectivity values of one of at least 2 experiments. 
 
Although A3 is thought to act independently of the infected target cell type, in order to 
verify this statement the VSV-G pseudotyped JSRV-GFP were prepared in other cell 
lines, which are non permissive for JSRV Env mediated entry. The JSRV-GFP 
pseudotyped either with JSRV or VSV-G envelope protein, were restricted to a similar 
degree by ruminant A3s (see Fig. 3.19). Flow cytometry results showed that there is a 
similar decrease in the percentage of GFP-positive cells and their fluorescence 
intensity caused by ruminant A3 irrespective of envelope used. 
 
Therefore no evasion of A3 mediated by JSRV envelope was detected. It should be 
noted that all JSRV-GFP production occurred by a co-transfection with SP-FLAG 
which is a fragment of JSRV Env gene, in order to enhance the stock titre. There is a 
need to be aware that SP may influence the ratio of transcripts, since it has been 
described to act as a postranstriptional regulator of expression (Caporale et al., 2009).  
A3-Z1 A3-Z2 
A3-Z3 A3-Z2Z3 
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3.2.5 Effect of sheep APOBEC3 on the number of integrated proviruses  
 
In order to further investigate the detected inhibition of JSRV by sheep A3 the 
integrated proviruses were quantified. The activity of sheep A3 against the wild type 
JSRV virus and JSRV-GFP was measured by qPCR (see Section 2.10.4). Integration 
events which occurred as the effect of JSRV-GFP or JSRV21 infections were compared 
(see Fig. 3.20). Note that this was a preliminary experiment and requires further 
confirmation, preferably with utilisation of stocks made in presence of other quantities 
of A3 expressing vector. 
 
 
Fig. 3.20 Reduction of JSRV integration events by sheep A3 proteins 
The qPCR measured the relative number of proviruses in cells infected by JSRV-GFP (A) or 
JSRV21 (B). Virus was produced in the presence of the indicated sheep A3s (4µg of A3 
encoding vector used during transfection) and a vector control (no A3). Results show an 
average of duplicate qPCR samples. 
 
The results show there were at least four-fold fewer proviruses detected in cells 
infected by either JSRV-GFP or a wild type JSRV21 containing A3-Z2 or Z2Z3 virus 
stocks compared to cells infected by “No A3” stock. Due to time constraints this assay 
was only done once, therefore it needs to be repeated in order to confirm the result 
obtained. As negative controls heat inactivated or heat inactivated and DNAse treated 
viruses were used. However, carryover DNA was detected in some negative controls 
and those values were subtracted during interpretation of the proviral copy number. 
  
- 
A3-Z2Z3 A3-Z3 A3-Z2 No A3 A3-Z2Z3 A3-Z3 A3-Z2 No A3 
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3.2.6 Hypermutation caused by sheep APOBEC3 
 
The previous experiments provide clear evidence that ruminant A3 can restrict JSRV, 
at least in vitro. As hypermutation mediated by the cytidine deaminase activity of A3 
is a common mechanism of viral restriction mediated by A3 in other species, I next 
examined whether sheep A3 proteins also exhibit this activity against JSRV. Genomic 
DNA was extracted from cells infected by JSRV21 and JSRV-GFP made in the 
presence of sheep A3-Z2, Z3 and Z2Z3. The DNA was subjected to high fidelity 
amplification of 928 bp fragments of EGFP (JSRV-GFP) or env (JSRV21) sequences 
present in those proviruses. Subsequently, the amplified sequences were cloned into 
pGEM-T Easy (see Section 2.10.7), and up to 21 clones of each were sequenced to 
identify possible hypermutation. 
 
Countermeasures were introduced to minimise the risk of amplifying the possible 
carryover of DNA which was used during transfection during virus production. All 
virus stocks were treated with DNAse prior to infection (see Sections 2.3.11 and 
2.10.5) and cells were washed twice after the infection before adding the medium. In 
addition, DNA was extracted from non-infected cells and from cells exposed to a heat 
inactivated “no A3” stock and was utilised as a negative control for PCR. Provirus 
fragments from up to 21 separate integration events were sequenced for each of the A3 
variants. The mutation frequency caused by the various A3s is shown in Table 3.2. 
 
The results provided evidence of deamination of JSRV-GFP by sheep A3-Z2 and 
Z2Z3. Cells infected with “No A3” virus stocks provided DNA which was used to 
characterise the background error of sequences readout in the assay. 
 
Table 3.2 Mutation frequencies observed in proviruses affected by sheep A3  
APOBEC3 
No of 
clones 
sequenced 
Bases 
sequenced 
GA other 
GA 
freqency 
no A3  19 17632 2 2 0.00011 
Z2  17 15776 178 3 0.01128 
Z3 17 15776 3 1 0.00018 
Z2Z3 21 19488 51 4 0.00275 
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In this experiment A3-Z2 was identified as being a stronger JSRV hypermutator than 
A3-Z2Z3 (see Table 3.2). Sheep A3-Z2 and A3-Z2Z3 G to A mutation frequency was   
89-fold and 25.5 fold higher respectively than the negative control, which contained 
only one G to A mutation in the total of ninety 928 bp length fragments of proviruses 
from cells infected by “No A3” stock. Mutations observed in sequenced “A3-Z3” 
proviruses were close to the background of the assay. 
 
The experiment demonstrated that sheep A3-Z2 and A-Z2Z3 are able to hypermutate 
JSRV in vitro. The sequencing results shown in graphs generated by Hypermut 
software (see Fig. 3.21) demonstrate the distribution of mutations among a group of 
sequenced individual provirus clones from two separate experiments. 
 
There was an apparent difference in the editing pattern of A3-Z2 and A3-Z2Z3 on 
JSRV-GFP. Proviruses deaminated by A3-Z2Z3 showed a dispersed distribution of 
mutations among different sequences, whereas A3-Z2 induced hypermutation was 
focused on a smaller number of sequences which were edited more intensively than 
others (e.g. clones A3-Z2 marked by asterisk in Fig.3.20). This result could suggest a 
different enzymatic activity mechanism between A3 paralogues. The bases located 
next to a guanidine have impact on the occurrence of deamination (Ebrahimi et al., 
2014). This experiment determined the site preference of mutations caused by sheep 
A3-Z2 and A3-Z2Z3 (see Table 3.3). The most commonly mutated sites were GA 
(cyan), followed by GG (red) to GC (green) (see Fig. 3.21 and Table 3.3). The 
deamination site preference of analysed sheep A3 is shown in Table 3.3. 
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Fig. 3.21 Hypermutation of proviral genome caused by sheep A3 
Graphs were generated using Hupermut software. Horizontal lines represent 928 bp 
fragments of individually sequenced proviruses (letters). Coloured short vertical lines indicate 
mutation, indicating the base downstream of the mutated guanidine. Short black vertical lines 
represent non G  A mutations. 
 
Table 3.3 G to A mutation context observed in proviruses affected by sheep A3 
 
APOBEC3  GG GA GC GT 
no A3  1 0 1 0 
Z2  32 113 30 3 
Z3 2 1 0 0 
Z2Z3 7 33 10 1 
Mutated residues    GA  AA  GT  AT  GC  AC  GG  AG  deletion   I - other 
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3.2.7 Ruminant APOBEC3 inhibits the enzymatic activity of JSRV’s RT 
 
Work on other retroviruses has shown that A3 proteins can restrict infection by 
mechanisms that do not involve hypermutation (Stenglein and Harris, 2006). In 
particular, several steps in reverse transcription may be inhibited by A3. In order to 
examine the mechanism of restriction, the effect of each of the A3 proteins on JSRV-
mediated reverse transcription was measured using a commercial colorimetric RT 
assay (see Section 2.10.9). The same virus stocks that were used in infectivity assays 
were subjected to analysis of their RT activity. Therefore, the detection of possible 
reverse transcription interference by A3 was performed by comparison to RT activity 
of “no A3” stocks. Similarly to infectivity experiments, standardized amounts of virus 
were tested. As a negative control for background control of the assay, the IMDM 
medium which had been used for resuspension of ultracentrifuged virus was utilised 
(see section 2.5.1).  
 
All of the ruminant A3s analysed inhibited JSRV reverse transcription in Roche 
Reverse Transcriptase Colorimetric assay’s settings (see Section 2.10.9) (see Fig. 
3.22). The results indicated that ruminant A3 proteins may influence the JSRV reverse 
transcription by a cytidine deamination independent mechanism. 
 
For all the A3 analysed, the highest amount decreased the RT efficiency. Notably, the 
intermediate amounts A3-Z2 and A3-Z2Z3 also reduced the JSRV RT activity, in 
contrast to A3-Z1 and A3-Z3 where only the highest amounts of A3 inhibited RT. 
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Fig. 3.22 Inhibition of JSRV reverse transcriptase by ruminant A3 proteins 
Reverse transcriptase assay performed on concentrated JSRV-GFP produced in the presence 
of the indicated A3 (S- sheep, G- goat, C- cow) and a vector control (NoA3). Numbers 
represent µg of A3 encoding vector during transfection. Plots present relative reverse 
transcriptase activity compared to “NoA3” stock. Presented values show one of at least 2 
experiments. The student two-tailed t-test method with unequal variance was used to verify 
the significance of results. The error bars report the standard deviation value between wells 
infected in triplicate. 
 
3.2.8 APOBEC3 Z2, Z3 and Z2Z3 are not detected in lung fluid from OPA 
affected animals. 
 
The experiments described so far show that sheep, goat and cow A3 proteins can 
restrict JSRV by both deaminase dependent and deaminase independent mechanisms 
in an in vitro assay system. In order to investigate whether such restriction is also 
active in vivo, I examined virus from lung fluid from natural cases of OPA for 
evidence of A3 encapsidation. 
 
In order to determine whether lung fluid containing JSRV includes packaged A3, 
JSRV was purified and concentrated, and subsequently analysed by western blot. 
Antibodies against JSRV Gag (see Section 2.6) were used to confirm the presence of 
A3-Z1                                                                    
 
A3-Z2Z3                                                                    
 
A3-Z2                                                                   
 
A3-Z3                                                                    
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JSRV in lung fluid and polyclonal antibodies against sheep A3-Z2 or A3-Z3 (see 
Sections 2.9 and 2.10.8) were utilised to investigate if sheep A3 was associated with 
the purified virus. 
 
JSRV was purified from LF of 6 OPA cases by ultracentrifugation followed by a 
sucrose gradient purification and a second ultracentrifugation of fractions. The cases 
were natural OPA in sheep donated by farmers to Moredun Research Institute. Lung 
fluid samples had been stored at -80ºC for a few days up to six years prior to analysis. 
Concentration and purification of JSRV from lung fluid was necessary to perform 
accurate detection of proteins included in virions, and to avoid the detection of 
proteins in cellular debris or in the fluid itself. The procedure followed is shown in 
Fig. 3.23. 
 
 
Fig. 3.23 Process of concentration and purification of JSRV from lung fluid  
Where necessary, samples were stored at -80ºC between steps. 
 
Prior to the analysis, lung fluid obtained from OPA affected animals was clarified, 
concentrated and purified according to Section 2.9. In order to enhance JSRV purity, 
sucrose gradient purification was performed (see Section 2.8). Fractions were 
collected and those containing virus were identified by WB for detection of Gag 
protein. The sucrose fractions were pooled into four samples (W-Z). Fractions were 
pooled depending on the initial detection of Gag on western blot (see Fig. 3.24, panel 
A).
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Fig. 3.24 Detection of JSRV Gag in sucrose gradient fraction samples 
A) Every second gradient sample was tested (numbers top) by WB using anti-Gag antibody. 
Fractions were pooled (letters W-Z) according to the presence of Gag. B) Density gradient of 
each gradient fraction (points); density of fractions where JSRV was purified (red) are 
highlighted in orange C) Detection of JSRV Gag (CA) in pooled fraction samples after being 
further concentrated. Molecular weight marker See Blue2 bands representing protein size 
(kDa) are displayed on the left side of blots. 
  
CA 
CA 
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The first sample (sample W) contained fractions from the bottom of the gradient with 
the highest concentration of sucrose, where no JSRV Gag was detected. The second 
sample (X) contained the Gag-rich fractions with densities in the range of 1.15 to 
1.19 g/ml. The peak of Gag reactivity was in fractions in the range from 1.15-
1.16 g/ml which is the expected density of retroviral particles (York et al., 1991, 
Palmarini et al., 1995, Palmarini et al., 1999b). The third sample (Y) was a pool of 
Gag-negative fractions of lower sucrose concentration (density 1.09-1.14 g/ml). The 
last sample (Z) included the lowest concentration sucrose fractions from the top of the 
gradient (see Section 1.05-1.09 g/ml) where Gag was detected, which likely represents 
solubilised Gag proteins and the presence of virion debris (see Fig. 3.24). 
 
Each pool was concentrated by centrifugation at 100,000  g at 4°C for 2 h and 
resuspending the pellet in a minimum volume (at least 100 μl) of TNE. The 
resuspension volume was adjusted depending on the total volume of pooled fractions 
in order to keep the same  50 concentration factor. After the ultracentrifugation only 
sample X contained JSRV Gag (see Fig.3.24, panel C). The lack of Gag concentration 
in pooled fraction Z can be attributed to the presence of Gag in solution, but not in 
virions, as it was confirmed by Gag detection only in sucrose gradient fractions (see 
Fig.3.13.A. 22,24,26) and not after their subsequent concentration (see Fig.3.24, panel 
C. sample Z). Assuming that only sample X contained virus, it was concentrated 
approximately 200 times. Western blot detection of Gag, A3-Z2 or A3-Z3 in 
concentrated JSRV-GFP stocks or concentrated and purified lung fluids from 
8 animals (virus rich “X” fraction of each stock) is shown in (see Fig. 3.25). 
 
Western blot demonstrated that there is usually more Gag antigen in purified lung 
fluids than in concentrated JSRV-GFP stocks (see Fig. 3.25.A). There was no signal 
characteristic for A3-Z2 or A3-Z3 protein size corresponding to JSRV-GFP positive 
controls. However, there were other bands which may be a result of polyclonal 
antibody cross-reactivity with other antigens, present both in virus supernatants and 
analysed lung fluids. Notably, anti-Z2 antibody only weakly detected A3-Z2Z3 in 
JSRV-GFP samples (see Fig. 3.25B) but anti-Z3 efficiently detected this antigen. This 
result could be attributed to lower CA content of A3-Z2Z3 stock than present in other 
stocks (see Fig. 3.25A). 
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Fig. 3.25 Western blot analysis of JSRV concentrated and purified lung fluid from OPA 
affected sheep. 
 Antibodies against Gag (A), anti-Z2 (B) or anti-Z3 (C) were utilised. Samples tested included 
concentrated JSRV-GFP vector (N – No A3; 2 – sheep A3-Z2; 3 – sheep A3-Z3; 23 – sheep 
A3-Z2Z3) and concentrated and purified lung fluids (right, A to G). Molecular weight marker 
See Blue2 bands representing protein size (kDa) are displayed on the left side of figure. 
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3.2.9 Determination of sensitivity of anti A3-Z2 and A3-Z3 immunoblot 
  
In order to estimate the sensitivity of the method used, serial dilutions of sheep A3-Z2 
and A3-Z3 recombinant proteins (provided by the antibody provider, Proteintech) 
were analysed by western Blot in parallel with virus made in vitro (see Fig. 3.24). The 
result obtained highlighted the cross-reactivity of the anti-sheep Z2 antibody with 
sheep Z2 and Z3 proteins. 
 
Fig. 3.26 Estimation of the threshold amount of A3 detectable by western blot. 
The performance of antibodies, anti-sheep A3-Z2 (panel A) and anti-sheep A3-Z3 (panel B), 
was analysed by detection of A3 present in virus stocks prepared in vitro and serial dilutions of 
recombinant A3 peptide. Samples included concentrated virus stocks made in vitro:        
NC (15 μl “no A3” stock); 1 (15 μl A3-Z1); 2 (15 μl A3-Z2); 3- (5 μl A3-Z3); 3+ (15 μl A3-Z3); 
23 (15 μl A3-Z2Z3); E empty well. Numbers highlighted in green 20, 5, 1.25, 0.3, 0.07 are ng 
of serially diluted recombinant A3 proteins used to immunise rabbits in order to produce the 
antiserum. Molecular weight marker See Blue2 bands representing protein size (kDa) are 
displayed on the left side of figure. 
 
According to the recombinant A3 protein concentration provided, the WB assay can 
detect as little as 0.07 ng of A3. The anti-Z2 antibody cross-reacted with A3-Z3 and 
weakly detected A3-Z2Z3 in concentrated virus stocks made in vitro (panel A). The 
anti-Z3 antibody is specific to A3-Z3 and effectively detects A3-Z2Z3 (panel B), but 
using this exposure its estimated threshold of detection is limited to 0.3 ng. Therefore 
the antibodies provided could be utilised for in-vivo detection of A3, however their 
non-specific cross-reactivity, should be taken into account.  
123 
 
3.3. Chapter Discussion 
 
This project is the first study of the impact of A3 on JSRV replication. During this 
study the goat A3-Z2, A3-Z3 and A3-Z2Z3 were identified, cloned and their role in 
JSRV restriction was characterized. 
 
Initially ruminant A3 genes were isolated and cloned into mammalian expression 
vectors and their sequences were confirmed (Sections 3.2.1). After confirmation that 
JSRV is able to encapsidate ruminant A3 (Section 3.2.2), the restriction potential of 
ruminant A3 against JSRV was demonstrated by infection of a permissive cell line. 
Flow cytometry results (see Sections 3.2.3 and 3.2.4), qPCR quantification of 
integrated proviruses (see Section 3.2.5), sequencing of proviral sequences (see 
Section 3.2.6) and reverse transcriptase assays (See Section 3.2.7) provided insights 
into the restriction mechanism. However, no A3 proteins were detected in lung fluid 
(see Section 3.2.8). Collectively, these data indicate that JSRV is sensitive to 
restriction mediated by ruminant A3, but suggest that in vivo A3 does not act as a 
restriction factor because it is not packaged into virions present in lung fluid.  
 
3.3.1 Sheep APOBEC3 is not responsible for species specificity of JSRV 
infection 
 
Experiments conducted in vitro demonstrated the inhibitory potential of ruminant A3 
and investigated the restriction mechanism. Assuming that even minor sequence 
polymorphism among restriction factor homologues may be responsible for species-
specificity of infection it was possible that ruminant A3 plays such a role in species 
infectivity of JSRV. Unexpectedly the results showed that sheep A3 had similar 
properties in vitro to its ruminant homologues from goat and cow. Therefore, these 
in vitro experiments did not identify A3 as the species specificity factor. 
 
The comparable ability of ruminant A3-Z2 and A3-Z2Z3 homologues to interfere with 
JSRV in vitro, could be explained by an extremely high sequence similarity among the 
ruminant A3 homologues. However, this striking identity was quite unexpected and in 
future, attempts to clone various haplotypes from a larger group of animals and 
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different breeds might reveal A3 genes with other antiviral potential. Moreover, 
identification of other A3 homologues from both farm and wildlife ruminants might 
explain some aspects of JSRV epidemiology and species specificity.  
 
Despite the data showing that ovine A3 restricts JSRV replication, JSRV clearly 
successfully infects sheep. This suggests that JSRV might have an evasion strategy 
specific to endogenous A3 or alternatively that the restriction factor is not expressed to 
a sufficient level in cells where JSRV replicates (see Section 3.3.4). Therefore, A3 is 
not detected in field samples. There is also the possibility that various alleles of A3 
might have different antiviral potential among its various haplotypes (Krupp et al., 
2013). Results presented in this chapter identified a similar potential of sheep, goat 
and cow A3 to restrict JSRV in vitro. The similarity of results of experiments 
performed using JSRV pseudotyped with VSV-G or wtJSRV Env, strengthen the 
statement that wild type JSRV envelope does not protect against A3.  
 
The in vitro experiments described in this study have some nuances which could 
potentially lead to misinterpretation of conclusions. The lack of a robust in vitro model 
which supports complete JSRV replication made experiments only possible by 
transient transfection of a producer cell line. It needs to be taken into account that 
transient transfection creates an artificial stoichiometry of viral and A3 proteins. In 
nature, viral proteins and A3 may not be expressed to such a high level. However, 
even the smallest measured amount of A3-Z2 or A3-Z2Z3 expression vector decreased 
JSRV infectivity (see Fig. 3.17 and Fig. 3.19). 
 
3.3.1.1 Comment on flow cytometric analysis of A3 activity 
 
Several factors influenced the flow cytometry result of JSRV-GFP infectivity. To 
properly interpret the readout of the A3 and JSRV-GFP experiment, there is a need to 
be aware of the fact that some positives (especially those characterized by low 
fluorescence) come from cells which contained an edited either GFP gene or CMV 
promoter sequence. It is likely, that mutated GFP has less intense fluorescence or its 
expression is downregulated by mutations of its promoter (Harris et al., 2003). It is 
possible, that some negative cells contained a provirus mutated to a degree which 
prevented the GFP expression to a detectable level. Flow cytometry analysis of 
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samples containing low positives was quite troublesome due to the fact that it was 
difficult to distinguish truly non-infected negative cells from low fluorescent cells, 
possibly containing A3-edited GFP within the provirus. Flow cytometry based sorting 
of cells, whose DNA would be subjected to PCR for the detection of integrated 
proviruses would provide additional conclusions and improved quality control to the 
assay. 
 
There was a possibility of false positive readings of fluorescent cells due to the uptake 
of DNA carried over in transfection complexes from the virus production process. 
Moreover, previous studies have demonstrated that the use of VSV-G in retroviral 
pseudotyping can produce artifactual false positives. This phenomenon can arise from 
the transfer of GFP inside vesicles. When VSV-G viruses were prepared, 
tubovesicular structures carrying DNA might have been formed (Pichlmair et al., 
2007). Therefore, all analysed virus stocks were concentrated and heat inactivated 
virus was used as a negative control in every infection assay along with non-infected 
cells. 
 
Flow cytometry needs to be properly conducted and interpreted. In order to allow 
quantitative analysis, these experiments were performed using virus at multiplicity of 
infection (MOI) ideally higher than 0.01. By keeping the MOI low, the possibility of 
individual cells being infected by more than virus was minimized. In addition, 
maintaining at least 1% of infected cells ensured these results included an adequate 
sample size. To address this issue, in each experiment the “No A3” stock’s titre was 
estimated on a small scale prior to infection of cells with all stocks included in the 
experiment. To ensure a reliable result, cells were infected by two different amounts of 
a single virus stock in triplicate. 
 
3.3.1.2 Comment on RT assay based assessment of A3 activity 
 
All the analysed ruminant A3 proteins inhibited JSRV RT. However, only the highest 
concentration of A3-Z1 or A3-Z3 decreased reverse transcription. The Roche 
Colorimetric RT assay utilised here, works using virions that are lysed prior to the 
reverse transcription step. The detected inhibition of reverse transcriptase activity 
showed the enzymatic potential of A3. However, inside a virion there is a possibility 
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that A3 proteins are packaged in a location physically separated from where the 
reverse transcription takes place, because A3 must have access to ssDNA. Moreover, 
polyA RNA template was added to samples before the reverse transcription step, 
which might have influenced the result obtained. 
 
I utilised the Roche Colorimetric RT assay due to its robustness and the fact that there 
are publications where this kit was used (Kolokithas et al., 2010, Giroud et al., 2013). 
Other groups studying deaminase–independent A3 restriction have utilised an 
endogenous RT assay in which the RT step is conducted as the native retroviral RNA 
is reverse transcribed by viral particle components (Iwatani et al., 2007, Holmes et al., 
2007b, Holmes et al., 2007a). In order to verify those issues, an assay should be 
performed based on in situ reverse transcription without the virion lysis step and 
addition of artificial polyA template.  
 
The results obtained show that with the increase of A3 concentration inside a virion 
there is a gradual decrease of RT activity which confirms the statement of the 
inhibitory role of A3. However, the precise step of the JSRV RT reaction which is 
particularly inhibited by ruminant A3 remains unknown. Work on HIV and MLV has 
found that A3 can block reverse transcription at several steps including its initiation 
(Adolph et al., 2013), strong stop signal synthesis (Mbisa et al., 2007), first and second 
strand transfer (Mbisa et al., 2007) and accumulation of reverse transcriptase products 
(Bishop et al., 2008). In order to get an improved insight into the mechanism of JSRV 
RT interference caused by ruminant A3, a more detailed analysis of reverse 
transcription should be performed to identify the precise the step where interference 
occurs. 
 
3.3.1.3 Comment on analysis of hypermutations caused by sheep A3.  
 
Sequencing of JSRV proviruses clearly demonstrated the cytidine deaminase activity 
of sheep A3-Z2 and A3-Z2Z3. In contrast the small number of sequence alterations 
observed in proviruses of A3-Z3 stocks could be attributed to the background of the 
assay. Those mutations could be caused by a mutation arising during JSRV-GFP 
production, reverse transcription, somatic mutation during cellular division, PCR error 
and finally mutations occurring in bacterial cultures used to amplify pGEM clones. 
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Mutations other than G to A changes indicate non-A3 induced mutations and are an 
additional measurement of the experimental background. The calculated mutation 
frequency readout is affected by the sequence itself and is caused by the surrounding 
bases sequence context to guanidines (Harris and Liddament, 2004, Ebrahimi et al., 
2014). 
 
However, there is a need to be aware that the calculated frequencies of editing may be 
altered by a preference of PCR to more robustly amplify non-edited templates. This 
effect could be caused due to possible mis-matching of primers to edited sequences. 
Moreover denaturation temperature could decrease, due to the fact that the edited 
DNA which contains more A and T and in consequence makes it easier to dissociate 
than the one with higher G and C content. 
 
Moreover, bands were relatively fainter on agarose gel in all PCR amplifications when 
DNA from cells infected with A3-Z2 or A3-Z2Z3 stocks was used (data not shown). 
Therefore, taking into account the number of cycles used, the lower amount of product 
may not only be connected with decreased proviral copy number but may also be a 
result of decreased PCR performance. Additionally a selective PCR might be partially 
responsible for alteration of mutation frequencies between A3-Z2 and A3-Z2Z3, 
because of the different distribution pattern of mutations (see Fig. 3.21). Therefore, I 
speculate that the actual A3-Z2 hypermutation frequency could be even higher than 
measured. In order to examine this further, an extensive analysis of other regions in 
proviruses could be performed using multiple sets of primers and lower denaturation 
temperatures (MacMillan et al., 2013). 
 
In order to clarify the potential of sheep A3 to hypermutate JSRV, sequencing of 
proviruses resulting from JSRV21 containing A3 was performed. Sequencing of 1kb 
fragments of the env gene in proviruses demonstrated that JSRV21 may be 
hypermutated by sheep A3-Z2 and A3-Z2Z3 similarly to the JSRV-GFP. This finding 
suggests a possibility that JSRV might have an A3 evasion strategy in vivo, as there is 
a very low level of polymorphism among different isolates and lack of quasispecies. 
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3.3.2 JSRV appears not to have an interference mechanism against 
APOBEC3 
 
In a number of cases A3 is a determinant of species specificity in retroviral infections. 
Some retroviruses have evolved sophisticated evasive mechanisms targeted against 
their host’s A3, while remaining vulnerable to A3 proteins of other species. It could be 
speculated that JSRV might have a specific mechanism for inhibiting endogenous A3 
that is active in vivo but not in in vitro assays. 
 
Although A3-Z1 and A3-Z3 were packaged into JSRV virions in vitro, they did not 
have such a dramatic effect on JSRV infectivity as A3-Z2 or A3-Z2Z3. This suggests 
the possibility that JSRV might have a mechanism to protect against A3-Z1 or A3-Z3 
but not A3-Z2. It would partially explain the two results appearing to be contradictory. 
Firstly, the lack of detected hupermutations and lack of dramatic infectivity reduction 
among A3-Z3 stocks was demonstrated. Secondly, the reverse transcriptase activity 
was decreased in stocks containing the highest amounts of A3-Z1 and A3-Z3. There is 
a possibility that there are uncharacterised traits of JSRV virion structure or the 
existence of an interference mechanism against A3 might make it resistant to packaged 
A3-Z1 and A3-Z3. The A3-induced decrease of RT activity was detected in virions 
that were lysed during the RT assay. It is possible that the lysis step might bypass 
JSRV potential evasive mechanisms against A3. 
 
3.3.2.1 Could the use of an in vitro system have influenced the results?  
 
The observed vulnerability of JSRV to ruminant A3 in vitro may potentially be an 
artefact of the reporter vector system utilised and the lack of an in vitro method which 
permits complete replication. For example, the high expression of A3 proteins might 
have reduced the amount of extrachromosomal transfected DNA, which in turn may 
have affected the dynamics of virus production (Stenglein et al., 2010).  
 
The JSRV-GFP might have slightly different properties than JSRV21. However, this is 
unlikely to be the case because sheep A3 reduced provirus copy number and 
hypermutated the viral genome for both the JSRV-GFP and the JSRV21. However, the 
possibility that the virus producer cell line influenced the in vitro experiments should 
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not be excluded. JSRV was made in human derived 293T cells with a phenotype that 
is very different to the cells in which JSRV replicates in vivo. JSRV might have an 
unidentified factor which may be expressed or be active in sheep lung cells but not 
293T. In addition, endogenous retroviral proteins in sheep cells in vivo could 
potentially influence the activity of A3 (Arnaud et al., 2007a). However, the 
expression of enJSRV RNA in lung tissue is low (Palmarini et al., 1996). There is a 
chance that in cells where JSRV replicates, so far unidentified interactions could occur 
between both viral and host proteins and nucleic acids. The possibility of a role for the 
bacterial flora or the cellular miRNA transcriptome within the lung in JSRV biology 
cannot be excluded. Moreover, the state of cells to permit replication might be 
dependent on the chemokine environment and other factors linked to the fact that 
infection occurs in vivo. Additionally, the virus producing cells make replication-
defective virions and this effect is difficult to estimate both in vitro and in vivo, but 
possibly affects the dynamics of incorporation of molecules such as A3. 
 
Both the proteome and miRNA transcriptome of lung epithelial and OPA tumour cells 
might enable potential virus-host interactions that have not yet been characterized 
(Nathans et al., 2009, Bogerd et al., 2014). To address these uncertainties, an extensive 
comparison between the proteome and transcriptome of in vitro models and both the 
healthy lung and OPA tumour in the various stages and different age of animals could 
be performed. Additionally, cases of non-virally originated sheep and human lung 
tumours should be compared in this way in order to identify transformation patterns 
and eventual expression of viral genes. Such extensive comparison could provide a list 
of proteins and RNAs involved in the support or inhibition of JSRV replication. 
 
3.3.3 APOBEC3 is not detected in lung fluid samples from OPA sheep 
 
The in vitro experiments performed during this study demonstrated that ruminant A3 
has the potential to inhibit JSRV and suggests that hypermutation is an important 
mechanism of restriction. However, the high conservation of the JSRV genome among 
different field isolates and the lack of emergence of quasispecies during disease 
progression (Griffiths et al., 2010), suggests that JSRV is not affected by A3 activity 
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in vivo. Therefore, lung fluid from natural OPA cases was analysed in order to 
determine whether A3 is present inside in vivo produced JSRV (see Section 3.2.8). 
 
Analysis of the presence of A3-Z2 and A3-Z3 did not detect those proteins in lung 
fluids from OPA affected animals. The lung fluid was not analysed for the A3-Z1 
content, because RT-PCR analysis indicated that A3-Z1 is not expressed in sheep and 
cow lung tissue (see Section 2.2.1). Other experiments showed that A3-Z1 does not 
impact the disease pathology. Therefore, the lack of strong inhibition of JSRV in vitro 
by sheep and cow A3-Z1 discouraged the need to develop antibodies against this 
protein. 
 
Since A3-Z2, A3-Z3 or A3-Z2Z3 were not detected in field samples (see Sections 
3.2.8 and 3.3.4), it was necessary to determine the sensitivity of the assay. Therefore, I 
extrapolated from published studies on A3 content in ΔVif HIV virions in order to 
estimate the assay’s sensitivity threshold. 
 
Previous studies on A3 encapsidation by ΔVif-HIV provided an estimate of the 
quantities of structural proteins forming a single virus. Analysis performed on ΔVif 
HIV produced in the presence of 2 μg of pcDNA huA3G mammalian expression 
vector estimated by HPLC that the molar ratio of encapsidated huA3G to Gag is 1:439 
(Xu et al., 2007). Assuming that in a single HIV virion there are approximately 1500 
(Zhu et al., 2003) or 5000 (Briggs et al., 2004) Gag molecules, then according to the 
estimated molar ratio there should be 3-11 huA3G molecules per single virion. 
Therefore, there is a possibility that the method utilised in the present study was not 
sensitive enough to detect such a small amount of A3. Taking into account the Gag 
content in a single virion, I estimate that there are 4 or 20 molecules of A3 packaged 
as a result of 1 μg or 4 μg of A3 expression vectors utilised in transfection. Therefore, 
based on the molecular mass of A3-Z2Z3, there are between 200 kDa (4 × 50 kDa) 
and 1000 kDa (20 × 50 kDa) in a single virion, which is equal to 3.32 × 10
-18
 g and 
1.62 × 10
-17
 g respectively. 
 
The analysis performed by Cousens et al. demonstrated that there is from 10
4
 to 10
8
 
copies of JSRV RNA in 1 μl of lung fluid of sheep affected by OPA (Cousens et al., 
2009). Therefore, on average, 1 μl of lung fluid contains 5 × 105 virions. In the present 
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study, lung fluid was concentrated 200 times to yield approximately 10
9
 virions in 
each 10 μl sample analysed by western blot. The western blot analysis of Gag content 
showed that there is more JSRV present in the concentrated lung fluid samples, than in 
the virus produced in vitro. Therefore, extrapolating from values calculated above 
based on the HIV studies, we might expect that there should be at least 1.62 ng of   
A3-Z2 or A3-Z3 per lane. This should be detectable, given the sensitivity of the 
western blot (see Section 3.2.9). Thus, significantly less than the estimated 1.62 ng of 
A3 present in each sample of virus produced in vitro. In conclusion, I hypothesise that 
there is no A3-Z2, A3-Z3 or A3-Z2Z3 in JSRV from the lung fluid samples tested, to a 
level which is sufficient for JSRV restriction. These calculations are summarised in 
Fig. 3.27. 
 
 
Fig. 3.27 Estimation of A3 content in the JSRV samples produced in vitro 
Calculations are based on the reported estimated Gag content in HIV-1 and number of 
encapsidated A3 in ΔVif Virions and on the average amount of JSRV from lung fluid samples. 
 
The ideal imaging technique for the detection of A3 encapsidated inside a virion might 
be electron microscopy utilising gold labelled antibodies. Such an experiment might 
potentially determine the precise location of A3 proteins inside a virion. However, a 
relatively small number of encapisdated A3 protein molecules inside a single virion 
might still be difficult to detect with such an approach.  
 
In summary, in vitro produced JSRV is restricted by A3, even when made in the 
presence of 0.25 or 1 μg of A3-Z2 and A3-Z2Z3 expression vector. In vivo produced 
JSRV does not encapsidate a detectable amount of A3.  
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3.3.4 JSRV target cells in the lung do not express A3 
 
The failure to detect A3 in OPA lung fluid suggests that A3 does not restrict JSRV in 
vivo in lung epithelial cells. Despite the calculation presented in the preceding section, 
there remains a theoretical possibility that lung fluid may still contain a small but 
undetectable amount of A3-Z2 or A3-Z2Z3. However, the fact that the JSRV genome 
is stable among field isolates supports the finding that A3 is not present in JSRV 
virions. 
 
In order to clarify whether JSRV avoids A3 restriction in vivo because this restriction 
factor is not expressed in cells where JSRV replicates, OPA and normal healthy lung 
were analysed by immunohistochemistry (IHC) using antibodies to ovine A3-Z2 and 
A3-Z3 (see Section 2.10.8). (Note that the similarity of A3 protein sequence between 
ruminants should allow antibodies generated against sheep proteins to also be utilised 
against goat and cow). Due to time constraints the IHC was done by Jeanie Finlayson 
(MRI, Pathology Department). IHC of sheep and goat JSRV- transformed lung tissue 
labelled with anti A3-Z2 antibody or pre-immune serum is shown in Fig. 3.28. 
 
Antisera raised against sheep Z2 (Figure 3.28) or Z3 (not shown) did not label either 
normal lung epithelium or JSRV-transformed lung tissue. Similar results were 
observed in lung tissue from experimentally infected sheep and experimentally 
infected goats (from a previously published study (Caporale et al., 2013a) and kindly 
provided by Marco Caporale). In contrast, alveolar macrophages in both species 
labelled positively with the antibodies against Z2 and Z3 (see panels A and B in Fig. 
3.2). These results suggest that there is a lack of A3 expression in lung epithelial cells 
(the targets of JSRV replication) and suggests that JSRV avoids the activity of A3 
proteins in vivo by infecting cells that do not express this restriction factor. 
Furthermore, the similar pattern of labelling in goats as in lambs suggests that A3 
expression in vivo is not responsible for the species specificity of OPA for sheep. 
Further experiments are needed to determine whether cow lung epithelial cells express 
A3. 
 
Additional controls used in the IHC included analysis of transfected 293T cells 
expressing the different ruminant A3 proteins. These were embedded in gelatin and 
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fixed in wax blocks to mimic the tissue (see Section 2.10.10.3). These controls 
verified the cross reactivity of anti-Z2 and anti-Z3 between different ruminant A3 
family members. 
 
Fig. 3.28 Immunohistochemistry analysis of sheep and goat lung transformed by JSRV 
Anti A3-Z2 antibody labels only infiltrating macrophages in sheep (Panel A) and goat (Panel B) 
JSRV-transformed lung. Pre-immune sera from the same rabbit was utilised as a negative 
control for non-specific labelling of sheep (Panel C) and goat (Panel D) JSRV-transformed 
lung. Scale is indicated at the right bottom of each panel figure. 
 
Despite the data obtained so far, further analysis is required to rule out any role for 
evasion of A3 function by the product of the JSRV orf-x gene. However, there is an 
indication that Orf-X does not have any important role in tumourigenesis since 
experimentally animals infected by JSRV21 carrying a truncated orf-x resulted in no 
difference compared to wild type JSRV21 in experimental infections (Cousens et al., 
2007).  
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3.3.5 Impact of APOBEC3 on OPA epidemiology – Conclusions 
 
Only sheep develop OPA. Therefore, it is perhaps surprising that sheep A3-Z2 and        
A3-Z2Z3 are able to inhibit virus replication in vitro to a similar degree as their 
ruminant homologues in cows and goats. However, JSRV isolates are characterized by 
a stable genome among different isolates, and quasispecies do not emerge during 
infection, suggesting that there is a lack of ongoing hypermutation in vivo. Both the 
in vitro potential of sheep A3 to inhibit JSRV and the lack of hypermutation signatures 
present in infected animals, could be explained by a JSRV-specific evasion strategy 
against restriction factors or simply the lack of expression of A3 in the cells where 
JSRV replicates. The lack of detectable A3 in virus isolated from lung fluid from 
OPA-affected sheep and the absence of A3 protein in lung epithelial cells of both 
normal and transformed lung tissue strongly indicate that JSRV avoids A3 activity 
in vivo by replication in cells that do not express it. The evolution of retroviruses to 
use this strategy to avoid the activity of A3 has not been described previously. 
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Chapter 4 - The effect of mouse and human APOBEC3 
on JSRV replication 
 
  
136 
 
4.1 Introduction 
 
The results presented in Chapter 3 demonstrate the restrictive activity of ruminant A3 
proteins against JSRV. To extend these studies, I next investigated the interplay 
between JSRV and mouse APOBEC3 (muA3) and several human APOBEC proteins 
(huA1, huA2, huA3DE, huA3F, huA3G) in vitro. Although JSRV does not seem to be 
pathogenic among mice or humans, these experiments were performed in order to 
improve the understanding of species specificity of A3-JSRV interactions. 
 
4.1.1 Why study the interaction of human APOBEC3 with JSRV? 
 
Humans are not recognised as a natural host for JSRV and there is no documented 
human disease resembling the clinical signs of OPA. However, some forms of non-
invasive human lung cancer have features that resemble OPA at the histological level 
(Palmarini and Fan, 2001, Mornex et al., 2003) (See Section 1.1.4). In addition, this 
type of lung tumour has the weakest association with smoking, which suggests a 
possible role for genetic factors or other environmental factors, such as viruses (De las 
Heras et al., 2007, Sun et al., 2007). Notably, human Hyal-2 can be utilised as an entry 
receptor for JSRV and JSRV Env can transform some rodent and human cell lines in 
vitro (Maeda et al., 2001, Miller, 2008, Wootton et al., 2006a). 
 
Several groups have attempted to define the possible connection of human non-
invasive lung cancer with a viral aetiology. Most of those studies have focused on the 
detection of a virus related to JSRV in human tumour specimens (Hopwood et al., 
2010). Approximately 30% of human lung adenocarcinomas were positive for the 
presence of an epitope reacting with anti-JSRV Gag antibody (De las Heras et al., 
2000b). Additionally, a recent study reported the presence of an antigen related to 
JSRV Env and the presence of JSRV Env related sequences in a subset of lung 
adenocarcinomas and squamous cell carcinomas (Linnerth-Petrik et al., 2014). The 
positive staining of some lung tumour sections could be caused by expression of an 
endogenous retrovirus whose potential impact on transformation is not yet 
characterised. Alternatively, it might be a result of a non-specific cross-reaction of 
antibodies with a non-viral cellular protein, whose expression is upregulated by 
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transformation (De las Heras et al., 2007, Hopwood et al., 2010). Despite the lack of 
other viral markers in lung tumours, the possibility that the aetiology of these tumours 
is connected with an unknown exogenous retrovirus cannot be ruled out (Hopwood et 
al., 2010). In light of these studies of human infection with JSRV, it is of interest to 
ask whether human A3 proteins can restrict JSRV. 
 
4.1.2 Reasons for studying the effect of mouse APOBEC3 on JSRV 
replication 
 
An in vivo disease model of OPA in new-born lambs has been available for many 
years (Palmarini et al., 1999a). However, although this model has provided valuable 
insights into OPA pathogenesis it does have some disadvantages. For example, 
experiments in sheep are expensive and only available to a small number of 
laboratories with facilities capable of handling large animals. Therefore, the 
development of a small animal model of OPA would provide a more tractable in vivo 
tool for investigating JSRV biology and its role in carcinogenesis. 
 
Mice would be an ideal candidate as a small animal model of OPA due to the 
availability of reagents and a significant publication background as a cancer model. 
Notably, mice have already been used in experiments for JSRV Env-induced 
tumourigenesis. However, adeno-associated virus vectors were utilised in those 
experiments (Wootton et al., 2006a, Wootton et al., 2006b, Vaughan et al., 2012). 
 
An additional limitation for the utilisation of mice as a model for OPA is that mouse 
Hyal-2 is only a weak JSRV receptor (Miller, 2008). However, this issue could 
potentially be solved by the creation of a transgenic line expressing a permissive 
receptor or by utilising JSRV pseudotyped with an alternative envelope protein.  
 
Investigation of mouse restriction factors against JSRV may direct the development of 
a small animal model of OPA and further extend understanding of the species 
specificity of JSRV infection. In this project I investigated the impact of mouse       
A3-Z2Z3 on JSRV replication. 
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4.2 Results 
 
4.2.1 Impact of mouse and human APOBEC on JSRV replication 
 
In order to investigate the role of mouse and human APOBEC proteins on JSRV 
replication in vitro, mammalian expression plasmids encoding these proteins were 
obtained from AddGene. Murine A3 (muA3) and several human APOBEC proteins 
(huA1, huA2, huA3DE, huA3F, huA3G) were used in the JSRV-GFP reporter assay in 
parallel with sheep A3-Z2Z3 (see Section 2.10.6). 
 
4.2.2 Human and mouse APOBEC are packaged by JSRV 
 
The detection of encapsidation of APOBEC by JSRV was the first step in 
investigating of restriction mediated by mouse and human APOBEC proteins. 
Concentrated virus stocks were made in the presence of V5 epitope-tagged muA3 and 
huAPOBECs and then tested by western blot for evidence of their encapsidation (See 
section 2.10.7 and Fig. 4.1). Virus stocks were produced by cells transfected in 6-well 
plates, utilising 0.8 µg of APOBEC expressing vector (the molar ratio of Gag-Pol and 
envelope encoding DNA used is equivalent to the 4 µg samples on a T-75 flask scale; 
the highest amount tested in Chapter 3). 
 
This analysis indicated that mouse A3 and human A3DE, A3F, A3G and A2 are 
packaged by JSRV-GFP (JSRV Env pseudotyped), as shown by the detection of     
V5-tagged proteins by western blotting of concentrated virus (see Fig. 4.1.A). In 
contrast, hA1 was not packaged by JSRV in these experiments, supporting the 
specificity of encapsidation of the other APOBEC proteins. Note that, spill over of 
sample occurred in panel (A), since there is a faint band in the “No A3 stock” lane, but 
the  “S A3-Z2Z3” which lacks a V5 epitope tag and “No A3 cellular extract” lanes are 
negative. 
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Fig. 4.1 JSRV encapsidates V5-tagged human and mouse APOBECs 
Panel (A) demonstrates encapsidation of V5-tagged APOBEC proteins in concentrated JSRV 
virus stocks. Panel (B) shows detection of V5-tagged APOBECs in cellular extracts of 
transfected 293T cells. JSRV virus stocks were made by transfection together with the 
indicated A3s (mu-mouse, S-sheep, human APOBECs are described by their original names – 
letters and numbers) or a vector without A3 (No A3). The molecular weight marker bands 
representing protein size (kDa) are displayed on the right side of each figure. 
 
4.2.3 Effect of mouse and human APOBECs on JSRV infectivity 
 
The previous experiment showed that JSRV is able to package mouse and human 
APOBECs. Next, I tested the infectivity of these virus stocks in vitro, as had been 
done with ruminant A3s (see Chapter 3). Flow cytometric analysis demonstrated that 
JSRV-GFP (JSRV VSV-G pseudotyped) infectivity is reduced by mouse A3 and some 
of the human APOBECs tested (see Fig. 4.2). 
 
The mouse A3 was identified as a strong inhibitor of JSRV and was active to a similar 
degree as sheep A3-Z2Z3. Human A3F restricted the infectivity of JSRV GFP six-
fold, while A3G reduced the infectivity by 50% and A3DE had a mild restrictive 
activity. Although huA2 was packaged by JSRV GFP (see Fig.4.2. A), it did not show 
any antiviral activity. Since huA1 was not packaged, this stock became an additional 
internal reference control for infectivity. The difference of infectivity and fluorescence 
of cells infected by “A1” and “No A3” stocks, are most likely to be caused by 
variation in the assay system. The data presented in Fig. 4.2 shows the readout of one 
of two experiments, values represent an average of wells infected in duplicate. 
However, two virus amounts were tested and the results shown represent the average 
of cells infected in duplicate by the higher amount of virus.  
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Fig. 4.2 The impact of mouse and human APOBEC proteins on JSRV infectivity 
Flow cytometric result of CRFKovH2 cells infected by JSRV Env pseudotyped JSRV-GFP. 
Graph (A) shows the relative percentage of cells infected by virus produced in the presence of 
the indicated A3s (mu-mouse, hu-human, S-sheep) and a vector control without A3 (no A3). 
Graph (B) shows the relative fluorescence intensity (FITC median) of infected CRFKovH2 
cells. The relative infectivity values are based on the proportion of GFP-positive cells infected 
by “APOBEC stocks” compared to cells infected by “no A3 stock”. 
 
4.3 Discussion 
 
In this Chapter, mouse A3 was shown to be a strong inhibitor of JSRV replication. The 
human A3 proteins tested were packaged by JSRV but their impact on its replication 
was not as strong compared to the potent restriction of JSRV caused by muA3 and 
sheep A3-Z2Z3.  
 
While these data appear reproducible, it should be noted that the experiment was only 
performed twice and further work should be conducted to perform more replicates and 
analyse the impact of intermediate amounts of APOBEC. In addition, further analysis 
of the restriction mechanism by sequencing of proviral clones and RT-assays 
performed on virus stocks would extend understanding of the restriction mechanism of 
mouse and human A3s in JSRV. 
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4.3.1 Restrictive character of mouse APOBEC3 
 
Mouse A3 was identified as a potential JSRV restriction factor. However, as shown in 
Chapter 3 in ruminants, in vitro assays may not predict whether restriction factors are 
in vivo. Therefore, determining whether A3 is expressed in mouse lung epithelial cells 
would provide further clues towards understanding OPA species-specificity and the 
possibility of using mice as a small animal model. Even if mice do not express A3 in 
lung epithelial cells then the different anatomy of the mouse respiratory tract 
compared to that in sheep would need to be taken into account during interpretation of 
in vivo experiments.  
 
Mice would be a robust tool as a small animal model of OPA, because of the easy 
access to different lines or breeds, various reagents and a number of publications 
concerning carcinogenesis, where these animals were utilised. Moreover, the genetic 
engineering techniques available in mice are at a far more advanced level in 
comparison to other mammalian species. Mice deficient in A2 or A3 have been 
created and their deletion did not have any major effect on their survival or fertility 
(Mikl et al., 2005). Although A2 is expressed in all vertebrates in muscles, the tissue 
histology features of A2 knockout mice was unaffected. Notably, muA3 deficiency 
results in an increased vulnerability to retroviral infections caused by MMTV 
(Okeoma et al., 2009b) and MLV (Nair et al., 2014). 
 
Mouse APOBEC1 has been shown to restrict Friend-mouse leukaemia virus (Petit et 
al., 2009), and it would be interesting to determine its restriction potential against 
JSRV. However, creation of mice deficient in APOBEC1 could be difficult, because 
of its physiological function in gastrointestinal tissues, where it deaminates cytosine to 
uracil at position 6666 in the RNA encoding apolipoprotein B (Navaratnam et al., 
1993). Since mouse APOBEC1 may act as a potential restriction factor, it would also 
be interesting to evaluate the role of its ruminant homologue against JSRV. 
 
Although mice have only one A3 gene, several different alleles and splice variants 
have been described, and these different forms have a variety of inhibitory activities 
against MMTV (Okeoma et al., 2009b). A single nucleotide polymorphism present in 
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some A3 alleles affects its mRNA splicing pattern, and this impacts on the amount of 
muA3 packaged into MMTV and in consequence its infectivity (Okeoma et al., 
2009b). Therefore, this observation could direct further research on the epidemiology 
of OPA in different breeds and species of sheep, which may be dependent on A3 allele 
polymorphism. It is perhaps unlikely that there exists an allelic variant which protects 
against OPA significantly more than others, because it would be positively selected 
during the course of evolution of Ovis. Notably, the selection of a putative protective 
A3 variant would be difficult due to the fact that sheep develop disease after they 
reproduce. Moreover, since sheep A3 is not expressed in sheep lung epithelium (see 
Section 3.3.4), this suggests that JSRV avoided its restriction, by selecting a tissue 
tropism enabling its replication in the absence of A3 (see Chapter 4) and tetherin 
(Arnaud et al., 2010). I speculate that promoter polymorphism could contribute to 
variation in the expression pattern of A3 or other restriction factor’s in tissues, which 
might partially explain the differential susceptibility of some sheep to OPA among 
flocks. 
 
The weak interaction of murine Hyal-2 receptor with JSRV Env is a major factor 
limiting the utilisation of those animals as model organisms for OPA. When this 
difficulty regarding the utilisation of mice as a model for OPA is bypassed, it will be 
necessary to verify A3 expression patterns. If A3 is expressed in mouse lung 
epithelium, then there would be a need to utilise mice which are deficient in functional 
A3 (already available). However, utilising A3 knockout mice may also alter the tissue 
tropism of the virus.  
 
Published work on mouse APOBEC has demonstrated the significance of endogenous 
A3 in the context of protecting against retroviruses pathogenic in the same species 
(Ross, 2009). Furthermore, the observed restriction caused by endogenous A3 may in 
some way be beneficial for the virus, because mild restriction of infection prolongs the 
life of the virus-shedding animal. Moreover, A3 mediates the editing of the viral 
genome, which contributes to its increased evolution rate (Jern et al., 2009). 
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4.3.2 Restriction of JSRV by human APOBEC3 
 
Some human APOBEC proteins were identified as potential determinants of OPA 
species-specificity. Even though the majority of huAPOBECs are packaged by JSRV, 
only huA3F has relatively strong inhibitory potential against JSRV, almost as strong 
as its sheep and mouse paralogues. The huA3G is known to be one of the strongest 
retroviral inhibitors of ΔVif HIV-1, but it has only mild activity on JSRV. There is a 
possibility that some human A3 alleles might be more or less protective against JSRV, 
similar to the reported variable antiviral activity of various primate A3G haplotypes 
against SIV (Krupp et al., 2013). Moreover, other human A3 proteins which were not 
investigated in this project (huA3A, huA3B, huA3C, huA3H) may have different 
inhibitory potential against JSRV. Notably, human and mouse APOBECs were 
expressed by transfection utilising pcDNA1 not pCI-Neo vectors as was done with 
sheep A3-Z2Z3 (see Sections 2.1 and 2.10.6), which might have resulted in difference 
of their expression levels and there is a need to be aware of its possible influence on 
results. 
 
The function of human A2 is still largely unknown and there are no reports of its 
antiviral potential. Therefore, this study is exceptional due to the demonstration of A2 
being encapsidated by JSRV as previous studies have not reported A2 encapsidation 
by retroviruses, even in overexpression conditions. Even though encapsidated it was 
not antiviral. 
 
Although, there are no reports of JSRV being responsible for human disease, the 
results obtained indicate that the human APOBECs analysed protect against JSRV. 
However, other restriction factors may contribute to species specificity and JSRV may 
simply require other crucial host factors which enable it to cause tumours in sheep. 
 
There is only weak evidence of a possible association of JSRV-like virus causing 
human lung cancer. Firstly, the immunoreactivity of some lung tumour with 
polyclonal antibodies to betaretroviral Gag (see Section 4.1) and anti-JSRV Env 
(Linnerth-Petrik et al., 2014). Secondly, there is a study presenting correlation of the 
occurrence of lung tumours among farmers working with goats (Lutringer-Magnin et 
al., 2012). However, goats do not develop OPA and the highest occupational exposure 
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to JSRV is expected to be among sheep farmers and this group was not identified as 
under a high risk in that study (Lutringer-Magnin et al., 2012). In my opinion, 
examination of prevalence of the lung tumours in a group of farmers with ocupational 
exposure to JSRV could provide direct epidemiological evidence for JSRV-induced 
pathogenesis in humans. 
 
The detection of betaretroviral sequences from blood has been reported in only a few 
samples from African patients (Morozov et al., 2004). However, extensive attempts to 
detect the virus by PCR failed suggesting that if there is a virus responsible for some 
forms of lung cancers then it remains to be characterised (De las Heras et al., 2000b, 
Yousem et al., 2001, Hopwood et al., 2010). Therefore there is an interest in 
examining the interaction of JSRV with human A3 as this might provide information 
on whether JSRV or a related virus is likely to infect humans. An extensive 
investigation of lung cancer adenocarcinoma transcriptome in order to identify virus-
related transcripts could provide better understanding of this issue. 
 
Upregulated expression of human endogenous retroviruses has been detected in 
several types of cancer and their potential role in the transformation process remains to 
be determined (Voisset et al., 2008, Kassiotis, 2014). Given that around 8% of human 
DNA is derived from ERVs (Li et al., 2001), representing around 4000 proviruses 
(Bannert and Kurth, 2006), there are many possible targets to look for the evidence of 
retroviral association with cancer. Even though people have been exposed to JSRV by 
contact with OPA affected sheep, there is a lack of clinical reports of human infections 
and the human genome does not contain enJSRV. 
 
The results presented in this chapter imply that if there is any virus similar to JSRV, 
which is responsible for causing lung cancer among people, it would be restricted by 
huA3F. The fact that only huA3F was shown to have a strong inhibitory activity 
towards JSRV could be explained by the fact that primate A3 proteins evolved 
specifically to target their own viruses, not towards others which do not pose a threat 
like JSRV requiring additional host permissiveness factors for replication. Finally, the 
A3 expression patterns across different cell types would impact on the significance of 
restriction actively.  
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This study found that huA3G did restrict JSRV, but not as strongly as it is able to 
restrict ΔVif HIV (Harris and Liddament, 2004, Holmes et al., 2007a, Sheehy et al., 
2002). This difference in restriction potential may be due to the fact that A3G contains 
the Z1 domain, which among ruminants was found to mildly restrict JSRV (see 
Section 3.2.3). The observed similar median fluorescence level of cells infected with 
JSRV stocks carrying various human APOBECs (with the exception of A3F) suggests 
that infected cells do not contain hypermutated JSRV proviruses, although that was 
not investigated directly in the present study. Additional sequencing of proviruses 
would provide more solid evidence regarding the deamination potential of human 
APOBECs against JSRV. Since huA3s have been demonstrated to cause genome 
editing in other viruses, this study highlights the differential sensitivity of the RT 
proteins of different retroviruses to diverse APOBEC family proteins. 
 
In summary, this chapter demonstrated that JSRV can encapsidate muA3, huA3DE, 
huA3F, huA3G and huA2, although only muA3 and A3F strongly restricted JSRV 
replication. In contrast, to the A3G and A3DE caused mild restriction, while no 
antiviral activity of huA1 and huA2 was detected. Further understanding of the 
comparison between retroviral RT enzymes and their vulnerability to various 
APOBECs could result in the development of new disease control strategies. 
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Chapter 5 – Impact of TRIM5 on JSRV replication 
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5.1 Introduction 
 
The TRIM family of proteins consists of approximately a hundred members in humans 
with a variety of different functions. Several TRIM proteins have been shown to 
interfere with viral replication at various stages (see Section 1.8.3.3) (Pertel et al., 
2011, Huthoff and Towers, 2008, Uchil et al., 2008). Interest in TRIM5α (T5α) was 
stimulated by the fact that T5α mediated restriction was demonstrated to be 
responsible for the resistance of Old World monkeys to HIV-1 (Stremlau et al., 2004). 
Since then T5α has emerged as an important mediator of species-specific restriction of 
a number of retroviral infections (Perron et al., 2004, Si et al., 2006, Li et al., 2013b, 
Rahm et al., 2011). 
 
TRIM5 (T5) proteins have been characterised mostly in primates and in several non-
primate species (Li et al., 2013b, McEwan et al., 2009, Si et al., 2006, Tareen et al., 
2009). This chapter investigates the sensitivity of JSRV to various T5 proteins. The 
restriction mediated by T5 is based on a post-entry block to incoming virions; by 
binding to their capsids, T5 targets them for degradation (Diehl et al., 2008). In 
addition to the direct inhibition of retrovirus, the ability of T5 to recognise capsids has 
been shown to mediate a virus sensing mechanism, which in consequence activates the 
signalling pathways which lead to expression of genes involved in antiviral responses 
(see Section 1.8.3.2) (Pertel et al., 2011, de Silva and Wu, 2011). 
 
However, due to the rapid evolution of TRIM family genes, the analysed ruminant 
proteins should not be properly referred to as “alleles or homologues of T5α” 
(Malfavon-Borja et al., 2013). The lability of those genes makes it is difficult to 
precisely define their origin and relativeness (Si et al., 2006, Han et al., 2011, 
Malfavon-Borja et al., 2013). However, for simplicity here they are referred to as 
“TRIM5 alleles or homologues”. 
 
The selective pressure caused by T5 recognition of capsids can drive evolution of 
structural retroviral genes in order to escape restriction. For some restriction factors, 
notably A3 and tetherin, retroviruses have acquired proteins to counteract their activity 
(Mariani et al., 2003, Neil et al., 2008, Morrison et al., 2014). Currently no viral 
protein that inhibits T5 has been described. Therefore, T5 may be a promising target in 
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disease control strategies. In addition, there is a need to be aware of possible T5 
mediated restriction during the development of viral vectors for use in gene therapy. 
 
Little has been reported previously on the activity of ruminant TRIM proteins (Si et 
al., 2006, Fletcher and Towers, 2013). Therefore, in the present study, I investigated 
the possibility of T5 being involved in the species-specificity of JSRV infection 
among ruminants. Additionally, rhesus macaque and human homologues were also 
tested for their ability to restrict JSRV. 
 
5.2 Results 
 
At the time this study was initiated (Oct 2009), the sheep and goat T5 genes had not 
been identified or cloned. Therefore, initially sheep and goat T5 genes had to be 
isolated by RT-PCR and cloned into a MLV retroviral vector backbone (see Section 
5.2.3). Subsequently, these MLV viral vectors were used to transduce the permissive 
cell line CRFKovH2, enabling antibiotic selection of cells stably expressing both the 
T5 and antibiotic resistance gene (see Section 5.2.4). Once the stable expression of T5 
had been demonstrated by flow cytometric analysis performed on intacellularly 
labelled cells (see Section 5.2.4.2), they were subjected to infections utilising      
JSRV-GFP (see Section 5.2.5.2). 
 
5.2.1 Pilot study on permissivity of cell lines to JSRV 
 
Four cell lines were infected with JSRV-GFP (VSV-G) in order to examine their 
permissiveness. Three days post-infection feline CRFK, rabbit RK 13-C, bovine 
MDBK and murine NIH 3T3 cells were subjected to flow cytometric analysis, shown 
in Fig. 5.1 (see Section 2.7.3). 
 
This preliminary experiment implied that murine NIH 3T3 and bovine MDBK cells 
might be protected against JSRV by a post-entry restriction factor such as T5 in 
contrast to the permissive CRFK. The VSV-G pseudotyped JSRV-GFP was used to 
avoid the effect of species differences in the JSRV receptor. Similarly, the use of a 
GFP reporter driven by CMV promoter avoided the requirement for JSRV-specific 
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transcription factors. However, it is possible that other dependency factors such as 
cellular division rate and molecules involved in intracellular trafficking, might have 
influenced the results. 
 
 
Fig. 5.1 Flow cytometric analysis of cellular permissiveness to JSRV-GFP 
Analysis of JSRV-GFP VSV-G infected CRFK, RK 13-C, MDBK and NIH 3T3 cells. Cells were 
infected by serial dilutions of concentrated JSRV-GFP VSV-G (2 μl, 20 μl, 200 μl). The results 
shown indicate the percentage of GFP-positive cells obtained by infection of a single well. 
 
5.2.2 Strategy for studying the impact of TRIM5 on JSRV replication 
  
The experimental design is based on the utilisation of JSRV-GFP to infect cell lines 
that stably express T5 from various species (see Fig. 5.2). Any differences found in the 
permissiveness of a tested cell line would identify an antiviral T5 homologue. 
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Fig. 5.2 The plan of investigation of the effect of TRIM5 on retroviral replication in vitro 
Blue boxes: assays; Red boxes: results 
 
5.2.3 Cloning of TRIM5 genes 
 
Cloning of sheep T5 and identification of a goat homologue were the initial steps 
towards research on their relevance to OPA. At the time this study was initiated no 
sequences were identified as sheep T5 transcripts. A BLAST search of the EST 
database was performed using the cow protein (Si et al., 2006) as a query to identify 
EST entries from sheep and goat. The results identified several sequences overlapping 
part of the sequence. This approach allowed the identification of 5’ and 3’ termini of 
the T5 ORF, which allowed the design of primers for cloning (Table 5.1). 
 
The products were amplified by RT-PCR and cloned into pGEM-T Easy, which 
enabled their sequencing (see Section 5.2.1.1). Representative clones were then chosen 
by alignment, re-amplified by high fidelity PCR and cloned into a MLV vector 
backbone (see Section 5.2.1.2), which was later modified by the addition of an     
IRES-Hyg cassette (see Section 5.2.1.3). The TRIM5 cloning steps are shown in Fig. 
5.3. 
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Table 5.1 Sequences of ruminant TRIM5 containing mRNA 
sequence origin, reference gene reference 
Cow [Moore, S.] – hypothalamus Gb  EH141776.1 
Sheep [Wilson, T.] – dendritic cells Gb  EE819900.1 
Sheep (Hecht et al. 2006) – bone Gb  DY491467.1 
Sheep (Hecht et al. 2006) - bone Gb  DY501375.1 
Sheep [Wilson, T.] – mucosal lymphoid tissue Gb  EE794007.1 
Sheep [Green, J.] Gb  GT880467.1 
Cow [Anderson, S.] – spleen Gb  AM031187.1 
Sheep [Wilson, T.] – gall bladder Gb  EE780393.1 
Sheep [Wilson, T.] – wool follicle Gb  EE855939.1 
Sheep [Wilson, T.] – wool follicle Gb  EE864175.1 
Sheep [Fell, M.] –Peyer’s Patch, terminal illeum Gb  FE034648.1 
 
 
 
 
Fig. 5.3 Cloning steps of TRIM5 transgene carrying MLV plasmid vectors. 
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5.2.3.1 Isolation of sheep and goat TRIM5 (RT-PCR) 
 
As a template for RT-PCR, I utilised RNA extracted from the sheep cell line CPT-Tert 
(Arnaud et al., 2010) and RNA from goat PBMC. Primers were designed to consensus 
regions located upstream of sheep and cow T5 ORF (TRIM-F1, TRIM-R1). The 
nucleotide alignment (see Fig. 5.4) was based on sequences shown in Table 5.1. 
 
EE819900.1  GGGCAGAATTTGAAAGATACACAAGAAAAAAACGGAATCTGCTTAGG.ATCTGCGAAGGAGAGAACTGT 
DY491467.1  -----------------------------------------------.G----T---C----------- 
DY501375.1  -----------------------------------------------.-----T---C----C------ 
EE794007.1  -----------------------------------------------.---------C----C------ 
GT880467.1  .....................................................T---C----C------ 
EH141776.1  -------------G---------------------------------G-----T--GT----------G 
 
EE819900.1  CAGAAATCTAGACAGTGAGGAGCACGTGAGCCACTGCCATGGCTTCAGGAATCC 
DY491467.1  --A-----A---------------G--C--------------------------  / ruminant  / 
DY501375.1  ------------------------G--C-------------------------- / TRIM5 ORF / 
EE794007.1  ------------------------G--C-------------------------- 
GT880467.1  ------------------------G--C-------------------------- 
EH141776.1  -----G--A-----A-A-------G------AG--------------------- 
 
EE819900.1  TTGAGTCTTCTTACACTCACACC.ACTCCTCTATAGTGCCCCTTACTGTAGGTGCATCTAACACACCTG 
EE855939.1  -----------------------C--C------------------------------------------ 
EE864175.1  -----------------------C--C------------------------------------------ 
FE034648.1  -----------------------.--------------------------------------------- 
AM031187.1  ---------------T------TA----G-----------T------------------G--------- 
 
Fig. 5.4 Alignment of sequences located external to the sheep and cow TRIM5 reading 
frame 
The forward primer (yellow) was designed to match published sheep mRNA sequence 
upstream of the start codon (green). The reverse primer (blue) is complementary to sheep 
sequences located downstream of the stop codons (red). The highlighted residue G indicates 
a base in the primer that was mismatched between cow (bottom sequence) and other sheep 
sequences. The majority of the ruminant TRIM5 coding region is not shown, dashes indicate 
sites where sequences are identical, dots indicate gaps or missing data. 
 
5.2.3.2 Sequencing results and protein alignment 
 
Amplified sequences were cloned into pGEM-T Easy and submitted for sequencing. 
At least ten of each sheep and goat clones were sequenced in order to choose a 
representative clone from each species. 
 
Subsequently, selected sheep and goat clones were reamplified by high fidelity PCR 
(see Section 2.11.1.3). The forward primer incorporated a Kozak consensus sequence 
upstream of the start codon. The reverse primer added a haemagglutinin (HA) tag 
encoding sequence at the 3’ of the ORF. The primers utilised also included restriction 
sites to facilitate the insertion of the T5 ORFs into a pLNCX-2 MLV vector backbone 
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(see Section 2.11.1.3). Once the T5 ORFs were cloned into pLNCX-2 vector, their 
sequences were again verified by sequencing (see Section 2.11.1.4). 
 
The isolated sheep T5 sequence was more similar to the goat homologue than to the 
cow protein, which is shown in the protein alignment (Fig. 5.5). 
 
  
Fig. 5.5 Alignment of ruminant TRIM5 protein sequences 
The sequences of the isolated sheep (OA), two goat alleles (G1 and G2) and cow LOC505265 
(C5) are shown. Dashes indicate amino acid similarity. Dots indicate gaps. Polymorphic 
residues relative to the sheep sequence are highlighted by letters. TRIM5 domains are 
highlighted by shaded boxes. Numbers on the left indicate residue number. 
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The highest polymorphism was detected in the C-terminal B30.2 domain, while the 
first 120 residues of T5 were more conserved. 
 
During the preparation of this thesis, the sequences of a number of sheep and goat T5 
homologues were published (Jauregui et al., 2012). The T5 clone studied in this 
project is not identical to any of those homologues but most closely resembles sheep 
T5 “Clone OV3” (Jauregui et al., 2012). The relationship of ‘the’ clones with those 
reported by Jauregui is shown in Fig. 5.6. 
  
 
Fig. 5.6 Phylogenetic relationship of TRIM5 protein homologues 
Five sheep TRIM5 alleles; 4 alleles OV1 to OV4 reported by (Jauregui et al., 2012) and the 
allele isolated in this study ‘myOV’; four goat alleles G1 and G2 involved in this study, 
JQ582849 and JQ582845 reported by (Jauregui et al., 2012); two cow sequences (C5 and C6 
- LOC505265, and LOC616948) (Si et al., 2006); human TRIM5α (NM_033034). T5 
homologues analysed in this study are highlighted by a green background. This phylogenetic 
tree was generated using MEGA 6.02 Software. The evolutionary history was inferred using 
the Neighbor-Joining method (Saitou and Nei, 1987). The tree is drawn to scale, with branch 
lengths in the same units as those of the evolutionary distances used to infer the phylogenetic 
tree. Numbers represent bootstrap values, utilising 1000 iterations. 
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5.2.3.3 Cloning of T5 and LacZ into retroviral vectors 
 
As a negative control, a LacZ transgene was cloned into pLNCX-2 instead of T5 (see 
Section 2.11.1.3). LacZ should not impact on JSRV replication and was useful for 
monitoring the progress of selection of cells stably expressing the transgene by 
staining for β-galactosidase activity (see Section 2.11.2.3). 
 
The CRFKovH2 cell line was created in order to permit viral entry by JSRV          
Env-pseudotyped vectors. Effective stable expression of T5 in this cell line could not 
be assessed by selection based on the geneticin resistance gene (neomycin transferase) 
present in pLNCX-2, because this cell line already had been created by geneticin 
selection (see Section 2.4.3). Therefore, in order to select for stably transduced cells 
expressing T5 transgene, the vector backbone was modified by the addition of an 
Internal Ribosomal Entry Site (see Section 2.11.1.4) and hygromycin (Hyg) resistance 
gene cassette downstream of the T5-HA ORF. This should ensure that only cells 
expressing the mRNA containing T5 will survive the antibiotic selection due to the 
translation of Hyg
R
 via IRES present on the same transcript. The features of the 
integrated vector are shown in Fig. 5.7. 
 
 
 
Fig. 5.7 pLNCX-2 TRIM5 IRES-Hyg vector 
 Features present in integrated pLNCX-2 vector: LTR – MLV 5’ and 3’ LTR; Ψ – packaging 
signal; Neo
R
 – neomyscin transferase (puromycin resistance gene in pLPCX vectors); CMV – 
CMV promoter; TRIM5 – HA tagged TRIM5; IRES – Internal Ribosomal Entry Site; Hyg
R 
- 
hygromycin resistance gene. Highlighted elements are not proportional to their actual size. 
 
Two alleles of cow T5 (in this thesis referred as C5 and C6 - LOC505265 and 
LOC616948), rhesus macaque (GI 48994823) and human (NM_033034) homologues 
cloned into pLPCX were kindly provided by Dr Joseph Sodroski (Dana-Farber Cancer 
Institute, USA). These expression plasmids were modified similarly to pLNCX-2 by 
utilisation of a ClaI site to insert the IRES-Hyg cassette downstream of the T5-HA 
ORF. Features included in the integrated pLPCX vector are similar to pLNCX-2     
(see Fig. 5.7), with the exception of a puromycin resistance gene, in a place of the 
neomycin transferase gene present in pLNCX-2. 
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All the clones were verified by sequencing of the TRIM5 transgene and junctions 
flanking the IRES-Hyg cassette (see Section 2.11.1.4). 
 
5.2.4 Creation of cell lines stably expressing TRIM5 
 
The creation of cell lines stably expressing different T5 homologues was the next step 
towards investigating the impact of T5 on JSRV replication in vitro. The retroviral 
vector method of transduction was chosen, because the expression of T5 was desired 
to be as high as possible and directed by the cellular genome. 
 
MLV viral vectors were prepared by three plasmid transfection of 293T cells with    
pLNCX-2 (sheep, goat T5 or LacZ) or pLPCX (cow, rhesus macaque, human T5); 
pHIT60, which encodes MLV structural proteins and pVSV-G (see Section 2.11.2.1). 
 
In order to reliably determine the ability of each T5 protein to block JSRV, a high 
proportion of cells expressing the analysed transgene was required. Therefore, cells 
were selected in the presence of antibiotic, and transgene expression was confirmed by 
various assays (see Sections 5.2.4.1 to 5.2.4.2). 
 
Infection of CRFKovH2 by MLV T5 or LacZ carrying viral vectors was performed 
according to Section 2.11.2.2. Three days post-infection hygromycin was added to cell 
culture medium in order to select the cells which express the transgene (see Section 
2.11.2.2). Two weeks of antibiotic selection eliminated all non-transduced cells in 
culture dish wells where no vector had been applied.  
 
Confirmation of stable expression of transgene was monitored by β-Gal assay, 
performed on LacZ transduced cells (see Section 5.2.4.1). Immunoblotting was 
performed in order to detect HA-tagged T5 homologues in cellular extracts (see 
Section 5.2.4.3). Stable expression of T5 transgenes was assessed by flow cytometric 
analysis of anti-HA labelled cells (see Section 5.2.4.2). 
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5.2.4.1 Assessment of stable transgene expression by β-galactosidase 
assay 
 
The creation of a cell line stably expressing the LacZ transgene was verified by 
staining transduced cells for β-galactosidase activity. Note that these cells were 
simultaneously transduced at the same time as cells that were treated with MLV 
vectors carrying T5 transgenes. Cells transduced with LacZ express β-galactosidase 
and gain the ability to digest the X-Gal substrate, yielding galactose and 5-bromo-4-
chloro-3-hydroxyindole, which later dimerizes and after oxidation forms the intensely 
blue stain 5,5'-dibromo-4,4'-dichloro-indigo (Kiernan, 2007). Therefore,                     
β-galactosidase staining enabled the estimation of transduction efficiency by 
comparison of the number of LacZ blue coloured cells to colourless non-transduced 
ones (see Fig. 5.8). 
 
 
 
Fig. 5.8 β-Gal assay confirmation of stable LacZ expression in transduced CRFK cells 
The majority of cells stably express the LacZ transgene (blue cells). However, some cells remained that 
did not to express β-galactosidase (an example is highlighted by a red circle). 
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5.2.4.2 Flow cytometry of immunocytostained cells expressing TRIM5 
 
Confirmation of T5 expression by the vast majority of cells was necessary to qualify 
the cell line for analysis of T5 restriction. Initially, cells were subjected to intracellular 
detection of HA-tagged T5 proteins (see Section 2.11.2.5). Primary anti-HA antibody 
bound to C-terminally HA tagged T5, then the secondary Alexa Fluor 488 fluorescent 
antibody enabled the readout by flow cytometry (see Section 2.7.3). 
 
Flow cytometric analysis of intacellularly labelled cell lines demonstrated that HA-
tagged T5 is expressed by the majority of cells in each of the transduced cell lines (see 
Fig. 5.9). As negative controls, non-transduced cells and the cell line transduced with 
LacZ were used. An additional control, consisting of each cell line exposed only to the 
secondary antibody, was employed as a negative control for non-specific binding (see 
Section 2.11.2.5). 
 
 
 
Fig. 5.9 Confirmation of stable expression of HA tagged TRIM5 homologues in 
transduced CRFK cell lines 
Flow cytometric determination of the percentage of cells expressing various T5 in 
intracellularly stained cells. Cells were selected to express the following T5 homologues         
S- sheep; G1- goat allele “1”; G2- goat allele “2”; C5- cow allele (LOC505265); C6- cow allele 
(LOC616948); Rh- rhesus macaque (GI 48994823); Hu- human (NM_033034). 
 
Cells stably transduced by cow (C5 and C6), rhesus macaque and human T5 were 
found to express the transgene in greater than 80% of the cell population. Sheep and 
“goat allele 1” of T5 was detected in approximately 70% of the cell population. It was 
notable that cells transduced utilising the pLPCX vector (C5, C6, Rh, Hu, T5) were 
characterised by a higher proportion of stable T5 expression than cells transduced 
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utilising the pLNCX-2 vector (S1, G1). The only exception is the G2 cell line, which 
was transduced with pLNCX-2 and where T5 was detected in over 80% of analysed 
cells. It should be noted that the assay was characterised by a relatively high 
background, since 6% of the LacZ also stained positive. However, no positive cells 
were detected in any of samples where only secondary Alexa Fluor 488 rabbit anti 
mouse antibody was utilised (not shown). 
 
5.2.4.3 Immunoblot analysis of T5 HA cell line extracts 
 
The expression of TRIM5 in stable expressing cell lines was tested by immunoblot 
detection of HA-tag present at the C-termini of those proteins. This analysis was 
performed in order to complement the previous flow cytometry experiments 
demonstrating the expression of the transgenes. Unexpectedly, the immunoblot 
analysis of cellular extracts did not detect any signal that corresponded to the expected 
size of the HA-tagged T5 (57.8 kDA). 
 
 
Fig. 5.10 Immunoblot analysis of cell line extracts using anti-HA antibody 
Cellular extracts of cell lines transduced with the following T5: sheep (S), two goat alleles (G1 
and G2); two cow variants (C5 and C6), rheseus macaque (Rh), human (Hu). Cellular extract 
from the Laz-Z cell line was utilised as a negative control for anti-HA activity. Detection of 
encapsidated sheep A3-Z2Z3 HA in 10 μl of concentrated virus stock (SN+) was utilised as a 
positive control for primary anti-HA antibody reactivity. Molecular weight marker (see Blue2) is 
shown on the left side of the figure. Note that image has a strong background signal because 
it was captured in overexposured conditions in an attempt to increase the assay’s sensitivity. 
 
Despite many attempts, none of the HA-tagged T5 expressing cell lines yielded any 
signal corresponding to the size of T5-HA by immunoblotting. Cellular extracts from 
cells transduced with sheep T5 (S) and cow T5 (C6) contained an immunoreactive 
Expected T5 
A3-Z2Z3 HA 
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antigen between 22 and 36 kDa, but this is smaller than the predicted size of 
T5 (57.8 kDa). 
 
Therefore, additional assays were performed to confirm T5 expression including     
RT-PCR detection of T5 mRNA transcripts and confirmation of previously published 
studies describing the ability of bovine allele (C5) and rhTRIM5 to restrict HIV-1. 
 
5.2.5 Impact of TRIM5 on retroviral replication 
 
Once the cell lines expressing T5 had been created and the stability of T5 expression 
had been confirmed, activity of each T5 was tested against JSRV (see Section 5.2.3.2). 
Some of the T5 proteins analysed in this study, were previously reported to restrict 
HIV (Stremlau et al., 2004, Si et al., 2006). Therefore, HIV-GFP infections were 
performed as an additional control of experimental system. 
 
5.2.5.1 Effect of T5 on HIV-1 replication 
 
The cell lines created in Section 5.2.4, that stably express various T5 were infected by 
a HIV-1-GFP in order to confirm their suitability for further experiments on the basis 
of comparison with previously published data. The rhT5 (GI 48994823) has been 
identified as a species specific determinant of HIV-1 infection (Stremlau et al., 2004). 
Two cow T5 alleles analysed in my project were characterised by different abilities to 
restrict HIV-1 restricting potential. The cow T5 LOC505265 (C5 T5) had been 
described as a potent HIV-1 inhibitor in contrast to the other bovine T5 allele 
LOC616948 (C6 T5), which is not active against HIV-1 (Si et al., 2006). 
 
In order to evaluate the ability of ruminant, rhesus macaque and human T5 to restrict 
HIV-1, cells which stably expressed T5 homologues were infected by HIV-1-GFP and 
later analysed by flow cytometry. Six different amounts of HIV-1-GFP VSV-G 
pseudotyped virus were used for infections and the percentage of infected             
GFP-positive cells is shown in Fig. 5.11. 
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Fig. 5.11 Flow cytometric analysis of T5 impact on permissiveness to HIV-1 GFP 
Analysis of HIV-1-GFP (VSV-G) infected CRFKovH2 expressing various T5 homologues S – 
sheep; C5 – LOC505265; C6 – LOC616948; Rh – Rhesus monkey (GI 48994823); Hu – 
human (NM_033034). Each cell line was infected using 6 different amounts of virus utilised for 
infection 1; 2; 4; 8; 16 and 32 μl. LacZ transduced cells were used as a negative control for T5 
function. 
 
This experiment showed that Rh and C5 T5 could restrict HIV-1. These results are in 
agreement with previous reports (Stremlau et al., 2004, Si et al., 2006). Therefore, 
although western blotting did not detect T5 expression (see Section 5.2.4.3), the 
confirmation of a biological effect exhibited by rhesus (Rh) T5 and cow (C5) T5 
supports the flow cytometric analysis that these cell lines do express T5. 
 
Comparing to LacZ cell line permissiveness, the expression of sheep and human T5 
did not protect against HIV-1 infection. The result obtained did not show the ability of 
huT5 to protect at all against HIV-1 in contrast to published work where huT5 
restricted HIV-1 but not as strongly as its macaque homologue (Stremlau et al., 2004). 
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5.2.5.2 Effect of T5 on JSRV replication 
 
In order to determine the ability of ruminant and human T5 to restrict JSRV, cells 
which stably expressed T5 homologues were infected by JSRV GFP and analysed by 
flow cytometry. The T5-expressing cell lines were plated in 12-well cell culture dishes 
in equal amounts and were then infected in triplicate by four different amounts of 
JSRV-GFP VSV-G vector. The percentage of GFP-positive cells is shown in Fig. 5.12. 
 
 
Fig. 5.12 Flow cytometric analysis of T5 impact on permissiveness to JSRV-GFP 
Analysis of JSRV-GFP VSV-G infected CRFKovH2 expressing various T5 homologues (right 
legend) sheep; goat T5 allele “1” and “2”; cow “5” – LOC505265; cow “6” – LOC616948; 
human. Each cell line was infected using 4 different amounts of virus 1; 4; 16 and 64 μl. LacZ 
transduced cells were used as a negative control for T5 function. The student two-tailed t-test 
method with unequal variance was used to verify the significance of results. The error bars 
report the standard deviation value between wells infected in triplicate. 
 
Flow cytometric analysis of cell lines expressing T5 homologues did not demonstrate 
any dramatic restriction caused by any of the analysed T5. The permissiveness of the 
tested cell lines which stably express various T5 was similar to LacZ NC. Notably, 
cells expressing the sheep T5 were about 30% less permissive to JSRV than the LacZ 
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cell line. However, this is a relatively modest restriction and further analysis is 
required to confirm whether this is reproducible. 
 
5.3 Discussion 
 
The experiments described in this chapter represent the first analysis of the potential 
role of T5 in JSRV replication. During this study one sheep allele, two goat alleles, 
two cow alleles and are human T5 homologue were examined for their ability to 
restrict JSRV.  
 
As a preliminary experiment the CRFK cell line, which is highly permissive to 
retroviruses and does not express T5, was tested by JSRV infection in parallel with 
murine and ovine cell lines. The observed differences in susceptibility suggested that 
resistance of less permissive cell lines to JSRV might be caused by a post-entry 
restriction factor such as T5 (see Section 5.2.1). 
 
Subsequently, one sheep and two goat T5 homologues were identified and cloned (see 
Section 5.2.3.1), then cell lines that stably express each of them were created by 
retroviral vector mediated transduction (see Section 5.2.5). Additionally, other cell 
lines were transduced with cow, rhesus macaque and human T5 homologues. Stable 
T5 expression in cell lines was assessed by antibiotic treatment and the detection of 
expressed transgene was verified by several assays (see Sections 5.2.4.1 to 5.2.4.3). 
 
The biological function of the selected T5s was determined by infection with HIV-1, 
and JSRV-GFP VSV-G pseudotyped viruses (see Sections 5.2.5.1 and 5.2.5.2). Prior 
to the investigation of T5 activity against JSRV, the suitability of the system used was 
verified by demonstrating the ability of previously reported T5 homologues to inhibit 
HIV-1. This work has generated some data supporting the scenario that analysedT5 
homologues do not exhibit inhibitory potential against JSRV. However, it should be 
noted that the presented experiments are preliminary and any discussion of the data is 
therefore speculative. Nevertheless, the data obtained so far provide a strong 
foundation for future work. 
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5.3.1 Ruminant TRIM5 does not restrict JSRV replication 
 
Flow cytometry performed on cell lines expressing various T5 proteins did not identify 
any significant restriction of JSRV caused by any of the T5s analysed (see Section 
5.2.5.2). For other retroviruses, the reported T5 antiviral activity in in vitro conditions 
reduce the virus titre in a range from 100 to 100,000 fold, and the restriction was more 
evident when smaller amounts of virus were tested (Stremlau et al., 2004). 
 
In this study, the observed variation in the percentage of GFP-positive cells was up to 
two fold. Such variation is more likely an effect of such experiment factors such as 
minor differences in number of cells and their condition. Cells expressing the sheep T5 
homologue were 33% less permissive to JSRV than LacZ transduced cells. However, 
referring to the intracellular labelling results (see Section 5.2.4.2), where the 
expression of sheep T5 was detected in 70% of the total cell line population, the 
presence of cells not expressing T5 could mask its inhibitory potential and could 
account in a part for fluorescence readings classified as positive. In order to resolve 
this uncertainty, either the infected-GFP-positive cell population should be verified for 
T5 expression or the proportion of cells expressing T5 should be increased.  
 
Two cell lines expressing the human or the ‘goat 1 allele’ of T5 were detected as more 
permissive to JSRV than the LacZ cell line, which was used as a negative control (see 
Fig. 5.13). Extended analysis of observed slight increase in permissiveness to JSRV 
among some created cell lines, could potentially identify mechanisms responsible for 
this phenomena such as involvement of T5 in uncoating. However, I attribute this 
result as variation related to the assay depending on such factors like cell condition 
and their number. A similar observation was reported in a study performed by Si et al. 
(2006), where cells transduced with the modified cow T5 LOC616948 allele were 
slightly more permissive to N-MLV than cells that had been transduced with an empty 
vector. 
 
5.3.1.1 Could the presence of HA tag have affected T5 activity? 
 
It is possible that the presence of the C-terminal HA Tag might affect the activity of 
the analysed T5 proteins. For example, a previous study found that rhT5 inhibited SIV, 
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whereas HA-tagged rhT5 did not (Stremlau et al., 2004). However, in that study both 
tagged and untagged rhT5 and huT5 blocked HIV-1 to the same degree (Stremlau et 
al., 2004). Those differences may be explained by the fact that the C-terminal B 30.2 
domain is responsible for binding to retroviral capsids and connecting to it an epitope 
tag might alter this interaction (Huthoff and Towers, 2008). Therefore, experiments on 
untagged and C-terminal tagged T5s may be performed in order to address this issue in 
the context of JSRV infection. 
 
5.3.1.2 Comment on the suitability of the cell lines used 
 
Since the immunoblot analysis did not detect T5 in cellular extracts of the analysed 
cell lines (see Section 5.2.2.3), it could be argued that either the various T5 alleles 
were not expressed or that their expression levels are low. It may be linked to an 
observation that a number of TRIM family members were described to be turned over 
by the proteasome, which depleted their levels (Versteeg et al., 2013). However, the 
intracellular flow cytometry results identified the immunoreactive HA-epitope in the 
majority of the population of each cell line. In addition, for rhT5 and C5 T5, actual 
biological activity was demonstrated in the context of HIV-1-GFP infection (see 
Section 5.2.5.1). However, huT5 is also reported to restrict HIV-1 although less 
strongly than rhT5 (Stremlau et al., 2004), but in the present study was not found to 
restrict HIV. Further work is needed to resolve this inconsistency. Moreover, the 
eventual restrictive potential of analysed T5s could be affected by a dominant negative 
effect due to a possible heterodimerisation with endogenous truncanted variant T5 
present in CRFK cell line (Perez-Caballero et al., 2005, McEwan et al., 2009). 
 
The stable expression of the T5 transgene in the vast majority of the cell population 
was desired in order to avoid the result being affected by the presence of highly 
permissive non-transduced cells. Therefore, flow cytometric analysis of HA-labelled 
cells was used to demonstrate that the majority of cells express the T5 transgene. For 
example, the intracellular detection of HA-tagged C5 T5 suggested that there were 
around 15% of cells which did not express the transgene (see Fig. 5.9). Those cells 
may be more permissive to infection than successfully transduced cells and 
subsequently the infection of this cell line should yield a higher proportion of GFP-
positive cells in the readout of HIV-1 infection (see Section 5.2.5.1). My interpretation 
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of this observation is that the proportion of cells stably expressing T5 is actually 
higher than detected by flow cytometric analysis of HA-labelled cells. There is a 
chance that some cells might be restrictive even if they have a relatively low 
expression level of T5 that is not detectable by intracellular anti-HA labelling. 
 
In addition, I speculate that some false negative readings are actually signals from 
improperly intracellularly stained cells. Several steps of this method might have 
affected the assay’s performance, for example permeabilisation of cellular membranes 
or fixation. Such factors might possibly influence the ability of antibody to penetrate 
cells equally in each sample. 
 
The flow cytometric analysis of intracellularly stained cells showed that 6% of cells in 
the negative control LacZ line were positive (see Fig. 5.9). My interpretation is that it 
represents a false positive and contributes to the assay’s background. Alternatively, 
those cells scored as positive might contain a cross-reactive antigen which is 
responsible for background labelling. In principle, expression of such a cross-reactive 
antigen could be caused by an alteration of an expressed protein by provirus insertion 
or a response of a fraction of the cells to the antibiotic selection. However, such a 
scenario is unlikely, due to the fact that monoclonal anti-HA antibodies were utilised 
for the detection of HA-tagged T5. 
 
In my opinion the relatively high ratio of positives (6%) in the LacZ cell line is 
unlikely to be attributed to biological factors, which should not account for such a high 
proportion of cells. On the other hand, antibiotic selection reduced the polyclonality of 
cellular population, which might in some way increase the proportion of cells 
expressing this putative cross-reactive epitope. 
 
However, given the disparity of flow cytometric analysis of labelled cells (see Section 
5.3.3.2) and western blot results (see Section 5.2.3.3), additional RT-PCR analysis 
should be performed in order to provide additional evidence of T5-HA expression. 
 
Various variants of MLV vector backbones were utilised in order to improve the 
proportion of transgene expression in the cell lines generated in this study. Initial 
experiments showed only about 50% of cells to be detected by intracellular labelling. 
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The highest transgene expression proportion was found when MLV vectors containing 
a IRES-Hyg cassette downstream of the T5 ORF were utilised (see section 5.2.3.3). 
 
5.3.2 Can TRIM5 be excluded as a species-specificity restriction factor for 
JSRV?  
 
Initially, the feline CRFK cell line was compared to the bovine MDBK cell line by 
infection with VSV-G pseudotyped JSRV-GFP. The result of this preliminary 
experiment indicated at least 10-fold lower permissiveness of MDBK compared to 
CRFK cells (see Section 5.2.1). Therefore, the detected resistance of the bovine cell 
line against JSRV might be attributed to post-entry restriction mediated by T5, since 
CRFK does not express it. However, none of the created cell lines expressing any of 
the investigated T5 homologues was characterised by an increased resistance to JSRV. 
This contrasts with a dramatic effect of various T5 mediated restriction against other 
retroviruses reported previously (Si et al., 2006). Therefore, the observation of MDBK 
resistance to JSRV cannot be attributed to restriction mediated by bovine T5 
molecules. 
 
Since it has been shown in many reports that various T5 alleles may be characterised 
by a varying restrictive potential on viral replication (Goldschmidt et al., 2006, Rahm 
et al., 2013), the possibility that T5 may be responsible for the species-specificity of 
OPA should not be completely excluded. For example, previous work (Si et al., 2006) 
was confirmed here by demonstration of the ability of the cow C5 T5 allele to inhibit 
HIV-1 in contrast to the other bovine allele C6 T5.  
 
Besides the direct post-entry inhibition of viral replication, T5 may be responsible for 
other activities which contribute to antiviral immunity (see Section 1.8.3.3). It is 
possible that there is a potential T5 ability to bind viral capsids, which results not in 
inhibition of replication, but acts as a kind of pattern recognition receptor and mediates 
the virus sensing mechanism (de Silva and Wu, 2011). Therefore, this project provided 
only data about the lack of direct T5-mediated restriction of JSRV and did not verify 
its other possible functions. In order to address this issue, the eventual intracellular 
response should be studied using a number of approaches, including transcriptomic 
and proteomic analysis and the identification of secreted chemokines. Moreover the 
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verification of the ability of T5 to bind JSRV capsids could be accessed by 
immunostaining followed with co-localisation using confocal microscopy. 
Alternatively, direct binding of T5 to capsids could be detected by protein-crosslinking 
or a yeast-two hybrid system. In addition, targeted mutagenesis could identify protein 
motifs involved in potential T5-mediated capsid recognition. 
 
5.3.2.1 Comment on sheep TRIM5 alleles as potential JSRV limiting 
factors. 
 
During the time of this project, several alleles of ovine and caprine T5 were published 
(Jauregui et al., 2012). In that study, the Ov1 and Ov2 alleles of sheep T5α 
demonstrated inhibition of MVV in contrast to the Ov4 allele which did not restrict 
MVV. Because the sheep T5 allele analysed in this project is similar to the OV3 (see 
Fig. 5.6) there is a chance that other sheep alleles might be characterised by different 
inhibitory potential against JSRV. 
 
There is a need to be aware that there is ongoing co-evolution between viruses and 
their restriction factors. Such natural selection on the basis of resilience to pathogens 
also applies in the case of domestic animals, although the process may be significantly 
affected by breeding strategies. Moreover, sheep usually develop OPA at the time they 
already have some offspring.  
 
5.3.3 Development of a strategy for effective TRIM5 expression 
 
As described above, the vast majority of cells would ideally express T5 in order to 
properly determine its eventual restrictive potential. Various MLV vectors were used 
in order to improve the proportion of cells expressing the T5 transgene. 
 
Initially the pBABE vector (Morgenstern and Land, 1990) was utilised for 
transduction of CRFK and RK-13C cells. Due to difficulties in obtaining the required 
percentage of transgene expressing cells, it was decided to clone the T5 ORFs into the 
pLNCX-2 vector [Clontech]. However, subsequent transduction of CRFK and RK-
13C cells found that the percentage of T5 positive cells was still too low (not shown).  
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To address this issue, the IRES-Hyg cassette was cloned into the backbones of 
pLNCX-2 (S, G1 and G2 T5) or pLPCX vector (C5, C6, Rh, Hu T5). A similar 
strategy was utilised by Diehl and collegues (Diehl et al., 2008). In this study linkage 
of T5 to an antibiotic resistance gene within the same translational unit, improved the 
expression ratios in cell lines created. 
 
The survival of some cells in hygromycin selection where T5 was not detected might 
be attributed to several issues. It could be speculated that the survival of cells not 
expressing T5 might be due to mutations generated in the T5 ORF due to RT or RNA 
polymerase II errors occurring during viral vector production and transduction. On the 
other hand it could be argued that the flow cytometry result was accurate, because cell 
lines stably expressing T5 have been created in parallel with LacZ, which contains a 
proportion of cells which were not stained by β-Gal assay (see section 5.2.2.1). This 
fraction of the cell line represents either unsuccessfully transduced cells or their LacZ 
expression was below the detection threshold. 
 
An alternative experimental strategy would involve examination of T5 function by 
transient transfection of cells, as was used for example by Hwang et al., (2010). 
However, I decided to create cell lines stably expressing T5 from vectors integrated in 
the genome in order to mimic their natural expression. Additionally, taking the 
transient approach, transfection would be necessary to repeat transfections prior to 
each infectivity assay, which would add further variability to the results obtained. 
Moreover, transfection efficiency dependent on the cell line would impact on the 
results. 
 
Some studies of T5 function have utilised T5 encoding vectors that also contain a 
fluorescent marker, for example, yellow fluorescent protein (YFP) (Diehl et al., 2008, 
Lukic et al., 2011). Taking this approach, the result is interpreted by the ratio of 
infected cells (GFP-positive) taking into account only transduced cells which express 
YFP. In my study I decided to create cell lines stably expressing T5 by an antibiotic 
selection in order to eliminate non-transduced cells to minimise their role in depletion 
of the virus pool used in infections. 
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In future experiments on T5 and JSRV, if biological activity of T5 is detected it would 
need to be confirmed by siRNA mediated knockdown to rescue infectivity (Sodroski, 
2004). In order to investigate the restriction mechanism, proteasomal inhibitors could 
be utilised, which in some cases may rescue the original permissiveness. Moreover, 
mutational analysis of T5 variants generated can define motifs required for a 
restriction of analysed virus or for generation a gain of inhibitory function (McCarthy 
et al., 2013, Neagu et al., 2009). 
 
5.3.4 Summary of TRIM5 impact on JSRV 
 
Although none of the analysed T5 mediated the restriction of JSRV, the work in this 
Chapter is a first step towards examining the interaction of T5 and JSRV. The 
possibility remains that other T5 alleles or other TRIM family members contribute to 
the species specificity of JSRV infection. At the time of this project the complete 
family of ruminant TRIM family protein sequences was not fully characterised. Once 
these data are available, a high throughput analysis should be performed similar to one 
reported by Uchil et al. (2008), where a significant proportion of the human TRIM 
family members were tested for their ability to inhibit various viruses. 
 
Notably, as the experiments on A3 demonstrated (see Chapters 3 and 4), the possible 
identification of TRIM mediated restriction of JSRV would require an additional 
confirmation that the restriction factor is expressed in cells targeted by JSRV in vivo. 
In the situation where JSRV was demonstrated to be resistant to TRIM-mediated 
restriction totally, then it might be utilised as a vector in a number of genetic 
engineering applications, which could potentially yield effective gene transduction in 
gene therapy or in the creation of transgenic animals. 
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Chapter 6 – General discussion 
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Recent work from many laboratories has focussed on host-pathogen interactions in 
retrovirus infection. In particular, a number of restriction factors have been identified 
that block replication at specific points in the replication cycle. For JSRV, previous 
work has identified tetherin (BST-2) (Arnaud et al., 2010), IFITM proteins (Li et al., 
2013a) and specific enJSRV Gag and Env proteins as potential inhibitory factors 
(Arnaud et al., 2007b). In this thesis I examined the potential activity of A3 and T5 
against JSRV within the context of species-specificity of infection. The results 
presented in Chapters 3 and 4 demonstrate the ability of various A3 proteins to restrict 
JSRV in vitro, but, none of the T5 homologues analysed was demonstrated to be active 
against JSRV (Chapter 5). These findings contribute to our understanding of host-
pathogen interactions in OPA and may help to direct the future development of 
effective disease control strategies. In addition, this work provides improved insight 
into the prospect of JSRV as a potential vector in gene delivery. In addition to 
restriction factors, the species specificity and epidemiology of OPA could also be 
dependent on sequence variation of other innate immunity genes and polymorphism of 
dependency factors, such as alleles of the HYAL 2 receptor. Figure 6.1 summarises 
some known dependency and restriction factors that are relevant to OPA. 
 
Restriction factors are now well recognised as important components of innate 
immunity. They are often consistently expressed but also activated by interferons and 
other cytokines (Koning et al., 2009, Gougeon and Herbeuval, 2012). They may act as 
a form of antiviral effector molecule, such as A3 and T5, and in some cases as a form 
of pathogen recognition sensor that triggers further cytokine expression (for example 
T5α). Whether the sheep homologues function in the same way remains to be 
determined. 
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Fig. 6.1. Dependency and restriction factors relevant to JSRV replication. 
Dependency factors such as the cellular receptor Hyal-2 and transcription factors are 
displayed in blue. Restriction factors whose activity against JSRV was confirmed in vitro, but 
are not expressed in cells where JSRV replicates, are highlighted by yellow boxes (APOBEC3, 
tetherin, enJSRV Gag and Env). The ability of TRIM5 to directly restrict JSRV was not 
detected in this study, but there are other possible functions for TRIM5 (violet box). The 
significance of other potential restriction factors and dependency factors remains to be 
investigated (orange box). 
 
6.1 Identification of the APOBEC3 proteins as potential JSRV inhibitors 
 
In this study, some ruminant, murine and human A3 proteins were demonstrated to be 
able to inhibit JSRV replication in vitro (see Chapter 3 and 4). Moreover, ovine A3-Z2 
and A3-Z2Z3 were demonstrated to be able to inhibit JSRV replication in vitro by 
hypermutation and by direct inhibition of the reverse transcriptase reaction. However, 
the impact of A3 on the pathogenesis of OPA appears to be rather limited since the 
stability of the JSRV genome among isolates suggests no occurrence of cytidine 
deamination-mediated restriction in vivo. This correlated with a lack of detectable A3 
in virus isolated from OPA lung fluid and little or no expression of A3 proteins in 
pulmonary epithelial cells. Collectively, the data presented in this thesis strongly 
indicate that JSRV avoids A3 in vivo by infecting and replicating in target cells that do 
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not express these restriction factors. This is a novel strategy and can be contrasted with 
the anti-A3 strategies adopted by HIV and other retroviruses. 
 
This project was supported by a grant aiming to develop transgenic sheep that would 
be resistant to OPA. In studies performed in parallel to those described here, 
transgenic sheep were produced that expressed the enJSRV Gag and Env proteins in 
the lung (D. Griffiths, C. Cousens, B. Whitelaw, M. Palmarini; Unpublished Data). 
Identification of ovine A3s as potential JSRV inhibitors makes them disease control 
candidates, if their expression can be targeted to lung epithelium. However, there is a 
need to be aware that even endogenous A3, may contribute to uncontrolled editing of 
the host genome, which might lead to transformation (Nowarski and Kotler 2013; 
Taylor et al. 2013). In addition, there is a chance that once A3 is expressed in lung 
epithelium, then although it would limit JSRV infectivity, it is possible that it could 
also increase the rate of JSRV viral evolution. I speculate that in order to create a 
transgenic sheep resistant to OPA, the best results would be obtained by coexpression 
of some JSRV inhibitors, such as A3, tetherin and specifically designed siRNAs 
targeting JSRV transcripts. Although due to strict regulations such an animal would 
unlikely to be used in food production, it could provide a better understanding of such 
disease control perspectives. 
 
6.2 Ruminant and human TRIM5 proteins do not restrict JSRV 
 
This study demonstrated a lack of JSRV inhibition by ruminant TRIM5 proteins 
including one ovine, two caprine and two bovine alleles (see Chapter 5). In addition, 
human T5α was also not effective against JSRV. Although some of these experiments 
were only performed once and need to be confirmed, they suggest that T5 is not an 
important factor determining the species-specificity of JSRV. Nevertheless, it remains 
possible that other T5 alleles and other members of the TRIM family may protect 
against JSRV (Uchil et al., 2008). In addition, although T5 is not responsible for the 
direct post-entry inhibition of JSRV replication, it could still potentially function as a 
virus recognition factor that stimulates innate immunity signalling pathways leading to 
antiviral responses such as mediated by NFκB (Pertel et al., 2011, de Silva and Wu, 
2011). 
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If JSRV is demonstrated to be completely resistant to TRIM mediated restriction, then 
there may be an advantage to using components of this virus as a vector in genetic 
engineering applications, such as gene therapy and the creation of transgenic animals.  
It has been demonstrated that modification of an originally inactive T5 protein may 
cause a gain of virus inhibitory function. If T5 could be modified to acquire the ability 
to inhibit JSRV, there is the prospect of development of novel disease control 
strategies (McCarthy et al., 2013, Neagu et al., 2009). 
 
6.3 Future studies on the species specificity 
 
The work presented in this thesis has provided new information on restriction factors 
and JSRV. However, further restriction factors are known that could contribute to 
limiting the natural course of infection and may be responsible for the species-
specificity of JSRV. Also, it is likely that there are additional restriction factors yet to 
be identified. 
 
One strategy for identifying new restriction factors that are active against JSRV would 
be to perform a high throughput genetic screen similar to studies performed on HIV-1. 
In one study, approximately 19,000 genes were screened by selective siRNA-mediated 
knockdown, this study identified polymerase-associated factor 1 (PAF1) as an HIV-1 
restriction factor (Liu et al., 2011). In a similar manner, RNA-associated Early-stage 
Anti-viral Factor (REAF) was also identified as an HIV inhibitor (Marno et al., 2014). 
An alternative approach for identifying novel restriction factors has been the high-
throughput testing of interferon-stimulated genes for their antiviral activity (Schoggins 
et al., 2011), which has uncovered many new targets for future research. 
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It is possible that allelic variation in genes encoding restriction factors may be 
responsible for the apparent selection of resistant animals that is observed in flocks 
affected by OPA. Typically, in the first few years of an outbreak, the prevalence of 
OPA in affected stock ranges may be as high as 20% but in subsequent years 
decreases to 1% to 5% (Griffiths et al., 2010). This resistance does not appear to be 
related to any detectable adaptive immunity to JSRV and, instead, a host genetic 
factor, such as a restriction factor, may be involved. Therefore comparison of 
restriction factor alleles present at the beginning of an epidemic to alleles present in 
OPA-endemic stock might identify protective alleles. Additional information could be 
provided by investigation of the genomes of animals which died of OPA compared to 
ones which were infected with JSRV but have not developed clinical disease. 
Moreover, the differential distribution of restriction or permissive factor alleles among 
sheep breeds (Jauregui et al., 2012) might result in variable susceptibility to OPA. For 
example, during the OPA outbreak in Iceland in 1930-1940 nearly 90% of Gottorp 
breed sheep died, comparing to only around 10% of Adalbol breed sheep (Dungal, 
1938). 
 
To obtain a more global perspective on host-pathogen interactions in OPA, extensive 
proteomic, genomic and transcriptomic profiling comparing healthy lung and 
transformed lung could be performed to identify factors involved in pathogenesis. 
Advances in sequencing technologies over recent years have now made this a realistic 
possibility in OPA, even though the sheep genome sequence is not yet fully annotated. 
Greater understanding of the transcriptional response to JSRV infection and 
transformation would provide numerous avenues for dissecting host-pathogen 
interactions in OPA. For example, increased understanding of cellular transformation 
pathways would help uncover how exactly the JSRV Env protein is able to induce 
tumours. Similarly, identification of the local cytokine response to JSRV infection, in 
infected cells and in the surrounding stroma and infiltrating cells, might reveal aspects 
of OPA biology relating to the lack of adaptive immunity. Furthermore, this 
information may inform the design of new diagnostic assays and disease control 
strategies for OPA and would strengthen the relevance of OPA as a model for human 
lung cancer. 
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One factor that has hampered studies on JSRV has been the lack of a suitable 
permissive cell line capable of supporting replication of the virus in vitro. The data 
generated on A3 and T5 in this thesis has contributed to our understanding of potential 
blocks to JSRV replication in vitro, and will inform future studies on developing a 
permissive cell line. For example, there are few sheep cell lines available, and those 
that do exist, such as CPT-Tert used here, express A3 and so may not be ideal 
candidates for use in in vitro infectivity studies. If a permissive cell line were 
available, this would greatly facilitate studies on JSRV replication, including the 
analysis of candidate species-specific restriction factors. 
 
6.4 Final Conclusion 
 
In conclusion, the work in this thesis has, for the first time, investigated the role of A3 
and T5 restriction factors in JSRV infection. I have shown that ovine A3 does restrict 
JSRV but is not expressed in the cells in which JSRV replicates, which represents a 
novel strategy of retroviral avoidance of this restriction factor. In addition, I have 
presented data supporting the notion that T5 does not restrict JSRV. The methods 
used, including cloning of ruminant A3 and the creation of cells that express various 
T5 may contribute to future studies not only on host-pathogen interactions present in 
OPA but also other viral diseases. Further work in this area will provide additional 
knowledge that can be utilised in the development of control strategies against OPA 
and other challenging diseases caused by retroviruses. 
 
‘Scientists have become the bearers of the torch of discovery in our quest for knowledge’.  
Stephen Hawking 
 
These words describe the mission of scientists to unravel the mysteries of nature. The 
aim of studying virus-host interactions is to translate the knowledge to much needed 
novel control strategies against many diseases including those that are currently 
incurable. 
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